CA3118537A1

CA3118537A1 - Modified double stranded oligonucleotides

Info

Publication number: CA3118537A1
Application number: CA3118537A
Authority: CA
Inventors: Donald Foster; Mark K. SCHLEGEL; Christopher Brown
Original assignee: Alnylam Pharmaceuticals Inc
Current assignee: Alnylam Pharmaceuticals Inc
Priority date: 2018-11-09
Filing date: 2019-11-05
Publication date: 2020-05-14
Also published as: JP2022506503A; AU2019376628A1; EP3877524A4; US20210388356A1; WO2020097044A1; EP3877524A1

Abstract

One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.

Description

DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:

MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDES
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims benefit under 35 U.S.C. 119(e) of U.S.
Provisional Application No. 62/758,094 filed November 9, 2018, the contents of which are incorporated herein by reference in its entirety.
FIELD OF THE INVENTION

[0002] The invention relates to dsRNA molecules having particular motifs that are advantageous for inhibition of target gene expression, as well dsRNA agent compositions, suitable for therapeutic use. Additionally, the invention provides methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various diseases.
BACKGROUND

[0003] RNA interference or "RNAi" is a term initially coined by Fire and co-workers to describe the observation that double-stranded RNAi (dsRNA) can block gene expression (Fire et at. (1998) Nature 391, 806-811; Elbashir et at. (2001) Genes Dev. 15, 188-200). Short dsRNA directs gene-specific, post-transcriptional silencing in many organisms, including vertebrates, and has provided a new tool for studying gene function. RNAi is mediated by RNA-induced silencing complex (RISC), a sequence-specific, multi-component nuclease that destroys messenger RNAs homologous to the silencing trigger. RISC is known to contain short RNAs (approximately 22 nucleotides) derived from the double-stranded RNA
trigger, but the protein components of this activity remained unknown.

[0004] There remains a need in the art for effective nucleotide or chemical motifs for dsRNA molecules, which are advantageous for inhibition of target gene expression. This invention is directed to that effort.
SUMMARY

[0005] This invention provides effective nucleotide or chemical motifs for dsRNA
molecules, which are advantageous for inhibition of target gene expression, as well as RNAi compositions suitable for therapeutic use.

[0006] In one aspect the invention provides a double stranded RNA (dsRNA) molecule comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2' -deoxy modifications on the sense and/or antisense strands; wherein the dsRNA molecule has a double stranded (duplex) region of between 19 to 25 base pairs; wherein the dsRNA
molecule comprises a ligand; and wherein the sense strand does not comprise a glycol nucleic acid (GNA).

[0007] It is understood that the antisense strand has sufficient complementarity to a target sequence to mediate RNA interference. In other words, the dsRNA molecules of the invention are capable of inhibiting the expression of a target gene.

[0008] In some embodiments, the dsRNA comprises at least three 2' -deoxy modifications, wherein the 2' -deoxy modifications are at positions 2 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at position 11 of the sense strand, counting from 5' -end of the sense strand.

[0009] In some embodiments, the dsRNA comprises at least five 2' -deoxy modifications, wherein the 2' -deoxy modifications are at positions 2, 12 and 14 of the antisense strand, counting from 5' -end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5' -end of the sense strand.

[0010] In some embodiments, the dsRNA comprises at least seven 2'-deoxy modifications, wherein the 2'-deoxy modifications are at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5' -end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5' -end of the sense strand.

[0011] In some embodiments, the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14, counting from 5'-end of the antisense strand. In some further embodiments of this, the antisense strand has a length of 18-25 nucleotides, preferably, a length of 18-23 nucleotides.

[0012] In some embodiments, the dsRNA agent can comprise one or more non-natural nucleotides. For example, the dsRNA agent can comprise less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides, or the dsRNA comprises no non-natural nucleotides. For example, the dsRNA agent comprises all natural nucleotides.
Some exemplary non-natural nucleotides include, but are not limited to, acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2' -0-allyl, 2' -C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-aminopropyl (2'-0-AP), and 2'-ara-F.

[0013]
Accordingly, in some embodiments, the dsRNA agent comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy nucleotides on the sense and/or antisense strands; and wherein the dsRNA molecule has a double stranded (duplex) region of between 19 to 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid (GNA); and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.

[0014] In some embodiments, at least one the sense strand and the antisence comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the sense strand or the antisense strand.
Accordingly, in some embodiments, the invention provides a dsRNA agent comprising a sense strand and an antisense strand, each strand independently having a length of

15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy nucleotides on the sense and/or antisense strands; and wherein the dsRNA
molecule has a double stranded (duplex) region of between 19 to 25 base pairs; wherein the dsRNA molecule comprises a ligand; and wherein the sense strand and/or the antisense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the sense strand and/or the antisense strand strand.
[0015] In some embodiment, the sense strand has length of 18 to 30 nucleotides and comprises at least two 2'-deoxy modifications in the central region of the sense strand. For example, the sense strand has length of 18 to 30 nucleotides and comprises at least two 2'-deoxy modifications within positions 7, 8, 9, 10, 11, 12, and 13, counting from 5'-end of the sense strand.

[0016] In some embodiments, the antisense strand has a length of 18 to 30 nucleotides and comprises at least two 2'-deoxy modifications in the central region of the antisense strand. For example, the antisense strand has length of 18 to 30 nucleotides and comprises at least two 2'-deoxy modifications within positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand.

[0017] In some embodiments, the invention provides a dsRNA agent comprising a sense strand and an antisense strand; wherein the sense strand has a length of 17-30 nucleotide and comprises at least one 2'-deoxy modification in the central region of the sense strand; wherein the antisense strand independently has a length of 17-30 nucleotides and comprises at least two 2'-deoxy modifications in the central region of the antisense strand.

[0018] In some embodiments, the invention provides a dsRNA agent comprising a sense strand and an antisense strand; wherein the sense strand has a length of 17-30 nucleotide and comprises at least two 2'-deoxy modifications in the central region of the sense strand; wherein the antisense strand independently has a length of 17-30 nucleotides and comprises at least one 2'-deoxy modification in the central region of the antisense strand.

[0019] In some embodiments, the dsRNA agent comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy nucleotides on the sense and/or antisense strands; and wherein the dsRNA molecule has a double stranded (duplex) region of between 19 to 25 base pairs; wherein the dsRNA molecule comprises a ligand; and wherein the sense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the sense strand strand.

[0020] In some embodiments, the dsRNA agent comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy nucleotides on the sense and/or antisense strands; and wherein the dsRNA molecule has a double stranded (duplex) region of between 19 to 25 base pairs; wherein the dsRNA molecule comprises a ligand; and wherein the antisense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand strand.

[0021] In some embodiments, the dsRNA agent comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy nucleotides on the sense and/or antisense strands; and wherein the dsRNA molecule has a double stranded (duplex) region of between 19 to 25 base pairs; wherein the dsRNA molecule comprises a ligand;
wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the sense strand and/or the antisense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the sense strand and/or the antisense strand strand.

[0022] In some embodiments, the dsRNA agent comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy nucleotides on the sense and/or antisense strands; and wherein the dsRNA molecule has a double stranded (duplex) region of between 19 to 25 base pairs; wherein the dsRNA molecule comprises a ligand;
wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the sense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the sense strand.

[0023] In some embodiments, the dsRNA agent comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy nucleotides on the sense and/or antisense strands; and wherein the dsRNA molecule has a double stranded (duplex) region of between 19 to 25 base pairs; wherein the dsRNA molecule comprises a ligand;
wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the antisense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand.

[0024] In some embodiments, when the dsRNA comprises less than 8 non-2'0Me nucleotides, the antisense stand comprises at least one DNA. For example, in any one of the embodiments of the invention when the dsRNA comprises less than 8 non-2'0Me nucleotides, the antisense stand comprises at least one DNA.

[0025] In some embodiments, when the antisense comprises two deoxy nucleotides and said nucleotides are at positions 2 and 14, counting from the 5'-end of the antisense strand, the dsRNA comprises 8 or less (e.g., 8, 7, 6, 5, 4, 3, 2, 1 or 0) non-2'0Me nucleotides. For example, in any one of the embodiments of the invention when the antisense comprises two deoxy nucleotides and said nucleotides are at positions 2 and 14, counting from the 5'-end of the antisense strand, the dsRNA comprises 0, 1, 2, 3, 4, 5, 6, 7 or 8 non 2'-0Me nucleotides.

[0026] In another aspect, the invention further provides a method for delivering the dsRNA
molecule of the invention to a specific target in a subject by subcutaneous or intravenous administration. The invention further provides the dsRNA molecules of the invention for use in a method for delivering said agents to a specific target in a subject by subcutaneous or intravenous administration.
BRIEF DESCRIPTION OF THE DRAWINGS

[0027]
This patent or application file contains at least one drawing executed in color.
Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0028]
Figs. 1-4 show in vivo efficacy of some exemplary dsRNAs of the invention in mice.

[0029]
Fig. 5-8 show in vivo efficacy of some exemplary dsRNA of the invention in non-human primates.
DETAILED DESCRIPTION

[0030] In one aspect, the invention provides a double-stranded RNA (dsRNA) agent capable of inhibiting expression of a target gene. Without limitations, the dsRNA agents of the invention can be substituted for the dsRNA molecules and can be used in RNA interference based gene silencing techniques, including, but not limited to, in vitro or in vivo applications.

[0031]
Generally, the dsRNA molecule comprises a sense strand (also referred to as passenger strand) and an antisense strand (also referred to as guide strand).
Each strand of the dsRNA molecule can range from 15-35 nucleotides in length. For example, each strand can be between, 17-35 nucleotides in length, 17-30 nucleotides in length, 25-35 nucleotides in length, 27-30 nucleotides in length, 17-23 nucleotides in length, 17-21 nucleotides in length, 17-19 nucleotides in length, 19-25 nucleotides in length, 19-23 nucleotides in length, 19-21 nucleotides in length, 21-25 nucleotides in length, or 21-23 nucleotides in length. Without limitations, the sense and antisense strands can be equal length or unequal length. For example, the sense strand and the antisense strand independently have a length of 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides.

[0032] In some embodiments, the antisense strand is of length 15-35 nucleotides. In some embodiments, the antisense strand is 15-35, 17-35, 17-30, 25-35, 27-30, 17-23, 17-21, 17-19, 19-25, 19-23, 19-21, 21-25, 21-25, or 21-23 nucleotides in length. For example, the antisense strand can be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 nucleotides in length. In some embodiments, the antisense strand is 19, 20, 21, 22, 23, 24 or 25 nucleotides in length. In some particular embodiments, the antisense strand is 23 nucleotides in length.

[0033]
Similar to the antisense strand, the sense strand can be, in some embodiments, 35 nucleotides in length. In some embodiments, the sense strand is 15-35, 17-35, 17-30, 25-35, 27-30, 17-23, 17-21, 17-19, 19-25, 19-23, 19-21, 21-25, 21-25, or 21-23 nucleotides in length. For example, the sense strand can be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 nucleotides in length. In some embodiments, the sense strand is 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length. In some particular embodiments, the sense strand is 21 nucleotides in length.

[0034] In some embodiments, the sense strand can be 15-35 nucleotides in length, and the antisense strand can be independent from the sense strand, 15-35 nucleotides in length. In some embodiments, the sense strand is 15-35, 17-35, 17-30, 25-35, 27-30, 17-23, 17-21, 17-19, 19-25, 19-23, 19-21, 21-25, 21-25, or 21-23 nucleotides in length, and the antisense strand is independently 15-35, 17-35, 17-30, 25-35, 27-30, 17-23, 17-21, 17-19, 19-25, 19-23, 19-21, 21-25, 21-25, or 21-23 nucleotides in length. For example, the sense and the antisense strand can be independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 nucleotides in length. In some embodiments, the sense strand and the antisense strand are independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length.
In some particular embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0035] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands; wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand; and wherein the sense strand does not comprise a glycol nucleic acid. In some embodiments, the sense and antisense strand the sense and the antisense strand can be independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably the sense strand and the antisense strand are independently 19, 20, 21, 22, 23, 24 or 25 nucleotides in length, more preferably, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0036] The sense strand and antisense strand typically form a double-stranded or duplex region. Without limitations, the duplex region of a dsRNA agent described herein can be 12-35 nucleotide pairs in length. For example, the duplex region can be between 14-35 nucleotide pairs in length, 17-30 nucleotide pairs in length, 25-35 nucleotides in length, 27-35 nucleotide pairs in length, 17-23 nucleotide pairs in length, 17-21 nucleotide pairs in length, 17-19 nucleotide pairs in length, 19-25 nucleotide pairs in length, 19-23 nucleotide pairs in length, 19- 21 nucleotide pairs in length, 21-25 nucleotide pairs in length, or 21-23 nucleotide pairs in length. In another example, the duplex region is selected from 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, and 27 nucleotide pairs in length. In some preferred embodiments, the duplex region is 18, 19, 20, 21, 22, 23, 24or 25 nucleotide pairs in length.

[0037] Thus, in some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; and wherein the sense strand does not comprise a glycol nucleic acid.
In some embodiments, the sense and antisense strand the sense and the antisense strand can be independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably the sense strand and the antisense strand are independently 19, 20, 21, 22, 23, 24 or 25 nucleotides in length, more preferably, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0038] As described herein, the dsRNA agent can comprise one or more non-natural nucleotides. For example, the dsRNA agent comprises no non-natural nucleotides or comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides. For clarification, by a "natural nucleotide" is meant a 2'-deoxy, 2'-OH, or 2'-0Me nucleotide with a nucleobase selected from adenine, guanine, cytosine, uracil, and thymine. In other words, a natural nucleotide has nucleobase selected from adenine, guanine, cytosine, uracil, and thymine, and a sugar selected from a 2'-deoxy, 2'-OH, or 2'-0Me ribose. By a "non-natural nucleotide" is meant a nucleotide having a nucleobase other than adenine, guanine, cytosine, uracil, or thymine, and/or a sugar other than a 2'-deoxy, 2'-OH, or 2'-0Me ribose. For clarity, when a non-natural nucleotide has a 2'-deoxy, 2'-OH, or 2'-0Me ribose sugar, then the nucleobase is not adenine, guanine, cytosine, uracil, or thymine.

[0039]
Exemplary nucleobases for the non-natural nucleotide include, but are not limited to, inosine, xanthine, hypoxanthine, nubularine, isoguanisine, tubercidine, and substituted or modified analogs of adenine, guanine, cytosine and uracil, such as 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5 -uracil (pseudouracil), 4-thi ouracil, 5 -hal ouracil, 5 -(2-aminopropyl)uracil, 5-amino allyl uracil, 8-halo, amino, thiol, thioalkyl, hydroxyl and other 8-substituted adenines and guanines, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine, 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine, dihydrouracil, 3-deaza-5-azacytosine, 2-aminopurine, 5-alkyluracil, 7-alkylguanine, 5-alkyl cytosine,7-deazaadenine, N6, N6-dimethyladenine, 2,6-diaminopurine, 5-amino-allyl-uracil, N3-methyluracil, substituted 1,2,4-triazoles, 2-pyridinone, 5-nitroindole, 3 -nitropyrrol e, 5 -m ethoxyuracil, uracil-5 -oxy aceti c acid, 5 -m ethoxy carb onylm ethyluracil, 5 -m ethy1-2-thi ouracil, 5 -m ethoxy carb onylm ethy1-2-thi ouracil, 5 -methylaminom ethy1-2-thi ouracil, 3 -(3 -amino-3 c arb oxypropyl)uracil, 3 -methyl cyto sine, 5 -methyl cyto sine, N4-acetyl cytosine, 2-thi ocyto sine, N6-m ethyl adenine, N6-i s op entyl adenine, 2-methylthio-N6-i sopentenyl adenine, N-methylguanines, or 0-alkylated bases. Further purines and pyrimidines include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in the Concise Encyclopedia of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, and those disclosed by Englisch et at., Angewandte Chemie, International Edition, 1991, 30, 613.

[0040] In some embodiments, nucleobase for the non-natural nucleotide is selected from the group consisting of inosine, xanthine, hypoxanthine, nubularine, isoguanisine, tubercidine, 2-(halo)adenine, 2-(alkyl)adenine, 2-(propyl)adenine, 2-(amino)adenine, 2-(aminoalkyll)adenine, 2-(aminopropyl)adenine, 2-(methylthio)-N6-(isopentenyl)adenine, 6-(alkyl)adenine, 6-(methyl)adenine, 7-(deaza)adenine, 8-(alkenyl)adenine, 8-(alkyl)adenine, 8-(alkynyl)adenine, 8-(amino)adenine, 8-(halo)adenine, 8-(hydroxyl)adenine, 8-(thioalkyl)adenine, 8-(thiol)adenine, N6-(i sopentyl)adenine, N6-(methyl)adenine, N6, N6-(dimethyl)adenine, 2-(alkyl)guanine,2-(propyl)guanine, 6-(alkyl)guanine, 6-(methyl)guanine, 7-(alkyl)guanine, 7-(methyl)guanine, 7-(deaza)guanine, 8-(alkyl)guanine, 8-(alkenyl)guanine, 8-(alkynyl)guanine, 8-(amino)guanine, 8-(halo)guanine, 8-(hydroxyl)guanine, 8-(thioalkyl)guanine, 8-(thiol)guanine, N-(methyl)guanine, (thi o)cytosine, 3 -(deaza)-5 -(aza)cytosine, 3 -(alkyl)cytosine, 3 -(methyl)cytosine, 5-(alkyl)cytosine, 5 -(alkynyl)cytosine, 5 -(halo)cytosine, 5 -(methyl)cytosine, -(propynyl)cytosine, 5 -(propynyl)cytosine, 5 -(trifluoromethyl)cytosine, 6-(azo)cytosine, N4-(acetyl)cytosine, 3 -(3 -amino-3 -carboxypropyl)uracil, 2-(thi o)uracil, 5 -(methyl)-2-(thio)uracil, 5 -(methylaminomethyl)-2-(thio)uracil, 4-(thio)uracil, 5 -(methyl)-4-(thio)uracil, 5 -(methylaminomethyl)-4-(thio)uracil, 5 -(methyl)-2,4-(dithio)uracil, 5 -(methylaminomethyl)-2,4-(dithio)uracil, 5 -(2-aminopropyl)uracil, 5 -(alkyl)uracil, 5 -(alkynyl)uracil, 5 -(allylamino)uracil, 5 -(aminoallyl)uracil, 5 -(aminoalkyl)uracil, 5 -(guanidiniumalkyl)uracil, 5 -(1,3 -di azol e- 1 -alkyl)uracil, 5 -(cyanoalkyl)uracil, 5 -(dialkylaminoalkyl)uracil, 5 -(dimethylaminoalkyl)uracil, 5 -(halo)uracil, 5 -(methoxy)uracil, uracil-5 -oxyacetic acid, 5 -(methoxycarbonylmethyl)-2-(thio)uracil, 5 -(methoxycarbonyl-methyl)uracil, 5 -(propynyl)uracil, 5 -(propynyl)uracil, 5 -(trifluoromethyl)uracil, 6-(azo)uracil, dihydrouracil, N3-(methyl)uracil, 5 -uracil (i.e., pseudouracil), 2-(thio)p seudouraci1,4-(thi o)p seudouraci1,2,4-(dithio)p suedouracil, 5 -(alkyl)pseudouracil, 5-(methyl)pseudouracil, 5 -(alkyl)-2-(thio)pseudouracil, 5 -(methyl)-2-(thio)pseudouracil, 5 -(alkyl)-4-(thio)pseudouracil, 5 -(methyl)-4-(thio)pseudouracil, 5 -(alkyl)-2,4-(dithio)pseudouracil, 5 -(methyl)-2,4-(dithio)pseudouracil, 1-substituted pseudouracil, 1-substituted 2(thio)-pseudouracil, 1-substituted 4-(thio)pseudouracil, 1-substituted 2,4-(dithio)pseudouracil, 1 -(aminocarbonylethyleny1)-pseudouracil, 1 -(aminocarbonylethyleny1)-2(thio)-pseudouracil, 1 -(aminocarb onyl ethyl eny1)-4-(thi o)p seudouracil, 1 -(aminocarb onyl ethyl eny1)-2,4-(dithi o)p seudouracil, 1 -(aminoalkylaminocarbonylethyleny1)-pseudouracil, 1 -(aminoalkylamino-carb onyl ethyl eny1)-2(thi o)-p seudouracil, 1 -(aminoalkylaminocarbonylethyleny1)-4-(thio)pseudouracil, 1-(aminoalkylaminocarbonylethyleny1)-2,4-(dithio)pseudouracil, 1,3 -(diaza)-2-(oxo)-phenoxazin-l-yl, 1-(aza)-2-(thio)-3 -(aza)-phenoxazin- 1 -yl, 1,3 -(diaza)-2-(oxo)-phenthiazin- 1 -yl, 1 -(aza)-2-(thio)-3 -(aza)-phenthiazin- 1 -yl, 7-substituted 1,3 -(di aza)-2-(oxo)-phenoxazin- 1 -yl, 7-substituted 1 -(aza)-2-(thio)-3 -(aza)-phenoxazin-1 -yl, 7-substituted 1,3 -(diaza)-2-(oxo)-phenthiazin- 1 -yl, 7-substituted 1 -(aza)-2-(thio)-3 -(aza)-phenthiazin- 1 -yl, 7-(aminoalkylhydroxy)- 1,3 -(diaza)-2-(oxo)-phenoxazin- 1 -yl, 7-(aminoalkylhydroxy)- 1 -(aza)-2-(thio)-3 -(aza)-phenoxazin- 1 -yl, 7-(aminoalkylhydroxy)- 1,3 -(diaza)-2-(oxo)-phenthiazin- 1 -yl, 7-(aminoalkylhydroxy)- 1 -(aza)-2-(thio)-3 -(aza)-phenthiazin- 1 -yl, 7-(guani diniumalkylhydroxy)- 1,3 -(di aza)-2-(oxo)-phenoxazin- 1 -yl, 7-(guani diniumalkylhydroxy)- 1 -(aza)-2-(thio)-3 -(aza)-phenoxazin- 1 -yl, 7-(guani diniumalkyl-hydroxy)- 1,3 -(di aza)-2-(oxo)-phenthi azin- 1 -yl, 7-(guani diniumal kylhydroxy)- 1 -(aza)-2-(thio)-3 -(aza)-phenthiazin- 1 -yl, 1,3 , 5 -(triaza)-2,6-(dioxa)-naphthalene, inosine, xanthine, hypoxanthine, nubularine, tubercidine, isoguanisine, inosinyl, 2-aza-inosinyl, 7-deaza-inosinyl, nitroimidazolyl, nitropyrazolyl, nitrobenzimidazolyl, nitroindazolyl, aminoindolyl, pyrrolopyrimidinyl, 3 -(methyl)i socarb ostyrilyl, 5-(methyl)isocarbostyrilyl, 3 -(methyl)-7-(propynyl)isocarbostyrilyl, 7-(aza)indolyl, 6-(methyl)-7-(aza)indolyl, imidizopyridinyl, 9-(methyl)-imidizopyridinyl, pyrrolopyrizinyl, isocarbostyrilyl, 7-(propynyl)isocarbostyrilyl, propyny1-7-(aza)indolyl, 2,4,5-(trimethyl)phenyl, 4-(methyl)indolyl, 4,6-(dimethyl)indolyl, phenyl, napthalenyl, anthracenyl, phenanthracenyl, pyrenyl, stilbenyl, tetracenyl, pentacenyl, difluorotolyl, 4-(fluoro)-6-(methyl)benzimidazole, 4-(methyl)benzimidazole, 6-(azo)thymine, 2-pyridinone, 5-nitroindole, 3-nitropyrrole, 6-(aza)pyrimidine, 2-(amino)purine, 2,6-(diamino)purine, 5-substituted pyrimidines, N2-substituted purines, N6-substituted purines, 06-substituted purines, substituted 1,2,4-triazoles, and any 0-alkylated or N-alkylated derivatives thereof.

[0041]
Some exemplary non-natural nucleotides include, but are not limited to, acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2' -0-allyl, 2'-C-allyl, 2' -fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.

[0042]
Thus, in some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2' -deoxy modifications on the sense and/or antisense strands; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
In some embodiments, the sense and antisense strand the sense and the antisense strand can be independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably the sense strand and the antisense strand are independently 19, 20, 21, 22, 23, 24 or 25 nucleotides in length, more preferably, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2' -methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.

Central region

[0043] As described herein, the dsRNA can comprise at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the sense strand and/or the antisense strand. As used herein, a "central region"
of a strand refers to positions 5-17, e.g., positions 6-16, positions 6-15, positions 6-14, positions 6-13, positions 6-12, positions 7-15, positions 7-14, positions 7-13, positions, 7-12, positions 8-16, positions 8-15, positions 8-14, positions 8-13, positions 8-12, positions 9-16, positions 9-15, positions 9-14, positions 9-13, positions 9-12, positions 10-16, positions 10-15, positions 10-14, positions 10-13 or positions 10-12, counting from the 5'-end of the strand. For example, the central region of a strand means positions 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 of the strand. A preferred central region for the sense strand is positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, counting from the 5'-end of the sense strand. A more preferred central region for the sense strand is positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand.
A preferred central region for the antisense strand is positions 9, 10, 11, 12, 13, 14, 15 16 and 17, counting from 5'-end of the antisense strand. A more preferred central region for the antisense strand is positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand.

[0044] Accordingly, at least one of the sense stand and the antisense can comprise at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modification in positions 5-17, e.g., positions 6-16, positions 6-15, positions 6-14, positions 6-13, positions 6-12, positions 7-15, positions 7-14, positions 7-13, positions, 7-12, positions 8-16, positions 8-15, positions 8-14, positions 8-13, positions 8-12, positions 9-16, positions 9-15, positions 9-14, positions 9-13, positions 9-12, positions 10-16, positions 10-15, positions 10-14, positions 10-13 or positions 10-12, counting from the 5'-end of the sense strand or the antisense strand.

[0045] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14 (preferably positions 7, 8, 9, 10, 11, 12 and 13) of the sense strand, counting from the 5'-end of the sense strand, and/or at positions 9, 10, 11, 12, 13, 14, 15 16 and 17 (preferably positions 10, 11, 12, 13, 14, 15 and 16) of the antisense strand counting from 5'-end of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0046] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14 (preferably positions 7, 8, 9, 10, 11, 12 and 13) of the sense strand, counting from the 5'-end of the sense strand, and/or at positions 9, 10, 11, 12, 13, 14, 15 16 and 17 (preferably positions 10, 11, 12, 13, 14, 15 and 16) of the antisense strand counting from 5'-end of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0047] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14 (preferably positions 7, 8, 9, 10, 11, 12 and 13) of the sense strand, counting from the 5'-end of the sense strand, and/or at positions 9, 10, 11, 12, 13, 14, 15 16 and 17 (preferably positions 10, 11, 12, 13, 14, 15 and 16) of the antisense strand counting from 5'-end of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.

[0048] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the sense strand comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the sense strand. In some embodiments, the sense strand is 18-30 nucleotides in length and comprises at least two 2'-deoxy modifications in a central region, e.g., positions 7, 8, 9, 10, 11, 12 and 13 of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0049] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the sense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the sense strand. In some embodiments, the sense strand is 18-30 nucleotides in length and comprises at least two 2'-deoxy modifications in a central region, e.g., positions 7, 8, 9, 10, 11, 12 and 13 of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0050] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the sense comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the sense strand. In some embodiments, the sense strand is 18-30 nucleotides in length and comprises at least two 2'-deoxy modifications in a central region, e.g., positions 7, 8, 9, 10, 11, 12 and 13 of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.

[0051] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the antisense strand comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand. In some embodiments, the sense strand is 18-30 nucleotides in length and comprises at least two 2'-deoxy modifications in a central region, e.g., positions 10, 11, 12, 13, 14, 15, and 16 of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0052] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the antisense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand. In some embodiments, the antisense strand is 18-30 nucleotides in length and comprises at least two 2'-deoxy modifications in a central region, e.g., positions 10, 11, 12, 13, 14, 15, and 16 of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0053] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the antisense comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand. In some embodiments, the antisense strand is 18-30 nucleotides in length and comprises at least two 2'-deoxy modifications in a central region, e.g., positions 10, 11, 12, 13, 14, 15 and 16 of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.

[0054] The antisense strand comprises one at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand, and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand

[0055] As used herein, a "non-central region" means a region of a strand that is not a central region. For example, the non-central region can be a terminal region, e.g., 1, 2, 3, 4, 5 or 6 nucleotides from either end of the strand.

[0056] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the antisense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand, and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand. In some embodiments, the antisense strand is 18-30 nucleotides in length and comprises at least one 2'-deoxy modifications in a central region, e.g., positions 10, 11, 12, 13, 14, 15, and 16 of the antisense strand, and at least one 2'-deoxy in positions 1, 2, 3, 4, 5 or 6 from either one of the 5'-end or the 3'-end.
In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0057] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the antisense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand. In some embodiments, the antisense strand is 18-30 nucleotides in length and comprises at least one 2'-deoxy modifications in a central region, e.g., positions 10, 11, 12, 13, 14, 15, and 16 of the antisense strand, and at least one 2'-deoxy in positions 1, 2, 3, 4, 5 or 6 from either one of the 5'-end or the 3'-end. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0058] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the antisense comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand. In some embodiments, the antisense strand is 18-30 nucleotides in length and comprises at least one 2'-deoxy modifications in a central region, e.g., positions 10, 11, 12, 13, 14, 15, and 16 of the antisense strand, and at least one 2'-deoxy in positions 1, 2, 3, 4, 5 or 6 from either one of the 5'-end or the 3'-end. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.

[0059] In some embodiments, the antisense strand comprises at least five 2'-deoxy modifications. For example, the antisense strand comprises at least five 2'-deoxy modifications and wherein the 2'-deoxy modifications are at positions 2, 5, 7, 12 and 14, counting from 5' -end of the antisense strand.

[0060] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the antisense strand comprises at least five, at least six, at least seven or more, 2'-deoxy modifications, e.g., at positions 2, 5, 7, 12 and 14, counting from 5-'end of the antisense strand. In some embodiments, the antisense strand is 18-23 nucleotides in length and comprises at least five 2'-deoxy modifications, e.g., at positions 2, 5, 7, 12 and 14, counting from 5'-end of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0061] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the antisense strand comprises at least five, at least six, at least seven or more, 2'-deoxy modifications, e.g., at positions 2, 5, 7, 12 and 14, counting from 5-'end of the antisense strand. In some embodiments, the antisense strand is 18-23 nucleotides in length and comprises at least five 2'-deoxy modifications, e.g., at positions 2, 5, 7, 12 and 14, counting from 5'-end of the antisense strand.
In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0062] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the antisense strand comprises at least five, at least six, at least seven or more, 2'-deoxy modifications, e.g., at positions 2, 5, 7, 12 and 14, counting from 5-'end of the antisense strand. In some embodiments, the antisense strand is 18-23 nucleotides in length and comprises at least five 2'-deoxy modifications, e.g., at positions 2, 5, 7, 12 and 14, counting from 5'-end of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.

[0063] In some embodiments, the dsRNA comprises at least three 2'-deoxy modifications, wherein at least two of the 2'-deoxy modifications are in the antisense strand and at least one of the 2'-deoxy modification is in the sense strand. For example, the antisense strand comprises at least two 2'-deoxy modifications and the sense strand comprises at least one 2'-deoxy modification, wherein the 2'-deoxy modifications are at positions 2 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at position 11 of the sense strand, counting from 5'-end of the sense strand.

[0064] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;

wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein at least two of the 2'-deoxy modifications are in the antisense strand, and at least one of the 2'-deoxy modification is in the sense strand. In some embodiments, the antisense strand comprises at least two 2'-deoxy modifications and the sense strand comprises at least one 2'-deoxy modification, wherein the 2'-deoxy modifications are at positions 2 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at position 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0065] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate intemucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein at least two of the 2'-deoxy modifications are in the antisense strand, and at least one of the 2'-deoxy modification is in the sense strand.
In some embodiments, the antisense strand comprises at least two 2'-deoxy modifications and the sense strand comprises at least one 2'-deoxy modification, wherein the 2'-deoxy modifications are at positions 2 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at position 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0066] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate intemucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein at least two of the 2'-deoxy modifications are in the antisense strand, and at least one of the 2'-deoxy modification is in the sense strand. In some embodiments, the antisense strand comprises at least two 2'-deoxy modifications and the sense strand comprises at least one 2'-deoxy modification, wherein the 2'-deoxy modifications are at positions 2 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at position 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.

[0067] In some embodiments, the dsRNA comprises at least five 2'-deoxy modifications, wherein at least three of the 2'-deoxy modifications are in the antisense strand and at least two of the 2'-deoxy modifications are in the sense strand. For example, the antisense strand comprises at least three 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modification, wherein the 2'-deoxy modifications are at positions 2, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand.

[0068] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein at least three of the 2'-deoxy modifications are in the antisense strand, and at least two of the 2'-deoxy modifications are in the sense strand. In some embodiments, the antisense strand comprises at least three 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modification, wherein the 2'-deoxy modifications are at positions 2, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0069] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein at least three of the 2'-deoxy modifications are in the antisense strand, and at least two of the 2'-deoxy modifications are in the sense strand. In some embodiments, the antisense strand comprises at least three 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modifications, wherein the 2'-deoxy modifications are at positions 2, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0070] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein at least three of the 2'-deoxy modifications are in the antisense strand, and at least two of the 2'-deoxy modifications are in the sense strand.
In some embodiments, the antisense strand comprises at least three 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modifications, wherein the 2'-deoxy modifications are at positions 2, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.

[0071] In some embodiments, the dsRNA comprises at least seven 2'-deoxy modifications, wherein at least five of the 2'-deoxy modifications are in the antisense strand and at least two of the 2'-deoxy modification are in the sense strand. For example, the antisense strand comprises at least five 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modifications, wherein the 2'-deoxy modifications are at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand.

[0072] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate intemucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least seven 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA
molecule has a double stranded (duplex) region of between 18 to 25 base pairs;
wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein at least five of the 2'-deoxy modifications are in the antisense strand, and at least two of the 2'-deoxy modification is in the sense strand. In some embodiments, the antisense strand comprises at least five 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modifications, wherein the 2'-deoxy modifications are at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0073] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate intemucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least seven 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs;
wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein at least five of the 2'-deoxy modifications are in the antisense strand, and at least two of the 2'-deoxy modifications are in the sense strand. In some embodiments, the antisense strand comprises at least five 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modification, wherein the 2'-deoxy modifications are at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand.
In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[0074] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate intemucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein at least five of the 2'-deoxy modifications are in the antisense strand, and at least two of the 2'-deoxy modifications are in the sense strand.
In some embodiments, the antisense strand comprises at least five 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modifications, wherein the 2'-deoxy modifications are at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.

[0075] A wide variety of entities can be coupled to the dsRNA agents described herein.
Preferred moieties are ligands, which are coupled, preferably covalently, either directly or indirectly via an intervening tether. Generally, a ligand alters the distribution, targeting or lifetime of the molecule, e.g., a dsRNA described herein, into which it is incorporated. In some embodiments a ligand provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, receptor e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand.
Ligands providing enhanced affinity for a selected target are also termed targeting ligands herein.

[0076] Some ligands can have endosomolytic properties. The endosomolytic ligands promote the lysis of the endosome and/or transport of the composition of the invention, or its components, from the endosome to the cytoplasm of the cell. The endosomolytic ligand may be a polyanionic peptide or peptidomimetic which shows pH-dependent membrane activity and fusogenicity. In some embodiments, the endosomolytic ligand assumes its active conformation at endosomal pH. The "active" conformation is that conformation in which the endosomolytic ligand promotes lysis of the endosome and/or transport of the composition of the invention, or its components, from the endosome to the cytoplasm of the cell. Exemplary endosomolytic ligands include the GALA peptide (Subbarao et al., Biochemistry, 1987, 26:
2964-2972, which is incorporated by reference in its entirety), the EALA peptide (Vogel et al., J. Am. Chem. Soc., 1996, 118: 1581-1586, which is incorporated by reference in its entirety), and their derivatives (Turk et al., Biochem. Biophys. Acta, 2002, 1559: 56-68, which is incorporated by reference in its entirety). In some embodiments, the endosomolytic component may contain a chemical group (e.g., an amino acid) which will undergo a change in charge or protonation in response to a change in pH. The endosomolytic component may be linear or branched.

[0077] Ligands can improve transport, hybridization, and specificity properties and can also improve nuclease resistance of the resultant natural or modified oligoribonucleotide, or a polymeric molecule comprising any combination of monomers described herein and/or natural or modified ribonucleotides.

[0078] Ligands in general can include therapeutic modifiers, e.g., for enhancing uptake;
diagnostic compounds or reporter groups e.g., for monitoring distribution;
cross-linking agents;
and nuclease-resistance conferring moieties. General examples include lipids, steroids, vitamins, sugars, proteins, peptides, polyamines, and peptide mimics.

[0079] Ligands can include a naturally occurring substance, such as a protein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), high-density lipoprotein (HDL), or globulin); a carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid); or a lipid. The ligand may also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid, an oligonucleotide (e.g. an aptamer).
Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolide) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacryllic acid), N-isopropylacrylamide polymers, or polyphosphazine. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.

[0080] Ligands can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid or protein, e.g., an antibody, that binds to a specified cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, multivalent fucose, glycosylated polyamino acids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, biotin, an RGD
peptide, an RGD peptide mimetic or an aptamer. Table 2 shows some examples of targeting ligands and their associated receptors.

[0081] Other examples of ligands include dyes, intercalating agents (e.g.
acridines), cross-linkers (e.g. psoralen, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases or a chelating agent (e.g. EDTA), lipophilic molecules, e.g., cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-0(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid,03-(oleoyl)lithocholic acid, 03-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine)and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG]2, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g.
biotin), transport/absorption facilitators (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or AP.

[0082] Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a cancer cell, endothelial cell, or bone cell. Ligands may also include hormones and hormone receptors. They can also include non-peptide species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, multivalent fucose, or aptamers.
The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP
kinase, or an activator of NF-KB.

[0083] The ligand can be a substance, e.g., a drug, which can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cell's cytoskeleton, e.g., by disrupting the cell's microtubules, microfilaments, and/or intermediate filaments. The drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.

[0084] The ligand can increase the uptake of the dsRNA into the cell by activating an inflammatory response, for example. Exemplary ligands that would have such an effect include tumor necrosis factor alpha (TNF-alpha), interleukin-1 beta, or gamma interferon.

[0085] In some embodiments, the ligand is a lipid or lipid-based molecule.
Such a lipid or lipid-based molecule preferably binds a serum protein, e.g., human serum albumin (HSA).
An HSA binding ligand allows for distribution of the conjugate to a target tissue, e.g., a non-kidney target tissue of the body. For example, the target tissue can be the liver, including parenchymal cells of the liver. Other molecules that can bind HSA can also be used as ligands.
For example, naproxen or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, and/or (c) can be used to adjust binding to a serum protein, e.g., HSA. A
lipid based ligand can be used to modulate, e.g., control the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A
lipid or lipid-based ligand that binds to HSA less strongly can be used to target the conjugate to the kidney.

[0086] In a preferred embodiment, the lipid based ligand binds HSA.
Preferably, it binds HSA with a sufficient affinity such that the conjugate will be preferably distributed to a non-kidney tissue. However, it is preferred that the affinity not be so strong that the HSA-ligand binding cannot be reversed.

[0087] In another preferred embodiment, the lipid based ligand binds HSA
weakly or not at all, such that the conjugate will be preferably distributed to the kidney.
Other moieties that target to kidney cells can also be used in place of or in addition to the lipid based ligand.

[0088] In some embodiments, the ligand is a moiety, e.g., a vitamin, which is taken up by a target cell, e.g., a proliferating cell. These are particularly useful for treating disorders characterized by unwanted cell proliferation, e.g., of the malignant or non-malignant type, e.g., cancer cells. Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include B vitamins, e.g., folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by cancer cells. Also included are HAS, low density lipoprotein (LDL) and high-density lipoprotein (HDL).

[0089] In another aspect, the ligand is a cell-permeation agent, preferably a helical cell-permeation agent. Preferably, the agent is amphipathic. An exemplary agent is a peptide such as tat or antennapedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids.
The helical agent is preferably an alpha-helical agent, which preferably has a lipophilic and a lipophobic phase.

[0090] The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long. A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (e.g., consisting primarily of Tyr, Trp or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or cross-linked peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS). An exemplary hydrophobic MTS-containing peptide is RFGF
having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 1). An RFGF
analogue (e.g., amino acid sequence AALLPVLLAAP (SEQ ID NO: 2)) containing a hydrophobic MTS can also be a targeting moiety. The peptide moiety can be a "delivery"
peptide, which can carry large polar molecules including peptides, oligonucleotides, and protein across cell membranes. For example, sequences from the HIV Tat protein (GRKKRRQRRRPPQ (SEQ ID NO: 3)) and the Drosophila Antennapedia protein (RQIKIWFQNRRMKWKK (SEQ ID NO: 4) have been found to be capable of functioning as delivery peptides. A peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature, 354:82-94, 1991, which is incorporated by reference in its entirety). Preferably the peptide or peptidomimetic tethered to an iRNA
agent via an incorporated monomer unit is a cell targeting peptide such as an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized. An RGD peptide moiety can be used to target a tumor cell, such as an endothelial tumor cell or a breast cancer tumor cell (Zitzmann et al., Cancer Res., 62:5139-43, 2002, which is incorporated by reference in its entirety). An RGD
peptide can facilitate targeting of an iRNA agent to tumors of a variety of other tissues, including the lung, kidney, spleen, or liver (Aoki et al., Cancer Gene Therapy 8:783-787, 2001, which is incorporated by reference in its entirety). Preferably, the RGD peptide will facilitate targeting of an iRNA agent to the kidney. The RGD peptide can be linear or cyclic, and can be modified, e.g., glycosylated or methylated to facilitate targeting to specific tissues.
For example, a glycosylated RGD peptide can deliver an iRNA agent to a tumor cell expressing avB3 (Haubner et al., Jour. Nucl. Med., 42:326-336, 2001, which is incorporated by reference in its entirety).
Peptides that target markers enriched in proliferating cells can be used. For example, RGD
containing peptides and peptidomimetics can target cancer cells, in particular cells that exhibit an integrin. Thus, one could use RGD peptides, cyclic peptides containing RGD, RGD
peptides that include D-amino acids, as well as synthetic RGD mimics. In addition to RGD, one can use other moieties that target the integrin ligand. Generally, such ligands can be used to control proliferating cells and angiogenesis. Preferred conjugates of this type ligands that targets PECAM-1, VEGF, or other cancer gene, e.g., a cancer gene described herein.

[0091] A "cell permeation peptide" is capable of permeating a cell, e.g., a microbial cell, such as a bacterial or fungal cell, or a mammalian cell, such as a human cell.
A microbial cell-permeating peptide can be, for example, an a-helical linear peptide (e.g., LL-37 or Ceropin P1), a disulfide bond-containing peptide (e.g., a -defensin, 0-defensin or bactenecin), or a peptide containing only one or two dominating amino acids (e.g., PR-39 or indolicidin). A cell permeation peptide can also include a nuclear localization signal (NLS). For example, a cell permeation peptide can be a bipartite amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-1 gp41 and the NLS of SV40 large T antigen (Simeoni et al., Nucl. Acids Res. 31:2717-2724, 2003, which is incorporated by reference in its entirety).

[0092] In some embodiments, a targeting peptide can be an amphipathic a-helical peptide.
Exemplary amphipathic a-helical peptides include, but are not limited to, cecropins, lycotoxins, paradaxins, buforin, CPF, bombinin-like peptide (BLP), cathelicidins, ceratotoxins, S. clava peptides, hagfish intestinal antimicrobial peptides (HFIAPs), magainines, brevinins-2, dermaseptins, melittins, pleurocidin, H2A peptides, Xenopus peptides, esculentinis-1, and caerins. A number of factors will preferably be considered to maintain the integrity of helix stability. For example, a maximum number of helix stabilization residues will be utilized (e.g., leu, ala, or lys), and a minimum number of helix destabilization residues will be utilized (e.g., proline, or cyclic monomeric units. The capping residue will be considered (for example Gly is an exemplary N-capping residue and/or C-terminal amidation can be used to provide an extra H-bond to stabilize the helix. Formation of salt bridges between residues with opposite charges, separated by i 3, or i 4 positions can provide stability. For example, cationic residues such as lysine, arginine, homo-arginine, ornithine or histidine can form salt bridges with the anionic residues glutamate or aspartate.

[0093] Peptide and peptidomimetic ligands include those having naturally occurring or modified peptides, e.g., D or L peptides; a, (3, or y peptides; N-methyl peptides; azapeptides;
peptides having one or more amide, i.e., peptide, linkages replaced with one or more urea, thiourea, carbamate, or sulfonyl urea linkages; or cyclic peptides.

[0094] The targeting ligand can be any ligand that is capable of targeting a specific receptor. Examples are: folate, GalNAc, galactose, mannose, mannose-6P, clusters of sugars such as GalNAc cluster, mannose cluster, galactose cluster, or an aptamer. A
cluster is a combination of two or more sugar units. The targeting ligands also include integrin receptor ligands, Chemokine receptor ligands, transferrin, biotin, serotonin receptor ligands, PSMA, endothelin, GCPII, somatostatin, LDL and HDL ligands. The ligands can also be based on nucleic acid, e.g., an aptamer. The aptamer can be unmodified or have any combination of modifications disclosed herein.

[0095] Endosomal release agents include imidazoles, poly or oligoimidazoles, PEIs, peptides, fusogenic peptides, polycarboxylates, polycations, masked oligo or poly cations or anions, acetals, polyacetals, ketals/polyketals, orthoesters, polymers with masked or unmasked cationic or anionic charges, dendrimers with masked or unmasked cationic or anionic charges.

[0096] PK modulator stands for pharmacokinetic modulator. PK modulator include lipophiles, bile acids, steroids, phospholipid analogues, peptides, protein binding agents, PEG, vitamins etc. Exemplary PK modulator include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglyceride, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin etc. Oligonucleotides that comprise a number of phosphorothioate linkages are also known to bind to serum protein, thus short oligonucleotides, e.g. oligonucleotides of about 5 bases, 10 bases, 15 bases or 20 bases, comprising multiple of phosphorothioate linkages in the backbone are also amenable to the present invention as ligands (e.g. as PK modulating ligands).

[0097] In addition, aptamers that bind serum components (e.g. serum proteins) are also amenable to the present invention as PK modulating ligands.

[0098] Other ligand conjugates amenable to the invention are described in U.S. Patent Applications USSN: 10/916,185, filed August 10, 2004; USSN: 10/946,873, filed September 21, 2004; USSN: 10/833,934, filed August 3, 2007; USSN: 11/115,989 filed April 27, 2005 and US SN: 11/944,227 filed November 21, 2007, which are incorporated by reference in their entireties for all purposes.

[0099] When two or more ligands are present, the ligands can all have same properties, all have different properties or some ligands have the same properties while others have different properties. For example, a ligand can have targeting properties, have endosomolytic activity or have PK modulating properties. In a preferred embodiment, all the ligands have different properties.

[00100] Ligands can be coupled to the dsRNA at various places, for example, 3' -end, 5' -end, and/or at an internal position of the sense and/or antisense strand. In preferred embodiments, the ligand is attached to the sense and/or antisense strand of the dsRNA via a linker or tether. The ligand or tethered ligand can be present on a monomer when said monomer is incorporated into the growing strand. In some embodiments, the ligand may be incorporated via coupling to a "precursor" monomer after said "precursor" monomer has been incorporated into the growing strand. For example, a monomer having, e.g., an amino-terminated tether (i.e., having no associated ligand), e.g., TAP-(CH2),,NH2 may be incorporated into a growing oligonucleotide strand. In a subsequent operation, i.e., after incorporation of the precursor monomer into the strand, a ligand having an electrophilic group, e.g., a pentafluorophenyl ester or aldehyde group, can subsequently be attached to the precursor monomer by coupling the electrophilic group of the ligand with the terminal nucleophilic group of the precursor monomer's tether.

[00101] In another example, a monomer having a chemical group suitable for taking part in Click Chemistry reaction may be incorporated e.g., an azide or alkyne terminated tether/linker.
In a subsequent operation, i.e., after incorporation of the precursor monomer into the strand, a ligand having complementary chemical group, e.g. an alkyne or azide can be attached to the precursor monomer by coupling the alkyne and the azide together.

[00102] The ligands can be attached to one or both strands. In some embodiments, a dsRNA
described herein comprises a ligand conjugated to the sense strand. In some embodiments, a dsRNA described herein comprises a ligand conjugated to the antisense strand.

[00103] In some embodiments, ligand can be conjugated to nucleobases, sugar moieties, or internucleosidic linkages of nucleic acid molecules. Conjugation to purine nucleobases or derivatives thereof can occur at any position including, endocyclic and exocyclic atoms. In some embodiments, the 2-, 6-, 7-, or 8-positions of a purine nucleobase are attached to a conjugate moiety. Conjugation to pyrimidine nucleobases or derivatives thereof can also occur at any position. In some embodiments, the 2-, 5-, and 6-positions of a pyrimidine nucleobase can be substituted with a conjugate moiety. Conjugation to sugar moieties of nucleosides can occur at any carbon atom. Example carbon atoms of a sugar moiety that can be attached to a conjugate moiety include the 2', 3', and 5' carbon atoms. The l' position can also be attached to a conjugate moiety, such as in an abasic residue. Internucleosidic linkages can also bear conjugate moieties. For phosphorus-containing linkages (e.g., phosphodiester, phosphorothioate, phosphorodithioate, phosphoroamidate, and the like), the conjugate moiety can be attached directly to the phosphorus atom or to an 0, N, or S atom bound to the phosphorus atom. For amine- or amide-containing internucleosidic linkages (e.g., PNA), the conjugate moiety can be attached to the nitrogen atom of the amine or amide or to an adjacent carbon atom.

[00104] In some embodiments, the ligand is conjugated to the sense strand. As described herein, the ligand can be conjugated at the 3'-end, 5'-end or at an internal position of the sense strand. In some embodiments, the ligand is conjugated to the 3'-end of the sense strand.
Further, the ligand can be conjugated to a nucleobase, sugar moiety or internucleotide linkage of the sense strand.

[00105] Any suitable ligand in the field of RNA interference may be used, although the ligand is typically a carbohydrate e.g. monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, polysaccharide.

[00106] Linkers that conjugate the ligand to the nucleic acid include those discussed above.
For example, the ligand can be one or more carbohydrates, e.g., GalNAc (N-acetylgalactosamine) derivatives attached through a monovalent, bivalent or trivalent branched linker.

[00107] In some embodiments, the dsRNA of the invention is conjugated to a bivalent and trivalent branched linkers include the structures shown in any of Formula (IV) ¨

.4 p2A_Q2A_R2A i_q2A T2A_CA /I/ p3 A_Q 3A _R3A 1__ T3A_L3A
q3A
I. p2 B_Q2B _R2 B I_ T2B_L2B \I\ p3 B_Q3 B_R3 B i_ T36_06 q2 B q3 B
Formula (IV) Formula (V) [ [ H pp55:Q55: R_ 55: 1_ T5A_ OA
p4A_Q4A_R4A 1 46i_ -OA_ OA :
q p4B _Q4B _R4B i_ -1-4.B_OB
q4B q5A p5B_Q5B_R5B i_T5B_L5B
q5B
K 11-5c-1-5c q Formula (VI) Formula (VII) .
, or , wherein:
q2A, q2B, q3A, q3B, q4A, q4B, q5A, q5B and 5C
q represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;
p2A, p2B, p3A, p3B, p4A, p4B, p5A, p5B, p5C, T2A, T2B, T3A, T3B, T4A, T4B, T5A, T5B, T5C
are each independently for each occurrence absent, CO, NH, 0, S, OC(0), NHC(0), CH2, CH2NH or CH20;
Q2A, Q2B, Q3A, Q3B, Q4A, Q4B, Q5A, Q5B, y e-s5C
are independently for each occurrence absent, alkylene, substituted alkylene wherein one or more methylenes can be interrupted or terminated by one or more of 0, S, S(0), S02, N(RN), C(R')=C(R"), CC or C(0);
R2A, R2h, R3A, R3h, R4A, R4a, R5A, Rsh, Rsc are each independently for each occurrence absent, NH, 0, S, CH2, C(0)0, C(0)NH, NHCH(Ra)C(0), -C(0)-CH(Ra)-NH-, ,L
CO, CH=N-0, sr-1\11--, H , S-S
\Prjor heterocyclyl;
L2A, oh, oA, oh, 0A, oh, L5A, ch and cc represent the ligand; i.e. each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; and Ra is H or amino acid side chain.

[00108] Trivalent conjugating GalNAc derivatives are particularly useful for use with dsRNA agents described herein for inhibiting the expression of a target gene, such as those of Formula (VII):

p5A_Q5A_R5A 1_1-5A_L5A
q5A
[ p5clp_Qc5B5_Q_R5B5_cR5B1_1-5B_L5BCI5B

ji-5C-1-5C
q Formula (VII) , wherein L5A, L5B and L5C represent a monosaccharide, such as GalNAc derivative.

[00109] Examples of suitable bivalent and trivalent branched linker groups conjugating GalNAc derivatives include, but are not limited to, the following compounds:
O
HO H

AcHN 0 -') HO (PH
H H
l'r AcHN 0 0 0 HOZI-1 ) HO ---------.\--C) NN0 AcHN H H
0 , Ligand 1 HO HO
HOFicif....) N..}:) HO HO H ...,...
HOH¨c-C) I
O., 0(:),.0N.___<\../J'PP/
HO HO HO (:) HOHc........\H .----I
",.., N
H , Ligand 2 OH
H00,...\,.._ HO......\...
0 HO 0 NHAc NHAc \----\
H
OH OH
W
HO......\...... r A' H00.\.,....

HO 0c)0"--i HO 00,-/n NHAc , NHAc , Ligand 3 Ligand 4 HO H HO OH
H
HOOrN\ HO OH NHAc NHAc 0 õ
HO OH JVlAf Fl s.1Ø \...1\ . 0 )7' / NHAcHo 0H
HO,õ\2......\,/NH
HO.....\2.0/j NHAc 0 NHAc , Ligand 5 Ligand 6 O
HO H

HO0.....õ,-,Ø---.......õ0,.....õ--...N1,01 AcHN H
HO C)F1 C) ...._;____....\-0 /0õ,õõ.=.,0..-0.õ...,.,-,N 0.,,..,..-,-, HO
AcHN H

) O
HO H

OccON0 HO
AcHN H ,or Ligand 7 HO C)1-1 0...)1...,.N.Ni \
HO
AcHN H 0 HO C)1-1 ON)c H
HO N---....---...----...-Nya....----..."'w AcHN

HO:) 0...% HO , ,-/NmN-11Ø.-AcHN H
Ligand 8.

[00110] In some embodiments, a dsRNA described herein comprises Ligand 1, i.e., a ligand having the following structure:
HO .._....1 HO---r- ( NN0 AcHN 0 AcHN 0 0 0 HOZ _El ) HO -------..\. N N 0 AcHN H H
0 .
1001111 In some embodiments, a dsRNA described herein comprises a ligand described in US Patent No. 5,994,517 or US Patent No. 6,906,182, content of each of which is incorporated herein by reference in its entirety.
[00112] In some embodiments, the ligand can be a tri-antennary ligand described in Figure 3 of US Patent No. 6,906,182. For example, a dsRNA described herein can comprise a ligand selected from the following tri-antennary ligands:

X. w, NH, 0, SI
Tri-entennery le-PorS -Z 4*, Nli-alkyl, Nlia, 0-, S-X IN.-A-t*N-4-.*A ,,,,,,k.----,,, ,i ----- , $ )y A - NH, CH2, O., S
r z n - 2 to 17 2-carbon mks Carbohy&ate ,Nr--A ------- 1------x,f \ Z

trisghetgroabmpriethyinietematomimethana P
\¨)rYIN'A k 1-7-4ANZ---z rt .õ4:1"N4 j 0 4/nO. N'ts-NeY'' '%k%nte-7 dightutanyr 0 =H
. rThr.4%('FlkP\Z. , j[

11 imaratyl 11 ryNi-s-1.2 .4 d õ..,..., H
teH
e'N'sei`4%'N.,4%-Nk., 9 , AdiN'e\) -IL . HOu1QH
js.r.fr 0 ,I1 o-----N,----,,e-N,.....--c. oti ,c HO liN mõtkc I'M tq H
moto =Ci oo [00113] The ligand may be attached to the polynucleotide via a carrier. The carriers include (i) at least one "backbone attachment point," preferably two "backbone attachment points" and (ii) at least one "tethering attachment point." A "backbone attachment point"
as used herein refers to a functional group, e.g. a hydroxyl group, or generally, a bond available for, and that is suitable for incorporation of the carrier into the backbone, e.g., the phosphate, or modified phosphate, e.g., sulfur containing, backbone, of a ribonucleic acid. A
"tethering attachment point" (TAP) in some embodiments refers to a constituent ring atom of the cyclic carrier, e.g., a carbon atom or a heteroatom (distinct from an atom which provides a backbone attachment point), that connects a selected moiety. The moiety can be, e.g., a carbohydrate, e.g.
monosacchari de, disaccharide, tri sacchari de, tetrasaccharide, oligosaccharide and polysaccharide. Optionally, the selected moiety is connected by an intervening tether to the cyclic carrier. Thus, the cyclic carrier will often include a functional group, e.g., an amino group, or generally, provide a bond, that is suitable for incorporation or tethering of another chemical entity, e.g., a ligand to the constituent ring.
[00114] In one embodimennt the dsRNA molecule of the invention is conjugated to a ligand via a carrier, wherein the carrier can be cyclic group or acyclic group;
preferably, the cyclic group is selected from pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolane, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl and decalin;
preferably, the acyclic group is selected from serinol backbone or diethanolamine backbone.
[00115] The ligand can be attached to the sense strand, antisense strand or both strands, at the 3'-end, 5'-end or both ends. For instance, the ligand can be conjugated to the sense strand, in particular, the 3'-end of the sense strand.
[00116] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands; wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) ¨ (VII); and wherein the sense strand does not comprise a glycol nucleic acid. In some embodiments, the sense and antisense strand the sense and the antisense strand can be independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably the sense strand and the antisense strand are independently 19, 20, 21, 22, 23, 24 or 25 nucleotides in length, more preferably, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00117] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2' -deoxy modifications on the sense and/or antisense strands; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) ¨ (VII); and wherein the sense strand does not comprise a glycol nucleic acid (GNA). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the sense and antisense strand the sense and the antisense strand can be independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably the sense strand and the antisense strand are independently 19, 20, 21, 22, 23, 24 or 25 nucleotides in length, more preferably, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00118] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2' -deoxy modifications on the sense and/or antisense strands; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) ¨ (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA
agent comprises all natural nucleotides. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the sense and antisense strand the sense and the antisense strand can be independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably the sense strand and the antisense strand are independently 19, 20, 21, 22, 23, 24 or 25 nucleotides in length, more preferably, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.
[00119] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14 (preferably positions 7, 8, 9, 10, 11, 12 and 13) of the sense strand, counting from the 5'-end of the sense strand, and/or at positions 9, 10, 11, 12, 13, 14, 15 16 and 17 (preferably positions 10, 11, 12, 13, 14, 15 and 16) of the antisense strand counting from 5'-end of the antisense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00120] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14 (preferably positions 7, 8, 9, 10, 11, 12 and 13) of the sense strand, counting from the 5'-end of the sense strand, and/or at positions 9, 10, 11, 12, 13, 14, 15 16 and 17 (preferably positions 10, 11, 12, 13, 14, 15 and 16) of the antisense strand counting from 5'-end of the antisense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00121] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14 (preferably positions 7, 8, 9, 10, 11, 12 and 13) of the sense strand, counting from the 5'-end of the sense strand, and/or at positions 9, 10, 11, 12, 13, 14, 15 16 and 17 (preferably positions 10, 11, 12, 13, 14, 15 and 16) of the antisense strand counting from 5'-end of the antisense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.
[00122] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein the sense strand comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the sense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the sense strand is 18-30 nucleotides in length and comprises at least two 2'-deoxy modifications in a central region, e.g., positions 7, 8, 9, 10, 11, 12 and 13 of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00123]
[00124] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein the sense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the sense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR).
In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the sense strand is 18-30 nucleotides in length and comprises at least two 2'-deoxy modifications in a central region, e.g., positions 7, 8, 9, 10, 11, 12 and 13 of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00125] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the sense comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the sense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
In some embodiments, the sense strand is 18-30 nucleotides in length and comprises at least two 2'-deoxy modifications in a central region, e.g., positions 7, 8, 9, 10, 11, 12 and 13 of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.
[00126] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein the antisense strand comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand.
In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
In some embodiments, the sense strand is 18-30 nucleotides in length and comprises at least two 2'-deoxy modifications in a central region, e.g., positions 10, 11, 12, 13, 14, 15, and 16 of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00127] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein the antisense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the antisense strand is 18-30 nucleotides in length and comprises at least two 2'-deoxy modifications in a central region, e.g., positions 10, 11, 12, 13, 14, 15, and 16 of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00128] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the antisense comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the antisense strand is 18-30 nucleotides in length and comprises at least two 2'-deoxy modifications in a central region, e.g., positions 10, 11, 12, 13, 14, 15 and 16 of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-aminopropyl (2'-0-AP), and 2'-ara-F.
[00129] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein the antisense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand, and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the antisense strand is 18-30 nucleotides in length and comprises at least one 2'-deoxy modifications in a central region, e.g., positions 10, 11, 12, 13, 14, 15, and 16 of the antisense strand, and at least one 2'-deoxy in positions 1, 2, 3, 4, 5 or 6 from either one of the 5'-end or the 3'-end. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00130] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein the antisense strand comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the antisense strand is 18-30 nucleotides in length and comprises at least one 2'-deoxy modifications in a central region, e.g., positions 10, 11, 12, 13, 14, 15, and 16 of the antisense strand, and at least one 2'-deoxy in positions 1, 2, 3, 4, 5 or 6 from either one of the 5'-end or the 3'-end. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00131] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the antisense comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in a central region of the antisense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the antisense strand is 18-30 nucleotides in length and comprises at least one 2'-deoxy modifications in a central region, e.g., positions 10, 11, 12, 13, 14, 15, and 16 of the antisense strand, and at least one 2'-deoxy in positions 1, 2, 3, 4, 5 or 6 from either one of the 5'-end or the 3'-end. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.
[00132] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein the antisense strand comprises at least five, at least six, at least seven or more, 2'-deoxy modifications, e.g., at positions 2, 5, 7, 12 and 14, counting from 5-'end of the antisense strand.
In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
In some embodiments, the antisense strand is 18-23 nucleotides in length and comprises at least five 2'-deoxy modifications, e.g., at positions 2, 5, 7, 12 and 14, counting from 5'-end of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00133] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein the antisense strand comprises at least five, at least six, at least seven or more, 2'-deoxy modifications, e.g., at positions 2, 5, 7, 12 and 14, counting from 5-`end of the antisense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the antisense strand is 18-23 nucleotides in length and comprises at least five 2'-deoxy modifications, e.g., at positions 2, 5, 7, 12 and 14, counting from 5'-end of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00134] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the antisense strand comprises at least five, at least six, at least seven or more, 2'-deoxy modifications, e.g., at positions 2, 5, 7, 12 and 14, counting from 5-'end of the antisense strand.
In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
In some embodiments, the antisense strand is 18-23 nucleotides in length and comprises at least five 2'-deoxy modifications, e.g., at positions 2, 5, 7, 12 and 14, counting from 5'-end of the antisense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.
[00135] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) ¨ (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein at least two of the 2'-deoxy modifications are in the antisense strand, and at least one of the 2'-deoxy modification is in the sense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the antisense strand comprises at least two 2'-deoxy modifications and the sense strand comprises at least one 2'-deoxy modification, wherein the 2'-deoxy modifications are at positions 2 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at position 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00136] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) ¨ (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein at least two of the 2'-deoxy modifications are in the antisense strand, and at least one of the 2'-deoxy modification is in the sense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the antisense strand comprises at least two 2'-deoxy modifications and the sense strand comprises at least one 2'-deoxy modification, wherein the 2'-deoxy modifications are at positions 2 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at position 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00137] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein at least two of the 2'-deoxy modifications are in the antisense strand, and at least one of the 2'-deoxy modification is in the sense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the antisense strand comprises at least two 2'-deoxy modifications and the sense strand comprises at least one 2'-deoxy modification, wherein the 2'-deoxy modifications are at positions 2 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at position 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.
[00138] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;

wherein the dsRNA molecule has a double stranded (duplex) region of between 18 to 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) ¨ (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein at least three of the 2'-deoxy modifications are in the antisense strand, and at least two of the 2'-deoxy modifications are in the sense strand. In some embodiments, the antisense strand comprises at least three 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modification, wherein the 2'-deoxy modifications are at positions 2, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00139] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) ¨ (VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein at least three of the 2'-deoxy modifications are in the antisense strand, and at least two of the 2'-deoxy modifications are in the sense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the antisense strand comprises at least three 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modifications, wherein the 2'-deoxy modifications are at positions 2, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[00140] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII); wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein at least three of the 2'-deoxy modifications are in the antisense strand, and at least two of the 2'-deoxy modifications are in the sense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the antisense strand comprises at least three 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modifications, wherein the 2'-deoxy modifications are at positions 2, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.
[00141] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least seven 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA
molecule has a double stranded (duplex) region of between 18 to 25 base pairs;
wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein at least five of the 2'-deoxy modifications are in the antisense strand, and at least two of the 2'-deoxy modification is in the sense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the antisense strand comprises at least five 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modifications, wherein the 2'-deoxy modifications are at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00142] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least seven 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs;
wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) ¨
(VII); wherein the sense strand does not comprise a glycol nucleic acid; and wherein at least five of the 2'-deoxy modifications are in the antisense strand, and at least two of the 2'-deoxy modifications are in the sense strand. In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein. In some embodiments, the antisense strand comprises at least five 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modification, wherein the 2'-deoxy modifications are at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00143] In some embodiments, the dsRNA comprises a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy modifications on the sense and/or antisense strands;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA molecule comprises a ligand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein at least five of the 2'-deoxy modifications are in the antisense strand, and at least two of the 2'-deoxy modifications are in the sense strand.
In some embodiments, the antisense strand comprises at least five 2'-deoxy modifications and the sense strand comprises at least two 2'-deoxy modifications, wherein the 2'-deoxy modifications are at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand, and at positions 9 and 11 of the sense strand, counting from 5'-end of the sense strand. In some embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length. In some embodiments, the non-natural nucleotides are selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA), HNA, CeNA, 2'-methoxyethyl, 2'-0-allyl, 2'-C-allyl, 2'-fluoro, 2'-0-N-methylacetamido (2'-0-NMA), a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE), 2'-0-aminopropyl (2'-0-AP), and 2'-ara-F.
[00144] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand). In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[00145] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.
[00146] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); and wherein the sense strand does not comprise a glycol nucleic acid.
[00147] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5' -end of the antisense strand); wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00148] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5' -end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5' -end of the antisense strand); and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00149] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5' -end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5' -end of the antisense strand); wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA
agent comprises all natural nucleotides.
[00150] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the sense strand does not comprise a glycol nucleic acid;
and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00151] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00152] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand).
In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00153] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.
[00154] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA

comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5' -end of the antisense strand);
and wherein the sense strand does not comprise a glycol nucleic acid.
[00155] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00156] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00157] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00158] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA
agent comprises all natural nucleotides.
[00159] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs;
wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00160] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5' -end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5' -end of the antisense strand); and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00161] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00162] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the sense strand does not comprise a glycol nucleic acid;
and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00163] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00164] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00165] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00166] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5' -end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5' -end of the antisense strand); wherein the sense strand does not comprise a glycol nucleic acid;
wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00167] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5' -end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5' -end of the antisense strand); wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.

[00168] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5' -end of the antisense strand);
and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00169] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5' -end of the antisense strand);
and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR).
In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00170] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00171] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs;
wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00172] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5' -end of the antisense strand);
wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5%
non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00173] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs;
wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00174] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2' -deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5' -end of the antisense strand);
wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00175] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the antisense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs;
wherein the sense strand does not comprise a glycol nucleic acid; the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00176]
[00177] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand). In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00178] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.
[00179] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); and wherein the sense strand does not comprise a glycol nucleic acid.
[00180] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00181] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00182] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00183] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00184] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.

[00185] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand). In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00186] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); and wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.
[00187] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); and wherein the sense strand does not comprise a glycol nucleic acid.
[00188] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00189] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); and wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5%
non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00190] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00191] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA
agent comprises all natural nucleotides.
[00192] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs;
wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00193] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR).

In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00194] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00195] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00196] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00197] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00198] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00199] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the sense strand does not comprise a glycol nucleic acid;
wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00200] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides;
and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00201] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00202] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand); and wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00203] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00204] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs;
wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00205] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5%
non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00206] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs;
wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00207] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00208] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand);
wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs;
wherein the sense strand does not comprise a glycol nucleic acid; the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00209] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand. In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00210] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.
[00211] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
and wherein the sense strand does not comprise a glycol nucleic acid.
[00212] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00213] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.

[00214] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00215] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5%
non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.

[00216] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00217] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand. In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

[00218] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.
[00219] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; and wherein the sense strand does not comprise a glycol nucleic acid.
[00220] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00221] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00222] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5%
non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00223] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.

[00224] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA
agent comprises all natural nucleotides.
[00225] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00226] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00227] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00228] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00229] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00230] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00231] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5%
non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00232] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the dsRNA comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand;
wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00233] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00234] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00235] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00236] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00237] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA

comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00238] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5%
non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA

molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00239] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA
comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00240] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; wherein the dsRNA

comprises at least two, e.g., at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 6, 7, 8, 9, 10, 11, 12, 13, and 14, preferably positions 7, 8, 9, 10, 11, 12 and 13, counting from the 5'-end of the sense strand), and at least one, e.g., at least two, at least three, at least four, at least five, at least six, at least seven or more, 2'-deoxy modifications in the central region of the sense strand (e.g., at positions 9, 10, 11, 12, 13, 14, 15 16 and 17, preferably positions 10, 11, 12, 13, 14, 15 and 16, counting from 5'-end of the antisense strand), and at least one 2'-deoxy modification in a non-central region, e.g., within 1, 2, 3, 4, 5 or 6 nucleotides from either 5'-end and/or 3'-end of the antisense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00241] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand. In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00242] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.

[00243] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; and wherein the sense strand does not comprise a glycol nucleic acid.
[00244] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00245] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00246] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00247] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00248] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00249] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand. In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00250] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; and wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.
[00251] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; and wherein the sense strand does not comprise a glycol nucleic acid.
[00252] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00253] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; and wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.

[00254] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5%
non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00255] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA
agent comprises all natural nucleotides.
[00256] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA
agent comprises all natural nucleotides.

[00257] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00258] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00259] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the

111 ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00260] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00261] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00262] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g.,

112 independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA
agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00263] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00264] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the dsRNA molecule has a double stranded (duplex) region of

113 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides;
and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00265] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00266] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; and wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs;
and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the

114 ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00267] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00268] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00269] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,

115 or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5' -end of the antisense strand; wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA
agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00270] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5%
non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00271] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand

116 comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00272] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand; wherein the dsRNA
molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00273] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from 5'-end of the

117 antisense strand. In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00274] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.
[00275] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; and wherein the sense strand does not comprise a glycol nucleic acid.
[00276] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00277] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2'-deoxy

118 modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00278] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00279] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00280] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19,

119 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00281] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from 5'-end of the antisense strand. In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00282] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.
[00283] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; and wherein the sense strand does not comprise a glycol nucleic acid.
[00284] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g.,

120 independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00285] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA
agent comprises all natural nucleotides.
[00286] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA
agent comprises all natural nucleotides.
[00287] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g.,

121 independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00288] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00289] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some

122 further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00290] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2' -deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00291] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2' -deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00292] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2' -deoxy

123 modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR).
In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00293] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides;
and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00294] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA comprises less than 20%, e.g., less than

124 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00295] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2' -deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00296] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least two 2' -deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -

125 (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00297] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00298] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.

126 [00299] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR).
In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00300] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00301] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,

127 or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00302] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00303] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25

128 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00304] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; antisense strand comprises at least two 2'-deoxy modifications at positions 2 and 14 of the antisense strand, counting from wherein the sense strand comprises at least one 2'-deoxy modification at position 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides;
and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00305] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,

129 or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand. In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00306] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.
[00307] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the sense strand does not comprise a glycol nucleic acid.
[00308] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00309] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g.,

130 independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00310] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00311] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00312] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2'-deoxy

131 modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00313] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand. In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00314] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.
[00315] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and

132 11, counting from 5'-end of the sense strand; and wherein the sense strand does not comprise a glycol nucleic acid.
[00316] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00317] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00318] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA

133 comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5%
non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00319] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00320] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA
agent comprises all natural nucleotides.
[00321] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2' -deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2' -deoxy modifications at positions 9 and 11, counting from 5'-

134 end of the sense strand; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR).
In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00322] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00323] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.

135 [00324] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00325] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00326] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25

136 nucleotides in length; wherein the antisense strand comprises at least three 2' -deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2' -deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00327] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2' -deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2' -deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid;
wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00328] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least three 2' -deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2' -deoxy modifications at positions 9 and 11, counting from 5'-

137 end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides;
and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00329] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00330] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA

138 molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00331] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00332] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of

139 Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00333] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00334] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5%
non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a

140 multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00335] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00336] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least three 2'-deoxy modifications at positions 2, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In

141 some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00337] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2' -deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5' -end of the antisense strand. In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00338] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2' -deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2' -deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.
[00339] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2' -deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2' -deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; and wherein the sense strand does not comprise a glycol nucleic acid.
[00340] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2' -deoxy

142 modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2' -deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00341] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2' -deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2' -deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00342] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2' -deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2' -deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00343] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2' -deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2' -deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid;

143 and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00344] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00345] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from 5'-end of the antisense strand. In some preferred embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.
[00346] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs.
[00347] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g.,

144 independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the sense strand does not comprise a glycol nucleic acid.
[00348] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the sense strand does not comprise a glycol nucleic acid.
[00349] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5'end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00350] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25

145 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5%
non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00351] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides.
[00352] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA
agent comprises all natural nucleotides.

146 [00353] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00354] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00355] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from

147 5'-end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid;
and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00356] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00357] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In

148 some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00358] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2' -deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2' -deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00359] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2' -deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2' -deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid;
wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.

149 [00360] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; wherein the antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides;
and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00361] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00362] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,

150 or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; and wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00363] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00364] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting

151 from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00365] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00366] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least five 2'-deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5'-end of the sense strand; wherein the dsRNA molecule has a double

152 stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the dsRNA
comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5%
non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA
molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) -(VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00367] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least five 2' -deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; wherein the sense strand does not comprise a glycol nucleic acid; wherein the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) - (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
[00368] In some embodiments, the invention provides a dsRNA comprising a sense strand and an antisense strand, each strand independently having a length of 15 to 35 nucleotides, e.g., independently 17-30 nucleotides in length, independently 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, preferably independently 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length; at least two phsophorothioate internucleotide linkages between the first five nucleotides, counting from the 5' end of the antisense strand; antisense strand comprises at least five 2' -deoxy modifications at positions 2, 5, 7, 12 and 14 of the antisense strand, counting from wherein the sense strand comprises at least two 2'-deoxy modifications at positions 9 and 11, counting from 5' -end of the sense strand; wherein the dsRNA molecule has a double

153 stranded (duplex) region of 18, 19, 21, 22, 23, 24 or 25 base pairs; wherein the sense strand does not comprise a glycol nucleic acid; the dsRNA comprises less than 20%, e.g., less than 15%, less than 10%, or less than 5% non-natural nucleotides or the dsRNA agent comprises all natural nucleotides; and wherein the dsRNA molecule comprises a ligand, e.g., a ligand of any one of Formula (IV) ¨ (VII). In some embodiments, the ligand binds with or targets a liver cell or receptor, e.g., the ligand binds with or target the asialoglycoprotein receptor (ASGPR). In some embodiments, the ligand is a multivalent ligand, e.g., a ligand of Formula (VII). In some further embodiments, the ligand is a GalNAc derivative, e.g., a ligand selected from the Ligands 1-8 disclosed herein.
Overhnags and blunt ends [00369] In some embodiments, the dsRNA molecule of the invention comprises one or more overhang regions and/or capping groups of dsRNA molecule at the 3'-end, or 5'-end or both ends of a strand. The overhang can be 1-10 nucleotides in length. For example, the overhang can be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides in length. In some embodiments, the overhang is 1-6 nucleotides in length, for instance 2-6 nucleotides in length, 1-5 nucleotides in length, 2-nucleotides in length, 1-4 nucleotides in length, 2-4 nucleotides in length, 1-3 nucleotides in length, 2-3 nucleotides in length, or 1-2 nucleotides in length. The overhangs can be the result of one strand being longer than the other, or the result of two strands of the same length being staggered. The overhang can form a mismatch with the target sequence or it can be complementary to the gene sequences being targeted or it can be the other sequence. The first and second strands can also be joined, e.g., by additional bases to form a hairpin, or by other non-base linkers.
[00370] In some embodiments, the nucleotides in the overhang region of the dsRNA
molecule of the invention can each independently be a modified or unmodified nucleotide including, but not limited to 2'-sugar modified, such as, 2'-Fluoro 2'-0-methyl, thymidine (T), 2' -0-methoxyethy1-5-methyluridine, 2' -0-methoxyethyladenosine, 2' -0-methoxyethy1-5-methylcytidine, GNA, SNA, hGNA, hhGNA, mGNA, TNA, h'GNA, and any combinations thereof. For example, dTdT can be an overhang sequence for either end on either strand. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be other sequence.
[00371] The 5'- or 3'- overhangs at the sense strand, antisense strand or both strands of the dsRNA molecule of the invention may be phosphorylated. In some embodiments, the overhang region contains two nucleotides having a phosphorothioate between the two nucleotides, where

154 the two nucleotides can be the same or different. In some embodiments, the overhang is present at the 3' -end of the sense strand, antisense strand or both strands. In some embodiments, this 3' -overhang is present in the antisense strand. In some embodiments, this 3'-overhang is present in the sense strand.
[00372] The dsRNA molecule of the invention may comprise only a single overhang, which can strengthen the interference activity of the dsRNA, without affecting its overall stability.
For example, the single-stranded overhang is located at the 3'-terminal end of the sense strand or, alternatively, at the 3'-terminal end of the antisense strand. The dsRNA
can also have a blunt end, located at the 5' -end of the antisense strand (or the 3' -end of the sense strand) or vice versa.
[00373] Generally, the antisense strand of the dsRNA has a nucleotide overhang at the 3' -end, and the 5'-end is blunt. While not bound by theory, the asymmetric blunt end at the 5' -end of the antisense strand and 3' -end overhang of the antisense strand favor the guide strand loading into RISC process. For example, the single overhang is at least one, two, three, four, five, six, seven, eight, nine, or ten nucleotides in length. In some embodiments, the dsRNA
has a 2 nucleotide overhang on the 3' -end of the antisense strand and a blunt end at the 5' -end of the antisense strand.
Modified nucleotides [00374] The dsRNA of the inventoion can comprise one or more modified nucleotides. For example, every nucleotide in the sense strand and antisense strand of the dsRNA molecule can be modified. Each nucleotide can be modified with the same or different modification which can include one or more alteration of one or both of the non-linking phosphate oxygens and/or of one or more of the linking phosphate oxygens; alteration of a constituent of the ribose sugar;
replacement of the ribose sugar; wholesale replacement of the phosphate moiety with "dephospho" linkers; modification or replacement of a naturally occurring base; and replacement or modification of the ribose-phosphate backbone.
[00375] As nucleic acids are polymers of subunits, many of the modifications occur at a position which is repeated within a nucleic acid, e.g., a modification of a base, or a phosphate moiety, or a non-linking 0 of a phosphate moiety. In some cases the modification will occur at all of the subject positions in the nucleic acid but in many cases it will not. By way of example, a modification may only occur at a 3' or 5' terminal position, may only occur in a central region, may only occur at a non-terminal tregion, or may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand.

155 A modification may occur in a double strand region, a single strand region, or in both. A
modification may occur only in the double strand region of a RNA or may only occur in a single strand region of a RNA. For example, a phosphorothioate modification at a non-linking 0 position may only occur at one or both termini, may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand, or may occur in double strand and single strand regions, particularly at termini. The 5' end or ends can be phosphorylated.
[00376] It may be possible, e.g., to enhance stability, to include particular bases in overhangs, or to include modified nucleotides or nucleotide surrogates, in single strand overhangs, e.g., in a 5' or 3' overhang, or in both. For example, it can be desirable to include purine nucleotides in overhangs. In some embodiments all or some of the bases in a 3' or 5' overhang may be modified, e.g., with a modification described herein.
Modifications can include, e.g., the use of modifications at the 2' position of the ribose sugar with modifications that are known in the art, e.g., the use of deoxyribonucleotides, 2' -deoxy-2' -fluoro (2'-F) or 2' -0-methyl modified instead of the ribosugar of the nucleobase, and modifications in the phosphate group, e.g., phosphorothioate modifications. Overhangs need not be homologous with the target sequence.
[00377] In some embodiments, each residue of the sense strand and antisense strand is independently modified with LNA, HNA, CeNA, 2' -methoxyethyl, 2'- 0-methyl, 2'-0-allyl, 2'-C- allyl, 2' -deoxy, or 2'-fluoro. The strands can contain more than one modification. In some embodiments, each residue of the sense strand and antisense strand is independently modified with 2'-0-methyl or 2' -fluoro.
[00378] At least two different modifications are typically present on the sense strand and antisense strand. Those two modifications may be the 2' -deoxy, 2'- 0-methyl or 2'-fluoro modifications, acyclic nucleotides or others. In some embodiments, the sense strand and antisense strand each comprises two differently modified nucleotides selected from 2'-0-methyl or 2'-deoxy. In some embodiments, each residue of the sense strand and antisense strand is independently modified with 2'-0-methyl nucleotide, 2' -deoxy nucleotide, 2"-deoxy-2' -fluor nucleotide, 2'-0-N-methylacetamido (2'-0-NMA) nucleotide, a 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE) nucleotide, 2'-0-aminopropyl (2'-0-AP) nucleotide, or 2'-ara-F nucleotide.
[00379] In some embodiments, the dsRNA molecule of the invention comprises modifications of an alternating pattern, particular in the Bl, B2, B3, B1', B2', B3', B4' regions.
The term "alternating motif' or "alternative pattern" as used herein refers to a motif having one

156 or more modifications, each modification occurring on alternating nucleotides of one strand.
The alternating nucleotide may refer to one per every other nucleotide or one per every three nucleotides, or a similar pattern. For example, if A, B and C each represent one type of modification to the nucleotide, the alternating motif can be "ABABABABABAB...,"
"AABBAABBAABB...," "AABAABAABAAB...,"
"AAABAAABAAAB...,"
"AAABBBAAABBB ," or "ABCABCABCABC ," etc.
[00380] The type of modifications contained in the alternating motif may be the same or different. For example, if A, B, C, D each represent one type of modification on the nucleotide, the alternating pattern, i.e., modifications on every other nucleotide, may be the same, but each of the sense strand or antisense strand can be selected from several possibilities of modifications within the alternating motif such as "ABABAB...", "ACACAC..."
"BDBDBD..." or "CDCDCD...," etc.
[00381] In some embodiments, the dsRNA molecule of the invention comprises the modification pattern for the alternating motif on the sense strand relative to the modification pattern for the alternating motif on the antisense strand is shifted. The shift may be such that the modified group of nucleotides of the sense strand corresponds to a differently modified group of nucleotides of the antisense strand and vice versa. For example, the sense strand when paired with the antisense strand in the dsRNA duplex, the alternating motif in the sense strand may start with "ABABAB" from 5'-3' of the strand and the alternating motif in the antisense strand may start with "BABABA" from 3' -5' of the strand within the duplex region. As another example, the alternating motif in the sense strand may start with "AABBAABB"
from 5' -3' of the strand and the alternating motif in the antisense strand may start with "BBAABBAA" from 3' -5' of the strand within the duplex region, so that there is a complete or partial shift of the modification patterns between the sense strand and the antisense strand.
[00382] The dsRNA molecule of the invention may further comprise at least one phosphorothioate or methylphosphonate internucleotide linkage. The phosphorothioate or methylphosphonate internucleotide linkage modification may occur on any nucleotide of the sense strand or antisense strand or both in any position of the strand. For instance, the internucleotide linkage modification may occur on every nucleotide on the sense strand and/or antisense strand; each internucleotide linkage modification may occur in an alternating pattern on the sense strand or antisense strand; or the sense strand or antisense strand comprises both internucleotide linkage modifications in an alternating pattern. The alternating pattern of the internucleotide linkage modification on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the internucleotide linkage modification on the

157 sense strand may have a shift relative to the alternating pattern of the internucleotide linkage modification on the antisense strand.
[00383] In some embodiments, the dsRNA molecule comprises the phosphorothioate or methylphosphonate internucleotide linkage modification in the overhang region.
For example, the overhang region comprises two nucleotides having a phosphorothioate or methylphosphonate internucleotide linkage between the two nucleotides.
Internucleotide linkage modifications also may be made to link the overhang nucleotides with the terminal paired nucleotides within duplex region. For example, at least 2, 3, 4, or all the overhang nucleotides may be linked through phosphorothioate or methylphosphonate internucleotide linkage, and optionally, there may be additional phosphorothioate or methylphosphonate internucleotide linkages linking the overhang nucleotide with a paired nucleotide that is next to the overhang nucleotide. For instance, there may be at least two phosphorothioate internucleotide linkages between the terminal three nucleotides, in which two of the three nucleotides are overhang nucleotides, and the third is a paired nucleotide next to the overhang nucleotide. Preferably, these terminal three nucleotides may be at the 3' -end of the antisense strand.
[00384] In some embodiments, the sense strand of the dsRNA molecule comprises blocks of two to ten phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said sense strand is paired with an antisense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.
[00385] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of two phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.
[00386] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of three phosphorothioate or methylphosphonate internucleotide linkages separated by

158 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.
[00387] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of four phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.
[00388] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of five phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.
[00389] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of six phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.
[00390] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of seven phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7 or 8 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide

159 sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.
[00391] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of eight phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5 or 6 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.
[00392] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of nine phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3 or 4 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.
[00393] In some embodiments, the dsRNA molecule of the invention further comprises one or more phosphorothioate or methylphosphonate internucleotide linkage modification within 1-10 of the termini position(s) of the sense and/or antisense strand. For example, at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides may be linked through phosphorothioate or methylphosphonate internucleotide linkage at one end or both ends of the sense and/or antisense strand.
[00394] In some embodiments, the dsRNA molecule of the invention further comprises one or more phosphorothioate or methylphosphonate internucleotide linkage modification within 1-10 of the internal region of the duplex of each of the sense and/or antisense strand. For example, at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides may be linked through phosphorothioate methylphosphonate internucleotide linkage at position 8-16 of the duplex region counting from the 5' -end of the sense strand; the dsRNA molecule can optionally further comprise one or more phosphorothioate or methylphosphonate internucleotide linkage modification within 1-of the termini position(s).

160 [00395] In some embodiments, the dsRNA molecule of the invention further comprises one to five phosphorothioate or methylphosphonate internucleotide linkage modification(s) within position 1-5 and one to five phosphorothioate or methylphosphonate internucleotide linkage modification(s) within position 18-23 of the sense strand (counting from the 5'-end), and one to five phosphorothioate or methylphosphonate internucleotide linkage modification at positions 1 and 2 and one to five within positions 18-23 of the antisense strand (counting from the 5'-end).
[00396] In some embodiments, the dsRNA molecule of the invention further comprises one phosphorothioate internucleotide linkage modification within position 1-5 and one phosphorothioate or methylphosphonate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate or methylphosphonate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5' -end).
[00397] In some embodiments, the dsRNA molecule of the invention further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and one phosphorothioate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).
[00398] In some embodiments, the dsRNA molecule of the invention further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and two phosphorothioate internucleotide linkage modifications within position 18-23 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).
[00399] In some embodiments, the dsRNA molecule of the invention further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and two phosphorothioate internucleotide linkage modifications within position 18-23 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18-23 of the antisense strand (counting from the 5' -end).
[00400] In some embodiments, the dsRNA molecule of the invention further comprises one phosphorothioate internucleotide linkage modification within position 1-5 and one

161 phosphorothioate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).
[00401] In some embodiments, the dsRNA molecule of the invention further comprises one phosphorothioate internucleotide linkage modification within position 1-5 and one within position 18-23 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modification at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18-23 of the antisense strand (counting from the 5' -end).
[00402] In some embodiments, the dsRNA molecule of the invention further comprises one phosphorothioate internucleotide linkage modification within position 1-5 (counting from the 5'-end) of the sense strand, and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18-23 of the antisense strand (counting from the 5'-end).
[00403] In some embodiments, the dsRNA molecule of the invention further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 (counting from the 5'-end) of the sense strand, and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).
[00404] In some embodiments, the dsRNA molecule of the invention further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and one within position 18-23 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18-23 of the antisense strand (counting from the 5' -end).
[00405] In some embodiments, the dsRNA molecule of the invention further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and one phosphorothioate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).
[00406] In some embodiments, the dsRNA molecule of the invention further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and one

162 phosphorothioate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5'-end).
[00407] In some embodiments, the dsRNA molecule of the invention further comprises two phosphorothioate internucleotide linkage modifications at position 1 and 2, and two phosphorothioate internucleotide linkage modifications at position 20 and 21 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and one at position 21 of the antisense strand (counting from the 5' -end).
[00408] In some embodiments, the dsRNA molecule of the invention further comprises one phosphorothioate internucleotide linkage modification at position 1, and one phosphorothioate internucleotide linkage modification at position 21 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications at positions 20 and 21 the antisense strand (counting from the 5'-end).
[00409] In some embodiments, the dsRNA molecule of the invention further comprises two phosphorothioate internucleotide linkage modifications at position 1 and 2, and two phosphorothioate internucleotide linkage modifications at position 21 and 22 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and one phosphorothioate internucleotide linkage modification at position 21 of the antisense strand (counting from the 5'-end).
[00410] In some embodiments, the dsRNA molecule of the invention further comprises one phosphorothioate internucleotide linkage modification at position 1, and one phosphorothioate internucleotide linkage modification at position 21 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications at positions 21 and 22 the antisense strand (counting from the 5'-end).
[00411] In some embodiments, the dsRNA molecule of the invention further comprises two phosphorothioate internucleotide linkage modifications at position 1 and 2, and two phosphorothioate internucleotide linkage modifications at position 22 and 23 of the sense strand (counting from the 5'-end), and one phosphorothioate internucleotide linkage modification at positions 1 and one phosphorothioate internucleotide linkage modification at position 21 of the antisense strand (counting from the 5'-end).

163 [00412] In some embodiments, the dsRNA molecule of the invention further comprises one phosphorothioate internucleotide linkage modification at position 1, and one phosphorothioate internucleotide linkage modification at position 21 of the sense strand (counting from the 5'-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications at positions 23 and 23 the antisense strand (counting from the 5'-end).
[00413] In some embodiments, compound of the invention comprises a pattern of backbone chiral centers. In some embodiments, a common pattern of backbone chiral centers comprises at least 5 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 6 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 7 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 8 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 9 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 10 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 11 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 12 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 13 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 14 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 15 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 16 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 17 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 18 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 19 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 8 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 7 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 6

164 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 5 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 4 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 3 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 2 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 1 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 8 internucleotidic linkages which are not chiral (as a non-limiting example, a phosphodiester). In some embodiments, a common pattern of backbone chiral centers comprises no more than 7 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 6 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 5 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 4 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 3 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 2 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 1 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least internucleotidic linkages in the Sp configuration, and no more than 8 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 11 internucleotidic linkages in the Sp configuration, and no more than 7 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 12 internucleotidic linkages in the Sp configuration, and no more than 6 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 13 internucleotidic linkages in the Sp configuration, and no more than 6 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 14 internucleotidic linkages in the Sp configuration, and no more than 5 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 15 internucleotidic linkages in the Sp configuration,

165 and no more than 4 internucleotidic linkages which are not chiral. In some embodiments, the internucleotidic linkages in the Sp configuration are optionally contiguous or not contiguous.
In some embodiments, the internucleotidic linkages in the Rp configuration are optionally contiguous or not contiguous. In some embodiments, the internucleotidic linkages which are not chiral are optionally contiguous or not contiguous.
[00414] In some embodiments, compound of the invention comprises a block is a stereochemistry block. In some embodiments, a block is an Rp block in that each internucleotidic linkage of the block is Rp. In some embodiments, a 5'-block is an Rp block.
In some embodiments, a 3'-block is an Rp block. In some embodiments, a block is an Sp block in that each internucleotidic linkage of the block is Sp. In some embodiments, a 5'-block is an Sp block. In some embodiments, a 3'-block is an Sp block. In some embodiments, provided oligonucleotides comprise both Rp and Sp blocks. In some embodiments, provided oligonucleotides comprise one or more Rp but no Sp blocks. In some embodiments, provided oligonucleotides comprise one or more Sp but no Rp blocks. In some embodiments, provided oligonucleotides comprise one or more PO blocks wherein each internucleotidic linkage in a natural phosphate linkage.
[00415] In some embodiments, compound of the invention comprises a 5'-block is an Sp block wherein each sugar moiety comprises a 2'-F modification. In some embodiments, a 5'-block is an Sp block wherein each of internucleotidic linkage is a modified internucleotidic linkage and each sugar moiety comprises a 2'-F modification. In some embodiments, a 5'-block is an Sp block wherein each of internucleotidic linkage is a phosphorothioate linkage and each sugar moiety comprises a 2'-F modification. In some embodiments, a 5'-block comprises 4 or more nucleoside units. In some embodiments, a 5'-block comprises 5 or more nucleoside units. In some embodiments, a 5'-block comprises 6 or more nucleoside units.
In some embodiments, a 5'-block comprises 7 or more nucleoside units. In some embodiments, a 3'-block is an Sp block wherein each sugar moiety comprises a 2'-F modification.
In some embodiments, a 3'-block is an Sp block wherein each of internucleotidic linkage is a modified internucleotidic linkage and each sugar moiety comprises a 2'-F modification.
In some embodiments, a 3'-block is an Sp block wherein each of internucleotidic linkage is a phosphorothioate linkage and each sugar moiety comprises a 2'-F modification.
In some embodiments, a 3'-block comprises 4 or more nucleoside units. In some embodiments, a 3'-block comprises 5 or more nucleoside units. In some embodiments, a 3'-block comprises 6 or more nucleoside units. In some embodiments, a 3'-block comprises 7 or more nucleoside units.

166 [00416] In some embodiments, compound of the invention comprises a type of nucleoside in a region or an oligonucleotide is followed by a specific type of internucleotidic linkage, e.g., natural phosphate linkage, modified internucleotidic linkage, Rp chiral internucleotidic linkage, Sp chiral internucleotidic linkage, etc. In some embodiments, A is followed by Sp. In some embodiments, A is followed by Rp. In some embodiments, A is followed by natural phosphate linkage (PO). In some embodiments, U is followed by Sp. In some embodiments, U
is followed by Rp. In some embodiments, U is followed by natural phosphate linkage (PO). In some embodiments, C is followed by Sp. In some embodiments, C is followed by Rp. In some embodiments, C is followed by natural phosphate linkage (PO). In some embodiments, G is followed by Sp. In some embodiments, G is followed by Rp. In some embodiments, G is followed by natural phosphate linkage (PO). In some embodiments, C and U are followed by Sp. In some embodiments, C and U are followed by Rp. In some embodiments, C
and U are followed by natural phosphate linkage (PO). In some embodiments, A and G are followed by Sp. In some embodiments, A and G are followed by Rp.
[00417] Various publications describe multimeric siRNA which can all be used with the dsRNA of the invention. Such publications include W02007/091269, US Patent No.
7858769, W02010/141511, W02007/117686, W02009/014887 and W02011/031520 which are hereby incorporated by their entirely.
'-Modifications [00418] In some embodiments dsRNA molecules of the invention are 5' phosphorylated or include a phosphoryl analog at the 5' prime terminus. 5'-phosphate modifications include those which are compatible with RISC mediated gene silencing. Suitable modifications include: 5'-monophosphate ((H0)2(0)P-0-5'); 5'-diphosphate ((H0)2(0)P-0-P(H0)(0)-0-5'); 5'-triphosphate ((H0)2(0)P-0-(H0)(0)P-0-P(H0)(0)-0-5'); 5'-guanosine cap (7-methylated or non-methylated) (7m-G-0-5'-(H0)(0)P-0-(H0)(0)P-O-P(H0)(0)-0-5'); 5'-adenosine cap (Appp), and any modified or unmodified nucleotide cap structure (N-0-5'-(H0)(0)P-0-(H0)(0)P-0-P(H0)(0)-0-5'); 5'-monothiophosphate (phosphorothioate; (H0)2(S)P-0-5'); 5'-monodithiophosphate (phosphorodithioate; (H0)(HS)(S)P-0-5'), 5'-phosphorothiolate ((H0)2(0)P-S-5'); any additional combination of oxygen/sulfur replaced monophosphate, diphosphate and triphosphates (e.g. 5'-alpha-thiotriphosphate, 5'-gamma-thiotriphosphate, etc.), 5'-phosphoramidates ((H0)2(0)P-NH-5', (H0)(NH2)(0)P-0-5'), 5'-alkylphosphonates (R=alkyl=methyl, ethyl, isopropyl, propyl, etc., e.g. RP(OH)(0)-0-5'-, 5'-alkenylphosphonates (i.e. vinyl, substituted vinyl), (OH)2(0)P-5'-CH2-), 5'-alkyletherphosphonates

167 (R=alkylether=methoxymethyl (MeOCH2-), ethoxymethyl, etc., e.g. RP(OH)(0)-0-5'-). In one example, the modification can in placed in the antisense strand of a dsRNA
molecule.
Thermally Destabilizing Modifications.
[00419] The dsRNA agents of the invention can comprise thermally destabilizing modifications in the seed region of the antisense strand (i.e., at positions 2-9 of the 5'-end of the antisense strand) to reduce or inhibit off-target gene silencing. Without wishing to be bound by a theory, dsRNAs with an antisense strand comprising at least one thermally destabilizing modification of the duplex within the first 9 nucleotide positions, counting from the 5' end, of the antisense strand have reduced off-target gene silencing activity.
Accordingly, in some embodiments, the antisense strand comprises at least one (e.g., one, two, three, four, five or more) thermally destabilizing modification of the duplex within the first 9 nucleotide positions of the 5' region of the antisense strand. In some embodiments, thermally destabilizing modification of the duplex is located in positions 2-9, or preferably positions 4-8, from the 5'-end of the antisense strand. In some further embodiments, the thermally destabilizing modification of the duplex is located at position 5, 6, 7 or 8 from the 5'-end of the antisense strand.
[00420] In still some further embodiments, the thermally destabilizing modification of the duplex is located at position 7 from the 5'-end of the antisense strand. The term "thermally destabilizing modification(s)" includes modification(s) that would result with a dsRNA with a lower overall melting temperature (Tm) (preferably a Tm with one, two, three or four degrees lower than the Tm of the dsRNA without having such modification(s). In some embodiments, the thermally destabilizing modification of the duplex is located at position 2, 3, 4, 5, 6, 7, 8 or 9 from the 5'-end of the antisense strand.
[00421] The thermally destabilizing modifications can include, but are not limited to, abasic modification; mismatch with the opposing nucleotide in the opposing strand;
and sugar modification such as 2'-deoxy modification or acyclic nucleotide, e.g., unlocked nucleic acids (UNA) or glycol nucleic acid (GNA). For example, the thermally destabilizing modifications can include, but are not limited to, mUNA and GNA building blocks as follows:

168 NH N---NH
t y "... N
s'(eY 4eY ss(0i) ss(eY
Oy 0,s Oy ay Mod 1 Mod 2 Mod 3 Mod 4 (GNA-C) (GNA-isoC) (GNA-G) (GNA-isoG) Base 0 Base 0.õ.._(:), Base 0Wase ----. ..........., 0-,?
OH µ.--0 OH ,,,c0 OH HO Oy Mod 5 Mod 6 Mod 7 Mod 8 (5'-mUNA) (3'-mUNA) (T-mUNA) (2-5-RNA) "Both stereoisomers tested 7 1 i oy-o o B
'IcLW Ow i ?,:) ¨Or*''ON
,_0_¨) O__/ N:,0 0,, 0 ay ,0 X b ,4.
Mod2 Mod1 (2-0Me Abasic Mod3 Mod4 Mod5 ' (GNA) Spacer) (T-OMe) (5-Me) (Hyp-spacer) X = OMe, F
B
OyJ
B B
B B
s...-C
l'4:3`

I 0õ, ay / 0../
Mod6 Mod7 Mod8 Mod9 Mod10 (SNA) (hGNA) (hhGNA) (mGNA) (TNA) B
\..Øõ...,..y, *Both stereoisomers tested Oy h'GNA

169 (" ,, ..õ, e(, eL,,H el'IVH eLz N-0 µ NO N" "0 t NO t N¨'0 t (v-r4o 0.0 o (D4 )SSO ...,,,,..r ., _0õO OH -0õ0 OH -0õ0 OH -0.,p,.0 OH -0,p,.0 OH -0,p,.0 OH
d% OP% % o' %

I
o B (U1c/ft/G) H El ?(, NH, ,.õ.
, 0N 0 %
.0 .õ0 cr0 er'N
' N NH, to_ ,N
- C:1¨/
0 OH 0 Me LOH O''.
'0 -0õ0 -Wp, -o-P=o 3 ,,o Nx-i-t'-. N)JH
N NI.1j1.5NH
I.,J1 erN
. N N 0 5 N N i N N--.0 i N N NH2 -0õ0 R -0õ0 R -0õ0 R -0õ0 R
P.,. P.,. P.
F1'0 1 0 1 0 l'O
isoG inosine xanthosine 2-aminopurine HN NH (R = H, F, OMe etc) A Nx-L,N
I
0 i N N

-0õ0 R -0õ0 R
pseudouracil N6-methyladenine [00422] In some embodiments, the destabilizing modification is selected from the group consisting of GNA-isoC, GNA-isoG, 5'-mUNA, 4' -mUNA, 3 '-mUNA, and 2' -mUNA.
[00423] In some embodiments, the destabilizing modification mUNA is selected from the group consisting of

170 i, R' i, R' 0 0 B AcHN 0 B 00 0 B MeHN)LNI-1 0 B
¨=
11, ss' AcHN 0õ ¨ MeHN µ )LNµ 07\
0 R R'0 R H 0 R R' 0 R

0 OyB Me0 Me0 NH 0 Me0 B Me0)LN 0 B
. =
11., õoss l; ( 07 )LN,µ ( 07\

0-0 B AcN 0 B 00 0 B MeHN)LN 0 B
)1,- mos'''.
AcN\ 07\µµ MeHN
R = H, OH; OMe; Cl, F; OH; 0-(CH2)20Me; SMe, NMe2; NH2; Me; CCH (alkyne), 0-nPr;
0-alkyl; 0-alkylamino;
R' =H, Me;
B = A; C; 5-Me-C; G; I; U; T; Y; 2-thiouridine; 4-thiouridine; CS-modified pyrimidines; C2-modified purines; N8-modiifed purines; phenoxazine; G-clamp; non-canonical mono, bi and tricyclic heterocycles; pseudouracil; isoC; isoG; 2,6-diamninopurine;
pseudocytosine; 2-aminopurine; xanthosine; N6-alkyl-A; 06-alkyl-G; 2-thiouridine; 4-thiouridine;
CS-modified pyrimidines; C2-modified purines; N8-modiifed purines; 7-deazapurines, phenoxazine; G-clamp; non-canonical mono, bi and tricyclic heterocycles; and Stereochemistry is R or S and combination of R and S for the unspecified chiral centers.
[00424] In some embodiments, the destabilizing modification mUNA is selected from the group consisting of R' i, R' 0-0 B Me0 0 B Me0: 0 B Me0"¨N.,-0 0 B
Mee R' 0-0 B F\(0 B
F\ 07\µµ ) 0 R R' 0 R

171 R = H, OH; OMe; Cl, F; OH; 0-(CH2)20Me; SMe, NMe2; NH2; Me; CCH (alkyne), 0-nPr;
0-alkyl; 0-alkylamino;
R' =H, Me;
B = A; C; 5-Me-C; G; I; U; T; Y; 2-thiouridine; 4-thiouridine; CS-modified pyrimidines; C2-modified purines; N8-modiifed purines; phenoxazine; G-clamp; non-canonical mono, bi and tricyclic heterocycles; pseudouracil; isoC; isoG; 2,6-diamninopurine;
pseudocytosine; 2-aminopurine; xanthosine; N6-alkyl-A; 06-alkyl-G; 2-thiouridine; 4-thiouridine;
CS-modified pyrimidines; C2-modified purines; N8-modiifed purines; 7-deazapurines, phenoxazine; G-clamp; non-canonical mono, bi and tricyclic heterocycles; and Stereochemistry is R or S and combination of R and S for the unspecified chiral centers.
[00425] In some embodiments, the destabilizing modification mUNA is selected from the group consisting of ss Et0 07,µ sr 0¨r 0¨.0 B OnPry B 0---0 B MeS 0 B
nPre 0-1\ =
MeSµ 07\

0 0 B H2NOC H ¨.c 0---0 B
It, osss 07\ 2NOC 0 B 07\

R = H, OMe; F; OH; 0-(CH2)20Me; SMe, NMe2; NH2; Me; 0-nPr; 0-alkyl; 0-alkylamino;
R' = H, Me;
B = A; C; 5-Me-C; G; I; U; T; Y; 2-thiouridine; 4-thiouridine; CS-modified pyrimidines; C2-modified purines; N8-modiifed purines; phenoxazine; G-clamp; non-canonical mono, bi and tricyclic heterocycles; pseudouracil; isoC; isoG; 2,6-diamninopurine;
pseudocytosine; 2-aminopurine; xanthosine; N6-alkyl-A; 06-alkyl-G; 7-deazapurines; and Stereochemistry is R or S and combination of R and S for the unspecified chiral centers.
[00426] In some embodiments, the destabilizing modification mUNA is selected from the group consisting of

172 R' HO
HO 0vB AcHNovB 0 0 B MeHNNH 0 )L
µ0 ¨= B
0 N(' R. HO R
AcHN1µ HO/ ( MeHN)LN HO
HO R R HO R "HO R

R' HO HO
Me0 Me0 µNI- Me0 N
CyB 0 0 B Me0)LN 0 B
R HO ( R
N H07`, riv7 H HO R IHO R R'/ HO R
' HO¨kovB AcNI 0 B 0 oB
Acl\lµ MeHN N MeHNNI -0 B H07`µss H07 1HO R R. HO R I:HO R HO R
R' R = H, OH; OMe; Cl, F; OH; 0-(CH2)20Me; SMe, NMe2; NH2; Me; CCH (alkyne), 0-nPr;
0-alkyl; 0-alkylamino;
R' =H, Me;
B = A; C; 5-Me-C; G; I; U; T; Y; 2-thiouridine; 4-thiouridine; CS-modified pyrimidines; C2-modified purines; N8-modiifed purines; phenoxazine; G-clamp; non-canonical mono, bi and tricyclic heterocycles; pseudouracil; isoC; isoG; 2,6-diamninopurine;
pseudocytosine; 2-aminopurine; xanthosine; N6-alkyl-A; 06-alkyl-G; 2-thiouridine; 4-thiouridine;
CS-modified pyrimidines; C2-modified purines; N8-modiifed purines; 7-deazapurines, phenoxazine; G-clamp; non-canonical mono, bi and tricyclic heterocycles; and Stereochemistry is R or S and combination of R and S for the unspecified chiral centers [00427] In some embodiments, the destabilizing modification mUNA is selected from the group consisting of R R' HO¨C) B Me0 0 B HO ¨O B Me0-%-0 0 B
Mee' ss. Zr.
H07`µsss Mea,fessµ'. H07 HO R R'i HO R HO R
R'/ HO R
R' HO¨'(OvB F\(OvB
F H07`µ\sss') ( HO R
R'/ HO R
R = H, OH; OMe; Cl, F; OH; 0-(CH2)20Me; SMe, NMe2; NH2; Me; CCH (alkyne), 0-nPr;
0-alkyl; 0-alkylamino;

173 R' =H, Me;
B = A; C; 5-Me-C; G; I; U; T; Y; 2-thiouridine; 4-thiouridine; CS-modified pyrimidines; C2-modified purines; N8-modiifed purines; phenoxazine; G-clamp; non-canonical mono, bi and tricyclic heterocycles; pseudouracil; isoC; isoG; 2,6-diamninopurine;
pseudocytosine; 2-aminopurine; xanthosine; N6-alkyl-A; 06-alkyl-G; 2-thiouridine; 4-thiouridine;
CS-modified pyrimidines; C2-modified purines; N8-modiifed purines; 7-deazapurines, phenoxazine; G-clamp; non-canonical mono, bi and tricyclic heterocycles; and Stereochemistry is R or S and combination of R and S for the unspecified chiral centers [00428] In some embodiments, the modification mUNA is selected from the group consisting of IT IT
HO 0 B Et0 0 B

oss Ee ¨7 IT HO R
HO R HO R
R' R' HO----(c0 B OnPrir0 B HO----.0 B MeS 0 B
1,3....
0.' nPrO HOis ) MeS HO `µss%

R' R' HO 0 B H2NOC 0 B HO--c0 B 0"s.
H2NOC H07 X¨k_ri 0 B
¨.c X_CNIµµµµµ... H07 HO R / HO R
N-r-N HO R R'/ HO R
R' R = H, OMe; F; OH; 0-(CH2)20Me; SMe, NMe2; NH2; Me; 0-nPr; 0-alkyl; 0-alkylamino;
R' = H, Me;
B = A; C; 5-Me-C; G; I; U; T; Y; 2-thiouridine; 4-thiouridine; CS-modified pyrimidines; C2-modified purines; N8-modiifed purines; phenoxazine; G-clamp; non-canonical mono, bi and tricyclic heterocycles; pseudouracil; isoC; isoG; 2,6-diamninopurine;
pseudocytosine; 2-aminopurine; xanthosine; N6-alkyl-A; 06-alkyl-G; 7-deazapurines; and Stereochemistry is R or S and combination of R and S for the unspecified chiral centers [00429] In some embodiments, the modification mUNA is selected from the group consisting of

174 H.. Me,.... H H.. Me, .., Me .% Me ==., H
X-0.---<0 B X-0 0 B X-0 0 B X-01:0 B
--'' sg .
,==
Fs Z./RI Fs µ Ri CIH2C¨ss CIH2C¨ss R1, R2= OTBS; F, H, Me, CI
B = ABz; CBz; 5-Me-C; G; I; U; T; Y; 2-thiouridine; 4-thiouridine; C5-modified pyrimidines; C2-modified purines; N8-modified purines; phenoxazine; G-clamp;
H.,, me Me, " , non-canonical mono, bi and tricyclic heterocycles; pseudouracil isoC; isoG; 2,6-'. diamninopurine; pseudocytosine; 2-aminopurine; xanthosine; N6-alkyl-A; 06-alkyl-G; 7-deazapurines ..=
ss . 4 (I:I) -- i r0-rN-114 HO-ILO-ILO-14 X = DMTr, tBu H

oyoO o OH
tBu IP

X-0-::44.. z/ 0 X-0:),- zr B 0 B
X-0-m:\4...¨.( 0 B
X-0::::)... z/
HO OBz HO OBz HO F HO F

X-04 z/me 0 :),.. ..(ve 0 B
4 =gme 0 B
X-0:44 z:me HO Cl HO Cl HO F HO F

-). M -N3 Me ,0y.B x-0-0 B X-0-µ0 B
5, Fs' Fs' Me F% µ..,/,K4e .g .ge (., HO F HO F HO Cl HO Cl X-0 Oy.B X-0-OyB X--\,-0 B x-0-,O B
µg ...(,M
(...Me K.Me Me e HO F HO F HO Cl HO Cl

175 x-og n B X-0:
0 B X-004 X-0:>5.-0..,::
.
Me" Me"
.Me ZMe HO F HO F HO CI HO CI

X-0:4 ,...,:me X-0:404 X-0204 X-0-0z/B
Me HO OBz HO OBz HO OMe HO OMe HO
sme X-0---NO/B X-0-"\n/B X-040zAB
X-0:40 zoB X-0 HO
sme HO HO OM
HO OMe HO ocH2cH2Ome OMe e F F X-0--"Fy/B
0 B 0 = 0 zB fr X-0--TB
X-07:..,5. z/B X-0 Me Me".
HO
sme HO OMe HO ocH2cH2Ome HO OMe HO OMe H21, Me MN H
H-., Me MN H
CIFI2C¨ 3 CIH2C¨`
R' R3 OH R' R3 OH R' R3 OH R, R2 OH
F2,, F22 = OTBS; F, H, Me, Cl R3 = H, Me Me Me, H B = Aaz; CBz; 5-Me-C.; G; I; U; 1; Y; 2-thiouridine;
4-thiouridine; C5-modified "-:
pyrimidines; C2-modified purines; NB-modified purines; phenoxazine; G-clamp;
),,O
z3 non-canonical mono, bi and tricyclic heterocycles; pseudouracil isoC; isoG;
2,8-diamninopurine; pseudocytosine; 2-aminopuiine; xanthosine; N6-alkyl-A; 08-alkyl-' R3 OH ' R3 OH G; 7-cleazapurines 0 ,_.1,01(.41. J-o-L-04 X = DMTr, tBu0---'0- HFLI

tBu ,-....

--.....5. ./Me X-0 0/B

--µ3- 'Me X-0-- B
µ5.0 sr,:Me X-0 0 B
3 Z' 0 0 B

Bz0 OH F OH F OH F OMe HO DI F OH
Bz0 OH
X-0:6,4,e Oz,mBe X-0:),e,,. 0,(..,mBe F OH F OH X - 0: =,4,e0e CI OH X-05:0,z/Ø,mHBe ,,..
HO F HO DI F
OH
0 B X0 0, XC:Oz,H B X

Me R3 F
-C):10 .40HB
F OH F OH DI OH DI O X-OF.J0 0406

176 X-0-'),0,y,B X-00vB
(==1:2, " ) ( X-0:3)., 0.4B x-0:),0,z13 3 ...
X-0.-)im rOy,..FRz3 Mess.F '(:)' e CI OH
Me F OH Me0 F Me0 CI N' CI x¨o"-O

B X-o;3>rYB X-0::),04B
X-C)M--)J0 Z F B
Me 'IsZ3 Me"' VR3 X-0Froz-,..), (:),(.:3 F OH F OH CI OH X-0--\,30::;) 0,v,(.(:;B3 HO OH x-oNTF 040HB
0 B x X-0,-,-:04B
X-C)M4eS Z/ORHB3 X-0404 X-0:44 z:me - :r:
X-0:\ye,, O:e X-040 040 Me0 OH Me0 OH HO OH F OH
BO OH Bz0 OH

X-0").- z, X-00z/B
X-0--µ3,04B X-0-)õ04B x-o--yzõB
Me R3 X-0:4;),04B X-0::),0 4B
Me0 OH Me0¨/¨ OH Me0 OH Me0 OH MeS OH Me0 OH F OH

X-0-Ny Oz.::
X-0;)( X-0:)...
zo X-0;),Oz/B X-0--.F).0z/B NO11 Me0 OH Me0 OH MeS OH Me0 OH F OH
Me0 OH Me0¨"¨ OH
[00430] Exemplified abasic modifications include, but are not limited to the following:
, , , \ , , R ,.
, . I 0 0¨
0 , , 0 0¨c .......iN
b ¨1 0 , 9 0 0 , , , , , , , , , , , 0¨

R",* R.
R R * R *
0 9 , 9 : , , , , , , , Wherein R = H, Me, Et or OMe; R' = H, Me, Et or OMe; R" = H, Me, Et or OMe I I
C) 7' 1-0/411*-cN
0 0 0 O, vO X 0 /
Mod2 Mod3 Mod4 Mod5 (T-OMe Abasic (3-OMe) (5'-Me) (Hyp-spacer) Spacer) X = OMe, F
wherein B is a modified or unmodified nucleobase and the asterisk on each structure represents either R, S or racemic.

177 [00431] Exemplified sugar modifications include, but are not limited to the following:
o NH
\
NO
b B
0¨õ
.1 ( , 1 , 2' -deoxy unlocked nucleic acid glycol nucleic acid R= H, OH, 0-alkyl R= H, OH, 0-alkyl RR
B

sµs lit:410 , B ,O-1_037 so¨õ.74 unlocked nucleic acid R= H, OH, CH3, CH2CH3, 0-alkyl, NH2, NHMe, NMe2 9 R 9 R = H, OH, CH3, CH2CH3, 0-alkyl, NH2, NHMe, NMe2 R" = H, OH, CH3, CH2CH3, 0-alkyl, NH2, NHMe, NMe2 R = H, methyl, ethyl glycol nucleic acid R= H, OH, 0-alkyl IR- = H, OH, CH3, CH2CH3, 0-alkyl, NH2, NHMe, NMe2 R'"' = H, OH, CH3, CH2CH3, 0-alkyl, NH2, NHMe, NMe2 wherein B is a modified or unmodified nucleobase and the asterisk on each structure represents either R, S or racemic.
[00432] In some embodiments the thermally destabilizing modification of the duplex is selected from the mUNA and GNA building blocks described in Examples 1-3 herein. In some embodiments, the destabilizing modification is selected from the group consisting of GNA-isoC, GNA-isoG, 5' -mUNA, 4' -mUNA, 3' -mUNA, and 2' -mUNA. In some further embodiments of this, the dsRNA molecule further comprises at least one thermally destabilizing modification selected from the group consisting of GNA, 2'-0Me, 3'-0Me, 5'-Me, Hy p-spacer, SNA, hGNA, hhGNA, mGNA, TNA and h'GNA (Mod A-Mod K).
[00433] The term "acyclic nucleotide" refers to any nucleotide having an acyclic ribose sugar, for example, where any of bonds between the ribose carbons (e.g., C1'-C2', C2'-C3', C3'-C4', C4'-04', or C1'-04') is absent and/or at least one of ribose carbons or oxygen (e.g., Cl', C2', C3', C4' or 04') are independently or in combination absent from the nucleotide. In nnr (5\
B (5\
B B
ON/I\ 0 / V a 1-µr=
some embodiments, acyclic nucleotide is , , ,

178 cB
)cr or , wherein B is a modified or unmodified nucleobase, R1 and R2 independently are H, halogen, 0R3, or alkyl; and R3 is H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar). The term "UNA" refers to unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked "sugar"
residue. In one example, UNA also encompasses monomers with bonds between C1'-C4' being removed (i.e.
the covalent carbon-oxygen-carbon bond between the Cl' and C4' carbons). In another example, the C2'-C3' bond (i.e. the covalent carbon-carbon bond between the C2' and C3' carbons) of the sugar is removed (see Mikhailov et. al., Tetrahedron Letters, 26 (17): 2059 (1985); and Fluiter et al., Mol. Biosyst., 10: 1039 (2009), which are hereby incorporated by reference in their entirety). The acyclic derivative provides greater backbone flexibility without affecting the Watson-Crick pairings. The acyclic nucleotide can be linked via 2'-5' or 3'-5' linkage.
[00434] The term `GNA' refers to glycol nucleic acid which is a polymer similar to DNA
or RNA but differing in the composition of its "backbone" in that is composed of repeating glycerol units linked by phosphodiester bonds:

/

,vvirvw (R)-GNA
[00435] The thermally destabilizing modification of the duplex can be mismatches (i.e., noncomplementary base pairs) between the thermally destabilizing nucleotide and the opposing nucleotide in the opposite strand within the dsRNA duplex. Exemplary mismatch base pairs include G:G, G:A, G:U, G:T, A:A, A:C, C:C, C:U, C:T, U:U, T:T, U:T, or a combination thereof. Other mismatch base pairings known in the art are also amenable to the present invention. A mismatch can occur between nucleotides that are either naturally occurring nucleotides or modified nucleotides, i.e., the mismatch base pairing can occur

179 between the nucleobases from respective nucleotides independent of the modifications on the ribose sugars of the nucleotides. In certain embodiments, the dsRNA molecule contains at least one nucleobase in the mismatch pairing that is a 2'-deoxy nucleobase; e.g., the 2'-deoxy nucleobase is in the sense strand.
[00436] In some embodiments, the thermally destabilizing modification of the duplex in the seed region of the antisense strand includes nucleotides with impaired W-C H-bonding to complementary base on the target mRNA, such as:
N
H2N Nr-sN H2N N N
,L
k , k =-.....N
N N
-L, N
=-=.. ---Nj. OyNO õI n r,i).N
N
j N
0=N! Nj ...... ..,..NH ,.. ..-- NH

N--N N----N Nr N N N N N N N
[00437] More examples of abasic nucleotide, acyclic nucleotide modifications (including UNA and GNA), and mismatch modifications have been described in detail in WO
2011/133876, which is herein incorporated by reference in its entirety.
[00438] The thermally destabilizing modifications may also include universal base with reduced or abolished capability to form hydrogen bonds with the opposing bases, and phosphate modifications.
[00439] In some embodiments, the thermally destabilizing modification of the duplex includes nucleotides with non-canonical bases such as, but not limited to, nucleobase modifications with impaired or completely abolished capability to form hydrogen bonds with bases in the opposite strand. These nucleobase modifications have been evaluated for destabilization of the central region of the dsRNA duplex as described in WO
2010/0011895, which is herein incorporated by reference in its entirety. Exemplary nucleobase modifications are:

180 N...../:=;-.N N-----"N
N---)NH
I I I
N--"N-- N---N- ,N NN H2 I I I
inosine nebularine 2-aminopurine F F
0 ri z 100 NO 2N N CH3 lel F N N N
I I I N
I
2,4-difluorotoluene 5-nitroindole 3-nitropyrrole 4-Fluoro-6- 4-Methylbenzimidazole methylbenzimidazole [00440] In some embodiments, the thermally destabilizing modification of the duplex in the seed region of the antisense strand includes one or more a-nucleotide complementary to the base on the target mRNA, such as:
oryFf 0 t 0--N FO /=N
/ \ NH N
5.-00 2 L--(1'3.'Lf FOL.
z .. ., ,,,.....d .,,, N,..iNH
s". : j -, R
Wherein R is H, OH, OCH3, F, NH2, NHMe, NMe2 or 0-alkyl [00441] Exemplary phosphate modifications known to decrease the thermal stability of dsRNA duplexes compared to natural phosphodiester linkages are:
I I .
I I .
I I .

I
0=P¨SH 0=P¨CH3 0=P¨CH2¨COOH 0=P¨R 0=P¨NH-R 0=P¨O-R

I I I
I I I
I I I
R = alkyl [00442] The alkyl for the R group can be a C1-C6alkyl. Specific alkyls for the R group include, but are not limited to methyl, ethyl, propyl, isopropyl, butyl, pentyl and hexyl.
[00443] In some embodiments, exemplary destabilizing modifications shown in Fig. 1.
[00444] In addition to the antisense strand comprising a thermally destabilizing modification, the dsRNA can also comprise one or more stabilizing modifications. For example, the dsRNA can comprise at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) stabilizing modifications. Without limitations, the stabilizing modifications all can be present in one strand. In some embodiments, both the sense and the antisense strands comprise at least two stabilizing modifications. The stabilizing modification can occur on any nucleotide of the sense strand or antisense strand. For instance, the stabilizing modification

181 can occur on every nucleotide on the sense strand and/or antisense strand;
each stabilizing modification can occur in an alternating pattern on the sense strand or antisense strand; or the sense strand or antisense strand comprises both stabilizing modification in an alternating pattern. The alternating pattern of the stabilizing modifications on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the stabilizing modifications on the sense strand can have a shift relative to the alternating pattern of the stabilizing modifications on the antisense strand.
[00445] In some embodiments, the antisense strand comprises at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) stabilizing modifications.
Without limitations, a stabilizing modification in the antisense strand can be present at any positions. In some embodiments, the antisense comprises stabilizing modifications at positions 2, 6, 8, 9, 14 and 16 from the 5'-end. In some other embodiments, the antisense comprises stabilizing modifications at positions 2, 6, 14 and 16 from the 5'-end. In still some other embodiments, the antisense comprises stabilizing modifications at positions 2, 14 and 16 from the 5'-end.
[00446] In some embodiments, the antisense strand comprises at least one stabilizing modification adjacent to the destabilizing modification. For example, the stabilizing modification can be the nucleotide at the 5'-end or the 3'-end of the destabilizing modification, i.e., at position -1 or +1 from the position of the destabilizing modification. In some embodiments, the antisense strand comprises a stabilizing modification at each of the 5'-end and the 3'-end of the destabilizing modification, i.e., positions -1 and +1 from the position of the destabilizing modification.
[00447] In some embodiments, the antisense strand comprises at least two stabilizing modifications at the 3'-end of the destabilizing modification, i.e., at positions +1 and +2 from the position of the destabilizing modification. In some embodiments, the sense strand comprises at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) stabilizing modifications. Without limitations, a stabilizing modification in the sense strand can be present at any positions. In some embodiments, the sense strand comprises stabilizing modifications at positions 7, 10 and 11 from the 5'-end. In some other embodiments, the sense strand comprises stabilizing modifications at positions 7, 9, 10 and 11 from the 5'-end. In some embodiments, the sense strand comprises stabilizing modifications at positions opposite or complimentary to positions 11, 12 and 15 of the antisense strand, counting from the 5'-end of the antisense strand. In some other embodiments, the sense strand comprises stabilizing modifications at positions opposite or complimentary to positions 11, 12, 13 and 15 of the

182 antisense strand, counting from the 5'-end of the antisense strand. In some embodiments, the sense strand comprises a block of two, three or four stabilizing modifications.
[00448] In some embodiments, the sense strand does not comprise a stabilizing modification in position opposite or complimentary to the thermally destabilizing modification of the duplex in the antisense strand.
[00449] Exemplary thermally stabilizing modifications include, but are not limited to 2'-fluoro modifications. Other thermally stabilizing modifications include, but are not limited to LNA.
[00450] In some embodiments, the dsRNA of the invention comprises at least four (e.g., four, five, six, seven, eight, nine, ten or more) 2'-fluoro nucleotides.
Without limitations, the 2'-fluoro nucleotides all can be present in one strand. In some embodiments, both the sense and the antisense strands comprise at least two 2'-fluoro nucleotides. The 2'-fluoro modification can occur on any nucleotide of the sense strand or antisense strand. For instance, the 2'-fluoro modification can occur on every nucleotide on the sense strand and/or antisense strand; each 2'-fluoro modification can occur in an alternating pattern on the sense strand or antisense strand; or the sense strand or antisense strand comprises both 2'-fluoro modifications in an alternating pattern. The alternating pattern of the 2'-fluoro modifications on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the 2'-fluoro modifications on the sense strand can have a shift relative to the alternating pattern of the 2'-fluoro modifications on the antisense strand.
[00451] In some embodiments, the antisense strand comprises at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) 2'-fluoro nucleotides.
Without limitations, a 2'-fluoro modification in the antisense strand can be present at any positions. In some embodiments, the antisense comprises 2'-fluoro nucleotides at positions 2, 6, 8, 9, 14 and 16 from the 5'-end. In some other embodiments, the antisense comprises 2'-fluoro nucleotides at positions 2, 6, 14 and 16 from the 5'-end. In still some other embodiments, the antisense comprises 2'-fluoro nucleotides at positions 2, 14 and 16 from the 5'-end.
[00452] In some embodiments, the antisense strand comprises at least one 2'-fluoro nucleotide adjacent to the destabilizing modification. For example, the 2'-fluoro nucleotide can be the nucleotide at the 5'-end or the 3'-end of the destabilizing modification, i.e., at position -1 or +1 from the position of the destabilizing modification. In some embodiments, the antisense strand comprises a 2'-fluoro nucleotide at each of the 5'-end and the 3'-end of the destabilizing modification, i.e., positions -1 and +1 from the position of the destabilizing modification.

183 [00453] In some embodiments, the antisense strand comprises at least two 2' -fluoro nucleotides at the 3' -end of the destabilizing modification, i.e., at positions +1 and +2 from the position of the destabilizing modification.
[00454] In some embodiments, the sense strand comprises at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) 2'-fluoro nucleotides. Without limitations, a 2' -fluoro modification in the sense strand can be present at any positions. In some embodiments, the antisense comprises 2'-fluoro nucleotides at positions 7, 10 and 11 from the 5' -end. In some other embodiments, the sense strand comprises 2' -fluoro nucleotides at positions 7, 9, 10 and 11 from the 5' -end. In some embodiments, the sense strand comprises 2' -fluoro nucleotides at positions opposite or complimentary to positions 11, 12 and 15 of the antisense strand, counting from the 5' -end of the antisense strand. In some other embodiments, the sense strand comprises 2' -fluoro nucleotides at positions opposite or complimentary to positions 11, 12, 13 and 15 of the antisense strand, counting from the 5' -end of the antisense strand. In some embodiments, the sense strand comprises a block of two, three or four 2'-fluoro nucleotides.
[00455] In some embodiments, the sense strand does not comprise a 2' -fluoro nucleotide in position opposite or complimentary to the thermally destabilizing modification of the duplex in the antisense strand.
Some selected definitions [00456] As used herein, the terms "dsRNA", "siRNA", and "iRNA agent" are used interchangeably to agents that can mediate silencing of a target RNA, e.g., mRNA, e.g., a transcript of a gene that encodes a protein. For convenience, such mRNA is also referred to herein as mRNA to be silenced. Such a gene is also referred to as a target gene. In general, the RNA to be silenced is an endogenous gene or a pathogen gene. In addition, RNAs other than mRNA, e.g., tRNAs, and viral RNAs, can also be targeted.
[00457] As used herein, the phrase "mediates RNAi" refers to the ability to silence, in a sequence specific manner, a target RNA. While not wishing to be bound by theory, it is believed that silencing uses the RNAi machinery or process and a guide RNA, e.g., an siRNA
agent of 21 to 23 nucleotides.
[00458] As used herein, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between a compound of the invention and a target RNA molecule. Specific binding requires a sufficient degree of complementarity to avoid non-specific binding of the oligomeric compound to non-target sequences under conditions in which specific binding is desired, i.e.,

184 under physiological conditions in the case of assays or therapeutic treatment, or in the case of in vitro assays, under conditions in which the assays are performed. The non-target sequences typically differ by at least 5 nucleotides.
[00459] In some embodiments, a dsRNA molecule of the invention is "sufficiently complementary" to a target RNA, e.g., a target mRNA, such that the dsRNA
molecule silences production of protein encoded by the target mRNA. In another embodiment, the dsRNA
molecule of the invention is "exactly complementary" to a target RNA, e.g., the target RNA
and the dsRNA duplex agent anneal, for example to form a hybrid made exclusively of Watson-Crick base pairs in the region of exact complementarity. A "sufficiently complementary" target RNA can include an internal region (e.g., of at least 10 nucleotides) that is exactly complementary to a target RNA. Moreover, in some embodiments, the dsRNA
molecule of the invention specifically discriminates a single-nucleotide difference. In this case, the dsRNA
molecule only mediates RNAi if exact complementary is found in the region (e.g., within 7 nucleotides of) the single-nucleotide difference.
[00460] The term `BNA' refers to bridged nucleic acid, and is often referred as constrained or inaccessible RNA. BNA can contain a 5-, 6- membered, or even a 7-membered bridged structure with a "fixed" C3' -endo sugar puckering. The bridge is typically incorporated at the 2'-, 4' -position of the ribose to afford a 2', 4'-BNA nucleotide (e.g., LNA, or ENA). Examples of BNA nucleotides include the following nucleosides:
HO
H3C' I IC o B
414(C) H3C.:f..., _. N14112 0 I
IICO
H .C71\1----:
, -C
-He (-) HO
0 I-1(3' -"=(-) 3 -oxyammo-BNA
Me BNA cEt BNA cM0E BNA

Ho I TO
vinyl-carbo-BNA .
[00461] The term 'LNA' refers to locked nucleic acid, and is often referred as constrained or inaccessible RNA. LNA is a modified RNA nucleotide. The ribose moiety of an LNA
nucleotide is modified with an extra bridge (e.g., a methylene bridge or an ethylene bridge)

185 connecting the 2' hydroxyl to the 4' carbon of the same ribose sugar. For instance, the bridge can "lock" the ribose in the 3'-endo North) conformation:
HO
Base HO OH

Base =

[00462] The term `ENA' refers to ethylene-bridged nucleic acid, and is often referred as constrained or inaccessible RNA.
[00463] The "cleavage site" herein means the backbone linkage in the target gene or the sense strand that is cleaved by the RISC mechanism by utilizing the iRNA
agent. And the target cleavage site region comprises at least one or at least two nucleotides on both side of the cleavage site. For the sense strand, the cleavage site is the backbone linkage in the sense strand that would get cleaved if the sense strand itself was the target to be cleaved by the RNAi mechanism. The cleavage site can be determined using methods known in the art, for example the 5'-RACE assay as detailed in Soutschek et at., Nature (2004) 432, 173-178, which is incorporated by reference in its entirety. As is well understood in the art, the cleavage site region for a conical double stranded RNAi agent comprising two 21-nucleotides long strands (wherein the strands form a double stranded region of 19 consecutive base pairs having 2-nucleotide single stranded overhangs at the 3'-ends), the cleavage site region corresponds to positions 9-12 from the 5'-end of the sense strand.
Cleavable Linking Groups [00464] A cleavable linking group is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In a preferred embodiment of the dsRNA molecule according to the present invention, the cleavable linking group is cleaved at least 10 times or more, preferably at least 100 times faster in the target cell or under a first reference condition (which can, e.g., be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, e.g., be selected to mimic or represent conditions found in the blood or serum).
[00465] Cleavable linking groups are susceptible to cleavage agents, e.g., pH, redox potential or the presence of degradative molecules. Generally, cleavage agents are more

186 prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include: redox agents which are selected for particular substrates or which have no substrate specificity, including, e.g., oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction; esterases; endosomes or agents that can create an acidic environment, e.g., those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.
[00466] A cleavable linkage group, such as a disulfide bond can be susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5Ø Some linkers will have a cleavable linking group that is cleaved at a preferred pH, thereby releasing the cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.
[00467] A linker can include a cleavable linking group that is cleavable by a particular enzyme. The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted. For example, liver targeting ligands can be linked to the cationic lipids through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other cell-types rich in esterases include cells of the lung, renal cortex, and testis.
[00468] Linkers that contain peptide bonds can be used when targeting cell types rich in peptidases, such as liver cells and synoviocytes.
[00469] In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group.
It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, e.g., blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It may be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In preferred embodiments, useful candidate compounds are cleaved at least 2, 4, 10 or 100 times faster in the cell (or under in vitro

187 conditions selected to mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).
Redox cleavable linking groups [00470] One class of cleavable linking groups is redox cleavable linking groups, which may be used in the dsRNA molecule according to the present invention that are cleaved upon reduction or oxidation. An example of reductively cleavable linking group is a disulfide linking group (-S-S-). To determine if a candidate cleavable linking group is a suitable "reductively cleavable linking group," or for example is suitable for use with a particular iRNA moiety and particular targeting agent one can look to methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents know in the art, which mimic the rate of cleavage which would be observed in a cell, e.g., a target cell. The candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions. In a preferred embodiment, candidate compounds are cleaved by at most 10% in the blood. In preferred embodiments, useful candidate compounds are degraded at least 2, 4, 10 or 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood (or under in vitro conditions selected to mimic extracellular conditions). The rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.
Phosphate-based cleavable linking groups [00471] Phosphate-based cleavable linking groups, which may be used in the dsRNA
molecule according to the present invention, are cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells. Examples of phosphate-based linking groups are -0-P(0)(ORk)-0-, -0-P(S)(ORk)-0-, -0-P(S)(SR10-0-, -S-P(0)(ORk)-0-, -0-P(0)(ORk)-S-, -S-P(0)(ORk)-S-, -0-P(S)(ORk)-S-, -S-P(S)(ORk)-0-, -0-P(0)(Rk)-0-, -0-P(S)(Rk)-0-, -S-P(0)(Rk)-0-, -S-P(S)(Rk)-0-, -S-P(0)(Rk)-S-, -0-P(S)( Rk)-S-. Preferred embodiments are -0-P(0)(OH)-0-, -0-P(S)(OH)-0-, -0-P(S)(SH)-0-, -S-P(0)(OH)-0-, -0-P(0)(OH)-S-, -S-P(0)(OH)-S-, -0-P(S)(OH)-S-, -S-P(S)(OH)-0-, -0-P(0)(H)-0-, -0-P(S)(H)-0-, -S-P(0)(H)-0-, -S-P(S)(H)-0-, -S-P(0)(H)-S-, -0-P(S)(H)-S-. A preferred embodiment is -0-P(0)(OH)-0-. These candidates can be evaluated using methods analogous to those described above.

188 Acid cleavable linking groups [00472] Acid cleavable linking groups, which may be used in the dsRNA molecule according to the present invention, are linking groups that are cleaved under acidic conditions.
In preferred embodiments acid cleavable linking groups are cleaved in an acidic environment with a pH of about 6.5 or lower (e.g., about 6.0, 5.5, 5.0, or lower), or by agents such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups. Examples of acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids. Acid cleavable groups can have the general formula -C=NN-, C(0)0, or -0C(0).
A preferred embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.
Ester-based linking groups [00473] Ester-based cleavable linking groups, which may be used in the dsRNA
molecule according to the present invention, are cleaved by enzymes such as esterases and amidases in cells. Examples of ester-based cleavable linking groups include but are not limited to esters of alkylene, alkenylene and alkynylene groups. Ester cleavable linking groups have the general formula -C(0)0-, or -0C(0)-. These candidates can be evaluated using methods analogous to those described above.
Peptide-based cleaving groups [00474] Peptide-based cleavable linking groups, which may be used in the dsRNA
molecule according to the present invention, are cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (e.g., dipeptides, tripeptides etc.) and polypeptides.
Peptide-based cleavable groups do not include the amide group (-C(0)NH-). The amide group can be formed between any alkylene, alkenylene or alkynylene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide based cleavage group is generally limited to the peptide bond (i.e., the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group.
Peptide-based cleavable linking groups have the general formula -

189 NHCHRAC(0)NHCHieC(0)-, where RA and le are the R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.
As used herein, "carbohydrate" refers to a compound which is either a carbohydrate per se made up of one or more monosaccharide units having at least 6 carbon atoms (which may be linear, branched or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom;
or a compound having as a part thereof a carbohydrate moiety made up of one or more monosaccharide units each having at least six carbon atoms (which may be linear, branched or cyclic), with an oxygen, nitrogen or sulfur atom bonded to each carbon atom.
Representative carbohydrates include the sugars (mono-, di-, tri- and oligosaccharides containing from about 4-9 monosaccharide units), and polysaccharides such as starches, glycogen, cellulose and polysaccharide gums. Specific monosaccharides include Cs and above (preferably Cs -Cs) sugars; di- and trisaccharides include sugars having two or three monosaccharide units (preferably Cs -Cs).
In vivo stability [00475] For the dsRNA molecules to be more effective in vivo, the antisense strand must have some metabolic stability. In other words, for the dsRNA molecules to be more effective in vivo, some amount of the antisense stand may need to be present in vivo after a period time after administration. Accordingly, in some embodiments, at least 40%, for example at least 45%, at least 50%, at least 55%, at least 60%., at least 65%, at least 70%, at least 75%, or at least 80% of the antisense strand of the dsRNA is present in vivo, for example in mouse liver, at day 5 after in vivo administration. In some embodiments, at least 40%, for example at least 45%, at least 50%, at least 55%, at least 60%., at least 65%, at least 70%, at least 75%, or at least 80% of the antisense strand of the dsRNA is present in vivo, for example in mouse liver, at day 6 after in vivo administration. In some embodiments, at least 40%, for example at least 45%, at least 50%, at least 55%, at least 60%., at least 65%, at least 70%, at least 75%, or at least 80% of the antisense strand of the dsRNA is present in vivo, for example in mouse liver, at day 7 after in vivo administration. In some embodiments, at least 40%, for example at least 45%, at least 50%, at least 55%, at least 60%., at least 65%, at least 70%, at least 75%, or at least 80% of the antisense strand of the dsRNA is present in vivo, for example in mouse liver, at day 8 after in vivo administration. In some embodiments, at least 40%, for example at least 45%, at least 50%, at least 55%, at least 60%., at least 65%, at least 70%, at least 75%, or at least 80% of the antisense strand of the dsRNA is present in vivo, for example in mouse liver, at day 9 after in vivo administration. In some embodiments, at least 40%, for example at least

190 45%, at least 50%, at least 55%, at least 60%., at least 65%, at least 70%, at least 75%, or at least 80% of the antisense strand of the dsRNA is present in vivo, for example in mouse liver, at day 10 after in vivo administration. In some embodiments, at least 40%, for example at least 45%, at least 50%, at least 55%, at least 60%., at least 65%, at least 70%, at least 75%, or at least 80% of the antisense strand of the dsRNA is present in vivo, for example in mouse liver, at day 11 after in vivo administration. In some embodiments, at least 40%, for example at least 45%, at least 50%, at least 55%, at least 60%., at least 65%, at least 70%, at least 75%, or at least 80% of the antisense strand of the dsRNA is present in vivo, for example in mouse liver, at day 12 after in vivo administration. In some embodiments, at least 40%, for example at least 45%, at least 50%, at least 55%, at least 60%., at least 65%, at least 70%, at least 75%, or at least 80% of the antisense strand of the dsRNA is present in vivo, for example in mouse liver, at day 13 after in vivo administration. In some embodiments, at least 40%, for example at least 45%, at least 50%, at least 55%, at least 60%., at least 65%, at least 70%, at least 75%, or at least 80% of the antisense strand of the dsRNA is present in vivo, for example in mouse liver, at day 14 after in vivo administration. In some embodiments, at least 40%, for example at least 45%, at least 50%, at least 55%, at least 60%., at least 65%, at least 70%, at least 75%, or at least 80% of the antisense strand of the dsRNA is present in vivo, for example in mouse liver, at day 15 after in vivo administration.
Uses of dsRNA
[00476] The present invention further relates to a use of a dsRNA molecule as defined herein for inhibiting expression of a target gene. In some embodiments, the present invention further relates to a use of a dsRNA molecule for inhibiting expression of a target gene in vitro.
[00477] The present invention further relates to a dsRNA molecule as defined herein for use in inhibiting expression of a target gene in a subject. The subject may be any animal, such as a mammal, e.g., a mouse, a rat, a sheep, a cattle, a dog, a cat, or a human [00478] In some embodiments, the dsRNA molecule of the invention is administered in buffer.
[00479] In some embodiments, siRNA compounds described herein can be formulated for administration to a subject. A formulated siRNA composition can assume a variety of states. In some examples, the composition is at least partially crystalline, uniformly crystalline, and/or anhydrous (e.g., less than 80, 50, 30, 20, or 10% water). In another example, the siRNA
is in an aqueous phase, e.g., in a solution that includes water.

191 [00480] The aqueous phase or the crystalline compositions can, e.g., be incorporated into a delivery vehicle, e.g., a liposome (particularly for the aqueous phase) or a particle (e.g., a microparticle as can be appropriate for a crystalline composition). Generally, the siRNA
composition is formulated in a manner that is compatible with the intended method of administration, as described herein. For example, in particular embodiments the composition is prepared by at least one of the following methods: spray drying, lyophilization, vacuum drying, evaporation, fluid bed drying, or a combination of these techniques;
or sonication with a lipid, freeze-drying, condensation and other self-assembly.
[00481] A dsRNA preparation can be formulated in combination with another agent, e.g., another therapeutic agent or an agent that stabilizes a dsRNA, e.g., a protein that complexes with dsRNA to form an iRNP. Still other agents include chelating agents, e.g., EDTA (e.g., to remove divalent cations such as Mg2+), salts, RNAse inhibitors (e.g., a broad specificity RNAse inhibitor such as RNAsin) and so forth.
[00482] In some embodiments, the dsRNA preparation includes another dsRNA
compound, e.g., a second dsRNA that can mediate RNAi with respect to a second gene, or with respect to the same gene. Still other preparation can include at least 3, 5, ten, twenty, fifty, or a hundred or more different siRNA species. Such dsRNAs can mediate RNAi with respect to a similar number of different genes.
[00483] In some embodiments, the dsRNA preparation includes at least a second therapeutic agent (e.g., an agent other than a RNA or a DNA). For example, a dsRNA
composition for the treatment of a viral disease, e.g., HIV, might include a known antiviral agent (e.g., a protease inhibitor or reverse transcriptase inhibitor). In another example, a dsRNA
composition for the treatment of a cancer might further comprise a chemotherapeutic agent.
[00484] Exemplary formulations which can be used for administering the dsRNA
molecule according to the present invention are discussed below.
[00485] Liposomes. A dsRNA preparation can be formulated for delivery in a membranous molecular assembly, e.g., a liposome or a micelle. As used herein, the term "liposome" refers to a vesicle composed of amphiphilic lipids arranged in at least one bilayer, e.g., one bilayer or a plurality of bilayers. Liposomes include unilamellar and multilamellar vesicles that have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the siRNA composition. The lipophilic material isolates the aqueous interior from an aqueous exterior, which typically does not include the siRNA composition, although in some examples, it may. Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological

192 membranes, when liposomes are applied to a tissue, the liposomal bilayer fuses with bilayer of the cellular membranes. As the merging of the liposome and cell progresses, the internal aqueous contents that include the dsRNA are delivered into the cell where the dsRNA can specifically bind to a target RNA and can mediate RNAi. In some cases the liposomes are also specifically targeted, e.g., to direct the dsRNA to particular cell types.
[00486] A liposome containing a dsRNA can be prepared by a variety of methods.
In one example, the lipid component of a liposome is dissolved in a detergent so that micelles are formed with the lipid component. For example, the lipid component can be an amphipathic cationic lipid or lipid conjugate. The detergent can have a high critical micelle concentration and may be nonionic. Exemplary detergents include cholate, CHAPS, octylglucoside, deoxycholate, and lauroyl sarcosine. The dsRNA preparation is then added to the micelles that include the lipid component. The cationic groups on the lipid interact with the siRNA and condense around the dsRNA to form a liposome. After condensation, the detergent is removed, e.g., by dialysis, to yield a liposomal preparation of dsRNA.
[00487] If necessary a carrier compound that assists in condensation can be added during the condensation reaction, e.g., by controlled addition. For example, the carrier compound can be a polymer other than a nucleic acid (e.g., spermine or spermidine). pH can also be adjusted to favor condensation.
[00488] Further description of methods for producing stable polynucleotide delivery vehicles, which incorporate a polynucleotide/cationic lipid complex as structural components of the delivery vehicle, are described in, e.g., WO 96/37194. Liposome formation can also include one or more aspects of exemplary methods described in Felgner, P. L.
et al., Proc. Natl.
Acad. Sc., USA 8:7413-7417, 1987; U.S. Pat. No. 4,897,355; U.S. Pat. No.
5,171,678;
Bangham, et al. M. Mot. Biol. 23:238, 1965; Olson, et al. Biochim. Biophys.
Acta 557:9, 1979;
Szoka, et at. Proc. Natl. Acad. Sci. 75: 4194, 1978; Mayhew, et at. Biochim.
Biophys. Acta 775:169, 1984; Kim, et at. Biochim. Biophys. Acta 728:339, 1983; and Fukunaga, et at.
Endocrinol. 115:757, 1984, which are incorporated by reference in their entirety. Commonly used techniques for preparing lipid aggregates of appropriate size for use as delivery vehicles include sonication and freeze-thaw plus extrusion (see, e.g., Mayer, et at.
Biochim. Biophys.
Acta 858:161, 1986, which is incorporated by reference in its entirety).
Microfluidization can be used when consistently small (50 to 200 nm) and relatively uniform aggregates are desired (Mayhew, et at. Biochim. Biophys. Acta 775:169, 1984, which is incorporated by reference in its entirety). These methods are readily adapted to packaging siRNA
preparations into liposomes.

193 [00489] Liposomes that are pH-sensitive or negatively-charged entrap nucleic acid molecules rather than complex with them. Since both the nucleic acid molecules and the lipid are similarly charged, repulsion rather than complex formation occurs.
Nevertheless, some nucleic acid molecules are entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et at., Journal of Controlled Release, 19, (1992) 269-274, which is incorporated by reference in its entirety).
[00490] One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.
[00491] Examples of other methods to introduce liposomes into cells in vitro and include U.S. Pat. No. 5,283,185; U.S. Pat. No. 5,171,678; WO 94/00569; WO 93/24640; WO

91/16024; Felgner, J. Biol. Chem. 269:2550, 1994; Nabel, Proc. Natl. Acad.
Sci. 90:11307, 1993; Nabel, Human Gene Ther. 3:649, 1992; Gershon, Biochem. 32:7143, 1993;
and Strauss EMBO 1 11:417, 1992.
[00492] In some embodiments, cationic liposomes are used. Cationic liposomes possess the advantage of being able to fuse to the cell membrane. Non-cationic liposomes, although not able to fuse as efficiently with the plasma membrane, are taken up by macrophages in vivo and can be used to deliver siRNAs to macrophages.
[00493] Further advantages of liposomes include: liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated siRNAs in their internal compartments from metabolism and degradation (Rosoff, in "Pharmaceutical Dosage Forms,"
Lieberman, Rieger and Banker (Eds.), 1988, volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.
[00494] A positively charged synthetic cationic lipid, N41-(2,3-dioleyloxy)propy1]-N,N,N-trimethylammonium chloride (DOTMA) can be used to form small liposomes that interact

194 spontaneously with nucleic acid to form lipid-nucleic acid complexes which are capable of fusing with the negatively charged lipids of the cell membranes of tissue culture cells, resulting in delivery of siRNA (see, e.g., Felgner, P. L. et al., Proc. Natl. Acad.
Sci., USA 8:7413-7417, 1987 and U.S. Pat. No. 4,897,355 for a description of DOTMA and its use with DNA, which are incorporated by reference in their entirety).
[00495] A DOTMA analogue, 1,2-bis(oleoyloxy)-3-(trimethylammonia)propane (DOTAP) can be used in combination with a phospholipid to form DNA-complexing vesicles. LipofectinTM Bethesda Research Laboratories, Gaithersburg, Md.) is an effective agent for the delivery of highly anionic nucleic acids into living tissue culture cells that comprise positively charged DOTMA liposomes which interact spontaneously with negatively charged polynucleotides to form complexes. When enough positively charged liposomes are used, the net charge on the resulting complexes is also positive. Positively charged complexes prepared in this way spontaneously attach to negatively charged cell surfaces, fuse with the plasma membrane, and efficiently deliver functional nucleic acids into, for example, tissue culture cells. Another commercially available cationic lipid, 1,2-bis(oleoyloxy)-3,3-(trimethylammonia)propane ("DOTAP") (Boehringer Mannheim, Indianapolis, Indiana) differs from DOTMA in that the oleoyl moieties are linked by ester, rather than ether linkages.
[00496] Other reported cationic lipid compounds include those that have been conjugated to a variety of moieties including, for example, carboxyspermine which has been conjugated to one of two types of lipids and includes compounds such as 5-carboxyspermylglycine dioctaoleoylamide ("DOGS") (TransfectamTm, Promega, Madison, Wisconsin) and dipalmitoylphosphatidylethanolamine 5-carboxyspermyl-amide ("DPPES") (see, e.g., U.S.
Pat. No. 5,171,678).
[00497] Another cationic lipid conjugate includes derivatization of the lipid with cholesterol ("DC-Chol") which has been formulated into liposomes in combination with DOPE
(See, Gao, X. and Huang, L., Biochim. Biophys. Res. Commun. 179:280, 1991).
Lipopolylysine, made by conjugating polylysine to DOPE, has been reported to be effective for transfection in the presence of serum (Zhou, X. et at., Biochim. Biophys. Acta 1065:8, 1991, which is incorporated by reference in its entirety). For certain cell lines, these liposomes containing conjugated cationic lipids, are said to exhibit lower toxicity and provide more efficient transfection than the DOTMA-containing compositions. Other commercially available cationic lipid products include DMRIE and DMRIE-HP (Vical, La Jolla, California) and Lipofectamine (DOSPA) (Life Technology, Inc., Gaithersburg, Maryland). Other cationic

195 lipids suitable for the delivery of oligonucleotides are described in WO
98/39359 and WO
96/37194.
[00498] Liposomal formulations are particularly suited for topical administration.
Liposomes present several advantages over other formulations. Such advantages include reduced side effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer siRNA, into the skin. In some implementations, liposomes are used for delivering siRNA to epidermal cells and also to enhance the penetration of siRNA into dermal tissues, e.g., into skin. For example, the liposomes can be applied topically. Topical delivery of drugs formulated as liposomes to the skin has been documented (see, e.g., Weiner et at., Journal of Drug Targeting, 1992, vol. 2,405-410 and du Plessis et al., Antiviral Research, 18, 1992, 259-265; Mannino, R. J. and Fould-Fogerite, S., Biotechniques 6:682-690, 1988;
Itani, T. et at.
Gene 56:267-276. 1987; Nicolau, C. et al. Meth. Enz. 149:157-176, 1987;
Straubinger, R. M.
and Papahadjopoulos, D. Meth. Enz. 101:512-527, 1983; Wang, C. Y. and Huang, L., Proc.
Natl. Acad. Sci. USA 84:7851-7855, 1987, which are incorporated by reference in their entirety).
[00499] Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome II
(glyceryl distearate/
cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver a drug into the dermis of mouse skin. Such formulations with dsRNA descreibed herein are useful for treating a dermatological disorder.
[00500] Liposomes that include dsRNA described herein can be made highly deformable. Such deformability can enable the liposomes to penetrate through pore that are smaller than the average radius of the liposome. For example, transfersomes are a type of deformable liposomes. Transfersomes can be made by adding surface edge activators, usually surfactants, to a standard liposomal composition. Transfersomes that include dsRNA
described herein can be delivered, for example, subcutaneously by infection in order to deliver dsRNA to keratinocytes in the skin. In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. In addition, due to the lipid properties, these transfersomes can be self-optimizing (adaptive to the shape of pores, e.g., in the skin), self-repairing, and can frequently reach their targets without fragmenting, and often self-loading.

196 [00501] Other formulations amenable to the present invention are described in United States provisional application serial nos. 61/018,616, filed January 2, 2008;
61/018,611, filed January 2, 2008; 61/039,748, filed March 26, 2008; 61/047,087, filed April 22, 2008 and 61/051,528, filed May 8, 2008. PCT application no PCT/U52007/080331, filed October 3, 2007 also describes formulations that are amenable to the present invention.
[00502] Surfactants. The dsRNA compositions can include a surfactant. In some embodiments, the dsRNA is formulated as an emulsion that includes a surfactant. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in "Pharmaceutical Dosage Forms,"
Marcel Dekker, Inc., New York, NY, 1988, p. 285).
[00503] If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical products and are usable over a wide range of pH values. In general, their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.
[00504] If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.
[00505] If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.
[00506] If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

197 [00507] The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in "Pharmaceutical Dosage Forms," Marcel Dekker, Inc., New York, NY, 1988, p. 285).
[00508] Micelles and other Membranous Formulations. For ease of exposition the micelles and other formulations, compositions and methods in this section are discussed largely with regard to unmodified siRNA compounds. It may be understood, however, that these micelles and other formulations, compositions and methods can be practiced with other siRNA
compounds, e.g., modified siRNA compounds, and such practice is within the invention. The siRNA compound, e.g., a double-stranded siRNA compound, or ssiRNA compound, (e.g., a precursor, e.g., a larger siRNA compound which can be processed into a ssiRNA
compound, or a DNA which encodes an siRNA compound, e.g., a double-stranded siRNA
compound, or ssiRNA compound, or precursor thereof)) composition can be provided as a micellar formulation. "Micelles" are defined herein as a particular type of molecular assembly in which amphipathic molecules are arranged in a spherical structure such that all the hydrophobic portions of the molecules are directed inward, leaving the hydrophilic portions in contact with the surrounding aqueous phase. The converse arrangement exists if the environment is hydrophobic.
[00509] A mixed micellar formulation suitable for delivery through transdermal membranes may be prepared by mixing an aqueous solution of the dsRNA composition, an alkali metal Cs to C22 alkyl sulphate, and a micelle forming compounds. Exemplary micelle forming compounds include lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof, chenodeoxycholate, deoxycholate, and mixtures thereof The micelle forming compounds may be added at the same time or after addition of the alkali metal alkyl sulphate. Mixed micelles will form with substantially any kind of mixing of the ingredients but vigorous mixing in order to provide smaller size micelles.
[00510] In one method, a first micellar composition is prepared which contains the dsRNA
composition and at least the alkali metal alkyl sulphate. The first micellar composition is then mixed with at least three micelle forming compounds to form a mixed micellar composition.
In another method, the micellar composition is prepared by mixing the dsRNA
composition,

198 the alkali metal alkyl sulphate and at least one of the micelle forming compounds, followed by addition of the remaining micelle forming compounds, with vigorous mixing.
[00511] Phenol and/or m-cresol may be added to the mixed micellar composition to stabilize the formulation and protect against bacterial growth. Alternatively, phenol and/or m-cresol may be added with the micelle forming ingredients. An isotonic agent such as glycerin may also be added after formation of the mixed micellar composition.
[00512] For delivery of the micellar formulation as a spray, the formulation can be put into an aerosol dispenser and the dispenser is charged with a propellant. The propellant, which is under pressure, is in liquid form in the dispenser. The ratios of the ingredients are adjusted so that the aqueous and propellant phases become one, i.e., there is one phase.
If there are two phases, it is necessary to shake the dispenser prior to dispensing a portion of the contents, e.g., through a metered valve. The dispensed dose of pharmaceutical agent is propelled from the metered valve in a fine spray.
[00513] Propellants may include hydrogen-containing chlorofluorocarbons, hydrogen-containing fluorocarbons, dimethyl ether and diethyl ether. In certain embodiments, HFA 134a (1,1,1,2 tetrafluoroethane) may be used.
[00514] The specific concentrations of the essential ingredients can be determined by relatively straightforward experimentation. For absorption through the oral cavities, it is often desirable to increase, e.g., at least double or triple, the dosage for through injection or administration through the gastrointestinal tract.
[00515] Particles. In some embodiments, dsRNA preparations can be incorporated into a particle, e.g., a microparticle. Microparticles can be produced by spray-drying, but may also be produced by other methods including lyophilization, evaporation, fluid bed drying, vacuum drying, or a combination of these techniques.
Pharmaceutical compositions [00516] The dsRNA agents of the invention can be formulated for pharmaceutical use. The present invention further relates to a pharmaceutical composition comprising the dsRNA
molecule as defined herein. Pharmaceutically acceptable compositions comprise a therapeutically-effective amount of one or more of the dsRNA molecules in any of the preceding embodiments, taken alone or formulated together with one or more pharmaceutically acceptable carriers (additives), excipient and/or diluents.
[00517] The pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for

199 example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally. Delivery using subcutaneous or intravenous methods can be particularly advantageous.
[00518] The phrase "therapeutically-effective amount" as used herein means that amount of a compound, material, or composition comprising a compound of the invention which is effective for producing some desired therapeutic effect in at least a sub-population of cells in an animal at a reasonable benefit/risk ratio applicable to any medical treatment.
[00519] The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
[00520] The phrase "pharmaceutically-acceptable carrier" as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium state, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate;
(13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid;

200 (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or polyanhydrides;
(22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; and (22) other non-toxic compatible substances employed in pharmaceutical formulations.
[00521] The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect.
Generally, out of one hundred per cent, this amount will range from about 0.1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.
[00522] In certain embodiments, a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides;
and a compound of the present invention. In certain embodiments, an aforementioned formulation renders orally bioavailable a compound of the present invention.
[00523] The dsRNA agent preparation can be formulated in combination with another agent, e.g., another therapeutic agent or an agent that stabilizes a dsRNA, e.g., a protein that complexes with the dsRNA to form an iRNP. Still other agents include chelating agents, e.g., EDTA (e.g., to remove divalent cations such as Mg2+), salts, RNAse inhibitors (e.g., a broad specificity RNAse inhibitor such as RNAsin) and so forth.
[00524] Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
[00525] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form.
Alternatively,

201 delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
[00526] The compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other pharmaceuticals.
[00527] The term "treatment" is intended to encompass therapy and cure. The patient receiving this treatment is any animal in need, including primates, in particular humans, and other mammals such as equines, cattle, swine and sheep; and poultry and pets in general.
[00528] Double-stranded RNA agents are produced in a cell in vivo, e.g., from exogenous DNA templates that are delivered into the cell. For example, the DNA templates can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (U.S. Pat. No.
5,328,470, which is incorporated by reference in its entirety), or by stereotactic injection (see, e.g., Chen et at. (1994) Proc. Natl. Acad. Sci. USA 91:3054-3057, which is incorporated by reference in its entirety). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. The DNA templates, for example, can include two transcription units, one that produces a transcript that includes the top strand of a dsRNA
molecule and one that produces a transcript that includes the bottom strand of a dsRNA
molecule. When the templates are transcribed, the dsRNA molecule is produced, and processed into siRNA agent fragments that mediate gene silencing.
Routes of Delivery [00529] The dsRNA molecule as defined herein or a pharmaceutical composition comprising a dsRNA molecule as defined herein can be administered to a subject using different routes of delivery. A composition that includes a dsRNA described herein can be delivered to a subject by a variety of routes. Exemplary routes include:
intravenous, subcutaneous, topical, rectal, anal, vaginal, nasal, pulmonary, ocular.
[00530] The dsRNA molecule of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically include one or more species of dsRNAs and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents

202 for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
[00531] The compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated.
Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, transdermal), oral or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, or intrathecal or intraventricular administration.
[00532] The route and site of administration may be chosen to enhance targeting. For example, to target muscle cells, intramuscular injection into the muscles of interest would be a logical choice. Lung cells might be targeted by administering the dsRNA in aerosol form. The vascular endothelial cells could be targeted by coating a balloon catheter with the dsRNA and mechanically introducing the dsRNA.
Dosage [00533] In one aspect, the invention features a method of administering a dsRNA molecule, e.g., a dsRNA agent described herein, to a subject (e.g., a human subject). In another aspect, the present invention relates to a dsRNA molecule as defined herein for use in inhibiting expression of a target gene in a subject. The method or the medical use includes administering a unit dose of the dsRNA molecule, e.g., a dsRNA agent described herein. In some embodiments, the unit dose is less than 10 mg per kg of bodyweight, or less than 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005 or 0.00001 mg per kg of bodyweight, and less than 200 nmole of RNA agent (e.g., about 4.4 x 10' copies) per kg of bodyweight, or less than 1500, 750, 300, 150, 75, 15, 7.5, 1.5, 0.75, 0.15, 0.075, 0.015, 0.0075, 0.0015, 0.00075, 0.00015 nmole of RNA agent per kg of bodyweight.
[00534] The defined amount can be an amount effective to treat or prevent a disease or disorder, e.g., a disease or disorder associated with the target gene. The unit dose, for example, can be administered by injection (e.g., intravenous, subcutaneous or intramuscular), an inhaled dose, or a topical application. In some embodiments dosages may be less than 10, 5, 2, 1, or 0.1 mg/kg of body weight.
[00535] In some embodiments, the unit dose is administered less frequently than once a day, e.g., less than every 2, 4, 8 or 30 days. In another embodiment, the unit dose is not administered

203 with a frequency (e.g., not a regular frequency). For example, the unit dose may be administered a single time.
[00536] In some embodiments, the effective dose is administered with other traditional therapeutic modalities. In some embodiments, the subject has a viral infection and the modality is an antiviral agent other than a dsRNA molecule, e.g., other than a siRNA
agent. In another embodiment, the subject has atherosclerosis and the effective dose of a dsRNA
molecule, e.g., a siRNA agent, is administered in combination with, e.g., after surgical intervention, e.g., angioplasty.
[00537] In some embodiments, a subject is administered an initial dose and one or more maintenance doses of a dsRNA molecule, e.g., a siRNA agent, (e.g., a precursor, e.g., a larger dsRNA molecule which can be processed into a siRNA agent, or a DNA which encodes a dsRNA molecule, e.g., a siRNA agent, or precursor thereof). The maintenance dose or doses can be the same or lower than the initial dose, e.g., one-half less of the initial dose. A
maintenance regimen can include treating the subject with a dose or doses ranging from 0.01 [ig to 15 mg/kg of body weight per day, e.g., 10, 1, 0.1, 0.01, 0.001, or 0.00001 mg per kg of bodyweight per day. The maintenance doses are, for example, administered no more than once every 2, 5, 10, or 30 days. Further, the treatment regimen may last for a period of time which will vary depending upon the nature of the particular disease, its severity and the overall condition of the patient. In certain embodiments the dosage may be delivered no more than once per day, e.g., no more than once per 24, 36, 48, or more hours, e.g., no more than once for every 5 or 8 days. Following treatment, the patient can be monitored for changes in his condition and for alleviation of the symptoms of the disease state. The dosage of the compound may either be increased in the event the patient does not respond significantly to current dosage levels, or the dose may be decreased if an alleviation of the symptoms of the disease state is observed, if the disease state has been ablated, or if undesired side-effects are observed.
[00538] The effective dose can be administered in a single dose or in two or more doses, as desired or considered appropriate under the specific circumstances. If desired to facilitate repeated or frequent infusions, implantation of a delivery device, e.g., a pump, semi-permanent stent (e.g., intravenous, intraperitoneal, intracisternal or intracapsular), or reservoir may be advisable.
[00539] In some embodiments, the composition includes a plurality of dsRNA
molecule species. In another embodiment, the dsRNA molecule species has sequences that are non-overlapping and non-adjacent to another species with respect to a naturally occurring target sequence. In another embodiment, the plurality of dsRNA molecule species is specific for

204 different naturally occurring target genes. In another embodiment, the dsRNA
molecule is allele specific.
[00540] The dsRNA molecules of the invention described herein can be administered to mammals, particularly large mammals such as nonhuman primates or humans in a number of ways.
[00541] In some embodiments, the administration of the dsRNA molecule, e.g., a siRNA
agent, composition is parenteral, e.g., intravenous (e.g., as a bolus or as a diffusible infusion), intradermal, intraperitoneal, intramuscular, intrathecal, intraventricular, intracranial, subcutaneous, transmucosal, buccal, sublingual, endoscopic, rectal, oral, vaginal, topical, pulmonary, intranasal, urethral or ocular. Administration can be provided by the subject or by another person, e.g., a health care provider. The medication can be provided in measured doses or in a dispenser which delivers a metered dose. Selected modes of delivery are discussed in more detail below.
[00542] The invention provides methods, compositions, and kits, for rectal administration or delivery of dsRNA molecules described herein [00543] In particular embodiments, the present invention relates to the dsRNA
molecules of the present invention for use in the methods described above.
Methods of inhibiting expression of the target gene [00544] Embodiments of the invention also relate to methods for inhibiting the expression of a target gene. The method comprises the step of administering the dsRNA
molecules in any of the preceding embodiments, in an amount sufficient to inhibit expression of the target gene.
The present invention further relates to a use of a dsRNA molecule as defined herein for inhibiting expression of a target gene in a target cell. In a preferred embodiment, the present invention further relates to a use of a dsRNA molecule for inhibiting expression of a target gene in a target cell in vitro.
[00545] Another aspect the invention relates to a method of modulating the expression of a target gene in a cell, comprising providing to said cell a dsRNA molecule of this invention. In some embodiments, the target gene is selected from the group consisting of Factor VII, Eg5, PCSK9, TPX2, apoB, SAA, TTR, RSV, PDGF beta gene, Erb-B gene, Src gene, CRK
gene, GRB2 gene, RAS gene, MEKK gene, JNK gene, RAF gene, Erk1/2 gene, PCNA(p21) gene, MYB gene, JUN gene, FOS gene, BCL-2 gene, hepcidin, Activated Protein C, Cyclin D
gene, VEGF gene, EGFR gene, Cyclin A gene, Cyclin E gene, WNT-1 gene, beta-catenin gene, c-MET gene, PKC gene, NFKB gene, STAT3 gene, survivin gene, Her2/Neu gene,

205 topoisomerase I gene, topoisomerase II alpha gene, mutations in the p73 gene, mutations in the p21(WAF1/CIP1) gene, mutations in the p27(KIP1) gene, mutations in the PPM1D
gene, mutations in the RAS gene, mutations in the caveolin I gene, mutations in the MD3 I gene, mutations in the MTAI gene, mutations in the M68 gene, mutations in tumor suppressor genes, and mutations in the p53 tumor suppressor gene.
[00546] In particular embodiments, the present invention relates to the dsRNA
molecules of the present invention for use in the methods described above.
[00547] The invention is further illustrated by the following examples, which should not be construed as further limiting. The contents of all references, pending patent applications and published patents, cited throughout this application are hereby expressly incorporated by reference.
EXAMPLES
Example 1: In vitro study Cell culture and 384-well transfections [00548] Hep3b cells (ATCC, Manassas, VA) were grown to near confluence at 37 C
in an atmosphere of 5% CO2 in Eagle's Minimum Essential Medium (Gibco) supplemented with 10% FBS (ATCC) before being released from the plate by trypsinization.
[00549] Transfection was performed by adding 4.91_11 of Opti-MEM plus 0.1 1 of Lipofectamine RNAiMax per well (Invitrogen, Carlsbad CA. cat # 13778-150) to 5 .1 of each siRNA duplex to an individual well in a 384-well plate. The mixture was then incubated at room temperature for 20 minutes. Firty 1 of complete growth media containing 5,000 Hep3b cells were then added to the siRNA mixture. Cells were incubated for 24 hours prior to RNA
purification. Single dose experiments were performed at lOnM and 0.1nM final duplex concentration, and dose response experiments were performed using an eight-point six-fold serial dilution over a range of lOnM to 37.5fM.
[00550] Sequences of dsRNA agents are listed in Table 1. Additional dsRNA
agents targeting an AGT mRNA are described in PCT Publication No. WO 2015/179724, the entire contents of which are incorporated herein by reference.
Total RNA isolation using DYNABEADS mRNA Isolation Kit (InvitrogenTM, part #:
610-12) [00551] Cells were lysed in 75 .1 of Lysis/Binding Buffer containing 3uL of beads per well and mixed for 10 minutes on an electrostatic shaker. The washing steps were automated on a Biotek EL406, using a magnetic plate support. Beads were washed (in 90 L) once in Buffer

206 A, once in Buffer B, and twice in Buffer E, with aspiration steps in between.
Following a final aspiration, complete 10 L RT mixture was added to each well, as described below.
cDNA synthesis using ABI High capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, Cat #4368813) [00552] A master mix of lul 10X Buffer, 0.41_11 25X dNTPs, 411 Random primers, 0.5 1 Reverse Transcriptase, 0.5 1 RNase inhibitor and 6.6 1 of H20 per reaction were added per well. Plates were sealed, agitated for 10 minutes on an electrostatic shaker, and then incubated at 37 degrees C for 2 hours. Following this, the plates were agitated at 80 degrees C for 8 minutes Real time PCR
[00553] Two IA of cDNA were added to a master mix containing 0.5 pl of human GAPDH
TaqMan Probe (4326317E), 0.5 1 human AGT (Hs00174854m1), 41 nuclease-free water and 1Lightcycler 480 probe master mix (Roche Cat # 04887301001) per well in a 384 well plates (Roche cat # 04887301001). Real time PCR was done in a LightCycler480 Real Time PCR
system (Roche).
[00554] To calculate relative fold change, data were analyzed using the AACt method and normalized to assays performed with cells transfected with 1 OnM AD-1955, or mock transfected cells. ICsos were calculated using a 4 parameter fit model using XLFit and normalized to cells transfected with AD-1955 or mock-transfected. The sense and antisense sequences of AD-1955 are: sense: cuuAcGcuGAGuAcuucGAdTsdT (SEQ ID NO: 5) and antisense UCGAAGuACUcAGCGuAAGdTsdT (SEQ ID NO: 6).
[00555]
[00556] Results are summarized in Table 2.

207 Table 1: Exemplary dsRNA agents SEQ SEQ

Duplex ID ID
w o w Number Target NO sOligoName sOligoSeq NO:
asOligoName asOligoSeq =
AD-157529.3 hAGT hAGT 7 A-250551.18 gsuscauccadCadAugagaguacaL96 8 A-311777.2 usdGsuacdTcucaudTgdTggaugacsgsa o o .6.
AD-191860.3 hAGT 9 A-250551.19 gsuscauccadCadAugagaguacaL96 10 A-379557.3 usdGsuadCucucaudTgdTggaugacsgsa .6.
AD-192113.1 hAGT 11 A-380001.1 gsuscauccadCadAugagadGuacaL96 12 A-379557.4 usdGsuadCucucaudTgdTggaugacsgsa AD-192114.1 hAGT 13 A-250551.20 gsuscauccadCadAugagaguacaL96 14 A-380002.1 usdGsdTadCucucaudTgdTggaugacsgsa AD-192115.1 hAGT 15 A-250551.21 gsuscauccadCadAugagaguacaL96 16 A-380003.1 usdGsudAdCucucaudTgdTggaugacsgsa AD-192116.1 hAGT 17 A-250551.22 gsuscauccadCadAugagaguacaL96 18 A-380004.1 usdGsuadCdTcucaudTgdTggaugacsgsa AD-192117.1 hAGT 19 A-250551.23 gsuscauccadCadAugagaguacaL96 20 A-380005.1 usdGsuadCudCucaudTgdTggaugacsgsa AD-192118.1 hAGT 21 A-250551.24 gsuscauccadCadAugagaguacaL96 22 A-380006.1 usdGsuadCucdTcaudTgdTggaugacsgsa P
AD-192119.1 hAGT 23 A-380007.1 gsuscaucdCadCadAugagaguacaL96 24 A-379557.5 usdGsuadCucucaudTgdTggaugacsgsa c, , AD-192120.1 hAGT 25 A-380008.1 gsuscadTcdCadCadAugagaguacaL96 26 A-379557.6 usdGsuadCucucaudTgdTggaugacsgsa , u, c' oe AD-157541.2 hAGT 27 A-250524.11 uscsucccacdCudTuucuucuaauL96 28 A-145692.4 asdTsuadGaagaaadAgdGugggagascsu r., c, AD-192121.1 hAGT 29 A-380009.1 uscsucccacdCudTuucuudCuaauL96 30 A-145692.5 asdTsuadGaagaaadAgdGugggagascsu "
, , c, AD-192122.1 hAGT 31 A-250524.12 uscsucccacdCudTuucuucuaauL96 32 A-380010.1 asdTsdTadGaagaaadAgdGugggagascsu ..
, c, AD-192123.1 hAGT 33 A-250524.13 uscsucccacdCudTuucuucuaauL96 34 A-380011.1 asdTsudAdGaagaaadAgdGugggagascsu AD-192124.1 hAGT 35 A-250524.14 uscsucccacdCudTuucuucuaauL96 36 A-380012.1 asdTsuadGdAagaaadAgdGugggagascsu AD-192125.1 hAGT 37 A-250524.15 uscsucccacdCudTuucuucuaauL96 38 A-380013.1 asdTsuadGadAgaaadAgdGugggagascsu AD-192126.1 hAGT 39 A-250524.16 uscsucccacdCudTuucuucuaauL96 40 A-380014.1 asdTsuadGaadGaaadAgdGugggagascsu AD-192127.1 hAGT 41 A-380015.1 uscsucccdAcdCudTuucuucuaauL96 42 A-145692.6 asdTsuadGaagaaadAgdGugggagascsu AD-192128.1 hAGT 43 A-380016.1 uscsucdCcdAcdCudTuucuucuaauL96 44 A-145692.7 asdTsuadGaagaaadAgdGugggagascsu 1-d n AD-157552.3 hAGT 45 A-250578.52 csascaaugadGadGuaccugugaaL96 46 A-311793.2 usdTscacadGguacdTcdTcauugugsgsa 1-3 AD-192129.1 hAGT 47 A-250578.53 csascaaugadGadGuaccugugaaL96 48 A-380017.1 usdTscadCagguacdTcdTcauugugsgsa cp AD-192130.1 hAGT 49 A-380018.1 csascaaugadGadGuaccudGugaaL96 50 A-380017.2 usdTscadCagguacdTcdTcauugugsgsa o AD-192131.1 hAGT 51 A-250578.54 csascaaugadGadGuaccugugaaL96 52 A-380019.1 usdTsdCadCagguacdTcdTcauugugsgsa 'a vi o AD-192132.1 hAGT 53 A-250578.55 csascaaugadGadGuaccugugaaL96 54 A-380020.1 usdTscdAdCagguacdTcdTcauugugsgsa oe oe AD-192133.1 hAGT 55 A-250578.56 csascaaugadGadGuaccugugaaL96 56 A-380021.1 usdTscadCdAgguacdTcdTcauugugsgsa AD-192134.1 hAGT 57 A-250578.57 csascaaugadGadGuaccugugaaL96 58 A-380022.1 usdTscadCadGguacdTcdTcauugugsgsa AD-192135.1 hAGT 59 A-250578.58 csascaaugadGadGuaccugugaaL96 60 A-380023.1 usdTscadCagdGuacdTcdTcauugugsgsa AD-192136.1 hAGT 61 A-380024.1 csascaaudGadGadGuaccugugaaL96 62 A-380017.3 usdTscadCagguacdTcdTcauugugsgsa 0 o AD-192137.1 hAGT 63 A-380025.1 csascadAudGadGadGuaccugugaa L96 64 A-380017.4 usdTscadCagguacdTcdTcauugugsgsa t,.) o AD-157563.2 hAGT 65 A-250605.12 cscsucaacudGgdAugaagaaacuL96 66 A-311802.2 asdGsuuucdTucaudCcdAguugaggsgsa 'a o AD-192138.1 hAGT 67 A-250605.13 cscsucaacudGgdAugaagaaacuL96 68 A-380026.1 asdGsuudTcuucaudCcdAguugaggsgsa .6.
.6.
AD-192139.1 hAGT 69 A-380027.1 cscsucaacudGgdAugaagdAaacuL96 70 A-380026.2 asdGsuudTcuucaudCcdAguugaggsgsa AD-192140.1 hAGT 71 A-250605.14 cscsucaacudGgdAugaagaaacuL96 72 A-380028.1 asdGsdTudTcuucaudCcdAguugaggsgsa AD-192141.1 hAGT 73 A-250605.15 cscsucaacudGgdAugaagaaacuL96 74 A-380029.1 asdGsudTdTcuucaudCcdAguugaggsgsa AD-192142.1 hAGT 75 A-250605.16 cscsucaacudGgdAugaagaaacuL96 76 A-380030.1 asdGsuudTdCuucaudCcdAguugaggsgsa AD-192143.1 hAGT 77 A-250605.17 cscsucaacudGgdAugaagaaacuL96 78 A-380031.1 asdGsuudTcdTucaudCcdAguugaggsgsa AD-192144.1 hAGT 79 A-250605.18 cscsucaacudGgdAugaagaaacuL96 80 A-380032.1 asdGsuudTcudTcaudCcdAguugaggsgsa AD-192145.1 hAGT 81 A-380033.1 cscsucaadCudGgdAugaagaaacuL96 82 A-380026.3 asdGsuudTcuucaudCcdAguugaggsgsa p AD-192146.1 hAGT 83 A-380034.1 cscsucdAadCudGgdAugaagaaacuL96 84 A-380026.4 asdGsuudTcuucaudCcdAguugaggsgsa , , .3 t-) AD-157574.2 hAGT 85 A-250632.18 gscsugagaadGadTugacagguua L96 86 A-311810.2 usdAsaccdTgucaadTcdTucucagcsasg u, o _.]
o AD-192147.1 hAGT 87 A-250632.19 gscsugagaadGadTugacagguua L96 88 A-380035.1 usdAsacdCugucaadTcdTucucagcsasg " r., , ' AD-192148.1 hAGT 89 A-380036.1 gscsugagaadGadTugacadGguua L96 90 A-380035.2 usdAsacdCugucaadTcdTucucagcsasg .
..
, AD-192149.1 hAGT 91 A-250632.20 gscsugagaadGadTugacagguua L96 92 A-380037.1 usdAsdAcdCugucaadTcdTucucagcsasg AD-192150.1 hAGT 93 A-250632.21 gscsugagaadGadTugacagguua L96 94 A-380038.1 usdAsadCdCugucaadTcdTucucagcsasg AD-192151.1 hAGT 95 A-250632.22 gscsugagaadGadTugacagguua L96 96 A-380039.1 usdAsacdCdTgucaadTcdTucucagcsasg AD-192152.1 hAGT 97 A-250632.23 gscsugagaadGadTugacagguua L96 98 A-380040.1 usdAsacdCudGucaadTcdTucucagcsasg AD-192153.1 hAGT 99 A-250632.24 gscsugagaadGadTugacagguua L96 100 A-380041.1 usdAsacdCugdTcaadTcdTucucagcsasg AD-192154.1 hAGT 101 A-380042.1 gscsugagdAadGadTugacagguua L96 102 A-380035.3 usdAsacdCugucaadTcdTucucagcsasg Iv AD-192155.1 hAGT 103 A-380043.1 gscsugdAgdAadGadTugacagguua L96 104 A-380035.4 usdAsacdCugucaadTcdTucucagcsasg n AD-157584.2 hAGT 105 A-250659.12 uscsucacuudTcdCagcaaaacua L96 106 A-311817.2 usdAsguudTugcugdGadAagugagascsc cp AD-192156.1 hAGT 107 A-250659.13 uscsucacuudTcdCagcaaaacua L96 108 A-380044.1 usdAsgudTuugcugdGadAagugagascsc t,.) o AD-192157.1 hAGT 109 A-380045.1 uscsucacuudTcdCagcaadAacua L96 110 A-380044.2 usdAsgudTuugcugdGadAagugagascsc o 'a AD-192158.1 hAGT 111 A-250659.14 uscsucacuudTcdCagcaaaacua L96 112 A-380046.1 usdAsdGudTuugcugdGadAagugagascsc vi o oe AD-192159.1 hAGT 113 A-250659.15 uscsucacuudTcdCagcaaaacua L96 114 A-380047.1 usdAsgdTdTuugcugdGadAagugagascsc 1-oe AD-192160.1 hAGT 115 A-250659.16 uscsucacuudTcdCagcaaaacua L96 116 A-380048.1 usdAsgudTdTugcugdGadAagugagascsc AD-192161.1 hAGT 117 A-250659.17 uscsucacuudTcdCagcaaaacuaL96 118 A-380049.1 usdAsgudTudTgcugdGadAagugagascsc AD-192162.1 hAGT 119 A-250659.18 uscsucacuudTcdCagcaaaacuaL96 120 A-380050.1 usdAsgudTuudGcugdGadAagugagascsc AD-192163.1 hAGT 121 A-380051.1 uscsucacdTudTcdCagcaaaacuaL96 122 A-380044.3 usdAsgudTuugcugdGadAagugagascsc 0 o AD-192164.1 hAGT 123 A-380052.1 uscsucdAcdTudTcdCagcaaaacuaL96 124 A-380044.4 usdAsgudTuugcugdGadAagugagascsc t,.) o AD-264555.1 F12 125 A-311744.4 ascsucaauadAadGugcuuugaaaL96 126 A-511273.1 usdTsucdAadAgcacdTudTauugagususc 'a o AD-264556.1 F12 127 A-492558.3 usgscuuugadGcdCucagcuucuaL96 128 A-511274.1 usdAsgadAgdCugagdGcdTcaaagcascsu .6.
.6.
AD-264557.1 F12 129 A-492560.2 cscscaagaadAgdTgaaagaccaaL96 130 A-511275.1 usdTsggdTcdTuucadCudTucuugggscsu AD-264558.1 F12 131 A-492562.2 gsgsaacucadAudAaagugcuuuaL96 132 A-511276.1 usdAsaadGcdAcuuudAudTgaguuccsusg AD-264559.1 F12 133 A-492564.2 gscsccaagadAadGugaaagaccaL96 134 A-511277.1 usdGsgudCudTucacdTudTcuugggcsusc AD-264560.1 F12 135 A-492566.2 asgsugcuuudGadGccucagcuuaL96 136 A-511278.1 usdAsagdCudGaggcdTcdAaagcacususc AD-264561.1 F12 137 A-492568.2 uscsaauaaadGudGcuuugaaaauL96 138 A-511279.1 asdTsuudTcdAaagcdAcdTuuauugasgsu AD-264562.1 F12 139 A-492570.2 gsasgcccaadGadAagugaaagaaL96 140 A-511280.1 usdTscudTudCacuudTcdTugggcucscsa AD-264563.1 F12 141 A-492572.2 usgsgagcccdAadGaaagugaaaaL96 142 A-511281.1 usdTsuudCadCuuucdTudGggcuccascsa p AD-264564.1 F12 143 A-492574.2 asascucaaudAadAgugcuuugaaL96 144 A-511282.1 usdTscadAadGcacudTudAuugaguuscsc , , .3 t-) AD-264565.1 F12 145 A-492576.2 gsusgcuuugdAgdCcucagcuucuL96 146 A-511283.1 asdGsaadGcdTgaggdCudCaaagcacsusu u, _.]
o AD-264566.1 F12 147 A-492578.2 usgsuggagcdCcdAagaaagugaaL96 148 A-511284.1 usdTscadCudTucuudGgdGcuccacascsa " r., , ' AD-264567.1 F12 149 A-492580.2 csuscaauaadAgdTgcuuugaaaaL96 150 A-511285.1 usdTsuudCadAagcadCudTuauugagsusu .
..
, AD-264568.1 F12 151 A-492582.2 gscsuuugagdCcdTcagcuucucaL96 152 A-511286.1 usdGsagdAadGcugadGgdCucaaagcsasc AD-264569.1 F12 153 A-492584.2 gsusggagccdCadAgaaagugaaaL96 154 A-511287.1 usdTsucdAcdTuucudTgdGgcuccacsasc AD-264570.1 F12 155 A-492586.2 gsgsagcccadAgdAaagugaaagaL96 156 A-511288.1 usdCsuudTcdAcuuudCudTgggcuccsasc AD-264571.1 F12 157 A-492588.2 gsasacucaadTadAagugcuuugaL96 158 A-511289.1 usdCsaadAgdCacuudTadTugaguucscsu AD-264572.1 F12 159 A-492590.2 gsgscuguggdTgdAccgcaacaaaL96 160 A-511290.1 usdTsugdTudGcggudCadCcacagccscsg AD-264573.1 F12 161 A-492592.2 asgscccaagdAadAgugaaagacaL96 162 A-511291.1 usdGsucdTudTcacudTudCuugggcuscsc Iv AD-264574.1 F12 163 A-492594.2 csasucagacdTudCucuguccaaaL96 164 A-511292.1 usdTsugdGadCagagdAadGucugaugsasu n AD-264575.1 F12 165 A-492596.2 gsusgaaagadCcdAuugcagcaaaL96 166 A-511293.1 usdTsugdCudGcaaudGgdTcuuucacsusu cp AD-264576.1 F12 167 A-492598.2 gsgsaaagacdTcdCaagaaauuuaL96 168 A-511294.1 usdAsaadTudTcuugdGadGucuuuccsasu t,.) o AD-264577.1 F12 169 A-492600.2 cscsagaagcdAudAuugcuucauaL96 170 A-511295.1 usdAsugdAadGcaaudAudGcuucuggsasu o 'a AD-264578.1 F12 171 A-492602.2 csasuaacuadAcdCaggcuuuauaL96 172 A-511296.1 usdAsuadAadGccugdGudTaguuaugsasa vi o oe AD-264579.1 F12 173 A-492604.2 ascsauugccdAgdAaagagaaauaL96 174 A-511297.1 usdAsuudTcdTcuuudCudGgcaaugususu 1-oe AD-264580.1 F12 175 A-492606.2 gsasaacucadAudAaagugcuuuaL96 176 A-511298.1 usdAsaadGcdAcuuudAudTgaguuucsusg AD-264581.1 F12 177 A-492608.2 csascuggaudAudTuuugcgacuuL96 178 A-511299.1 asdAsgudCgdCaaaadAudAuccagugsusa AD-264582.1 F12 179 A-492610.2 ascsuggauadTudTuugcgacuuaL96 180 A-511300.1 usdAsagdTcdGcaaadAadTauccagusgsu AD-264583.1 F12 181 A-492612.2 ascsuaaccadGgdCuuuauccuuaL96 182 A-511301.1 usdAsagdGadTaaagdCcdTgguuagususa 0 o AD-264584.1 F12 183 A-492614.2 asusuuuugcdGadCuuggaccuuuL96 184 A-511302.1 asdAsagdGudCcaagdTcdGcaaaaausasu t,.) o AD-264585.1 F12 185 A-492616.2 csasgaagcadTadTugcuucauaaL96 186 A-511303.1 usdTsaudGadAgcaadTadTgcuucugsgsa 'a o AD-264586.1 F12 187 A-492618.2 usgsgaaagadCudCcaagaaauuuL96 188 A-511304.1 asdAsaudTudCuuggdAgdTcuuuccasusg .6.
.6.
AD-264587.1 F12 189 A-492620.2 usascacuggdAudAuuuuugcgaaL96 190 A-511305.1 usdTscgdCadAaaaudAudCcaguguasgsc AD-264588.1 F12 191 A-492622.2 gsasaagacudCcdAagaaauuuaaL96 192 A-511306.1 usdTsaadAudTucuudGgdAgucuuucscsa AD-264589.1 F12 193 A-492624.2 ususuuugcgdAcdTuggaccuuuaL96 194 A-511307.1 usdAsaadGgdTccaadGudCgcaaaaasusa AD-264590.1 F12 195 A-492626.2 uscsaauaaadGudGcuuugaaaacL96 196 A-511308.1 gsdTsuudTcdAaagcdAcdTuuauugasgsu AD-264591.1 F12 197 A-492628.2 csasggcuacdAcdTggauauuuuuL96 198 A-511309.1 asdAsaadAudAuccadGudGuagccugsusa AD-264592.1 F12 199 A-492630.2 csasuggaaadGadCuccaagaaauL96 200 A-511310.1 asdTsuudCudTggagdTcdTuuccaugsgsu AD-264593.1 F12 201 A-492632.2 gsascugagadAgdCaagcgcuaaaL96 202 A-511311.1 usdTsuadGcdGcuugdCudTcucagucsasu p AD-264594.1 F12 203 A-492634.2 gsascuccaadGadAauuuaaggaaL96 204 A-511312.1 usdTsccdTudAaauudTcdTuggagucsusu , , .3 t-) AD-264595.1 F12 205 A-492636.2 csasagaaagdTgdAaagaccauuaL96 206 A-511313.1 usdAsaudGgdTcuuudCadCuuucuugsgsg u, _.]

AD-264596.1 F12 207 A-311744.5 ascsucaauadAadGugcuuugaaaL96 208 A-511314.1 usdTsucdAadAgcacdTudTauugagususu " r., , ' AD-264597.1 F12 209 A-492639.2 csusuccacgdAgdAaugagcuauaL96 210 A-511315.1 usdAsuadGcdTcauudCudCguggaagsasa .
..
, AD-264598.1 F12 211 A-492641.2 asascuaaccdAgdGcuuuauccuuL96 212 A-511316.1 asdAsggdAudAaagcdCudGguuaguusasu AD-264599.1 F12 213 A-492643.2 gsasgucuggdAudCugacacuuuaL96 214 A-511317.1 usdAsaadGudGucagdAudCcagacucsasu AD-264600.1 F12 215 A-492645.2 gscscagaaadGadGaaaugcuuuaL96 216 A-511318.1 usdAsaadGcdAuuucdTcdTuucuggcsasa AD-264601.1 F12 217 A-492558.4 usgscuuugadGcdCucagcuucuaL96 218 A-511319.1 usdAsgadAgdCugagdGcdTcaaagcasusu AD-237788.1 TTR 219 A-432275.2 csusugcucudAudAaaccguguuaL96 220 A-461233.1 usdAsacdAcdGguuudAudAgagcaagsasa AD-237789.1 TTR 221 A-432277.2 csasguguucdTudGcucuauaaaaL96 222 A-461234.1 usdTsuudAudAgagcdAadGaacacugsusu Iv AD-237790.1 TTR 223 A-432279.2 uscsuugcucdTadTaaaccguguuL96 224 A-461235.1 asdAscadCgdGuuuadTadGagcaagasasc n AD-237791.1 TTR 225 A-432281.2 gsusucuugcdTcdTauaaaccguaL96 226 A-461236.1 usdAscgdGudTuauadGadGcaagaacsasc cp AD-237792.1 TTR 227 A-432283.2 ususgcucuadTadAaccguguuaaL96 228 A-461237.1 usdTsaadCadCgguudTadTagagcaasgsa t,.) o AD-237793.1 TTR 229 A-432285.2 asgsuguucudTgdCucuauaaacaL96 230 A-461238.1 usdGsuudTadTagagdCadAgaacacusgsu o 'a AD-237794.1 TTR 231 A-432287.2 cscsucugaudGgdTcaaaguccuaL96 232 A-461239.1 usdAsggdAcdTuugadCcdAucagaggsasc vi o oe AD-237795.1 TTR 233 A-432289.2 asgsaacuggdAcdAccaaaucguaL96 234 A-461240.1 usdAscgdAudTuggudGudCcaguucusasc 1-oe AD-237796.1 TTR 235 A-432291.2 ascsaguguudCudTgcucuauaaaL96 236 A-461241.1 usdTsuadTadGagcadAgdAacacugususu AD-237797.1 TTR 237 A-432293.2 gsasacuggadCadCcaaaucguaaL96 238 A-461242.1 usdTsacdGadTuuggdTgdTccaguucsusa AD-237798.1 TTR 239 A-432295.2 csuscuauaadAcdCguguuagcaaL96 240 A-461243.1 usdTsgcdTadAcacgdGudTuauagagscsa AD-237799.1 TTR 241 A-432297.2 ascsuggacadCcdAaaucguacuaL96 242 A-461244.1 usdAsgudAcdGauuudGgdTguccagususc 0 o AD-237800.1 TTR 243 A-432299.2 csasggaucudTgdCcaaagcaguaL96 244 A-461245.1 usdAscudGcdTuuggdCadAgauccugsgsu t,.) o AD-237801.1 TTR 245 A-432301.2 usgsuucuugdCudCuauaaaccguL96 246 A-461246.1 asdCsggdTudTauagdAgdCaagaacascsu 'a o AD-237802.1 TTR 247 A-432303.2 csuscaccacdAgdAugagaaguuuL96 248 A-461247.1 asdAsacdTudCucaudCudGuggugagscsc .6.
.6.
AD-237803.1 TTR 249 A-432305.2 uscscucugadTgdGucaaaguccuL96 250 A-461248.1 asdGsgadCudTugacdCadTcagaggascsa AD-237804.1 TTR 251 A-432307.2 ususcuugcudCudAuaaaccguguL96 252 A-461249.1 asdCsacdGgdTuuaudAgdAgcaagaascsa AD-237805.1 TTR 253 A-432309.2 asgsgaucuudGcdCaaagcaguaaL96 254 A-461250.1 usdTsacdTgdCuuugdGcdAagauccusgsg AD-237806.1 TTR 255 A-432311.2 gscsucuauadAadCcguguuagcaL96 256 A-461251.1 usdGscudAadCacggdTudTauagagcsasa AD-237807.1 TTR 257 A-432313.2 csascuacacdCadTcgcagcccuaL96 258 A-461252.1 usdAsggdGcdTgcgadTgdGuguagugsgsc AD-237808.1 TTR 259 A-432315.2 usgscucuaudAadAccguguuagaL96 260 A-461253.1 usdCsuadAcdAcggudTudAuagagcasasg AD-237809.1 TTR 261 A-432317.2 gsgsacaccadAadTcguacuggaaL96 262 A-461254.1 usdTsccdAgdTacgadTudTgguguccsasg p AD-237810.1 TTR 263 A-432319.2 cscsaggaucdTudGccaaagcaguL96 264 A-461255.1 asdCsugdCudTuggcdAadGauccuggsusc , , .3 t-) AD-237811.1 TTR 265 A-432321.2 uscsgccacudAcdAccaucgcagaL96 266 A-461256.1 usdCsugdCgdAuggudGudAguggcgasusg u, _.]
AD-237812.1 TTR 267 A-432323.2 cscscaggagdGadCcaggaucuuaL96 268 A-461257.1 usdAsagdAudCcuggdTcdCuccugggscsu " r., , ' AD-237813.1 TTR 269 A-432325.2 gsuscaaagudCcdTggaugcuguaL96 270 A-461258.1 usdAscadGcdAuccadGgdAcuuugacscsa .
..
, AD-237814.1 TTR 271 A-432327.2 usascaccaudCgdCagcccugcuaL96 272 A-461259.1 usdAsgcdAgdGgcugdCgdAugguguasgsu AD-237815.1 TTR 273 A-432329.2 usgsgucaaadGudCcuggaugcuaL96 274 A-461260.1 usdAsgcdAudCcaggdAcdTuugaccasusc AD-237816.1 TTR 275 A-432331.2 asasaguccudGgdAugcuguccgaL96 276 A-461261.1 usdCsggdAcdAgcaudCcdAggacuuusgsa AD-237817.1 TTR 277 A-432333.2 csusguccgadGgdCagcccugcuaL96 278 A-461262.1 usdAsgcdAgdGgcugdCcdTcggacagscsa AD-237818.1 TTR 279 A-432335.2 gsusguucuudGcdTcuauaaaccaL96 280 A-461263.1 usdGsgudTudAuagadGcdAagaacacsusg AD-237819.1 TTR 281 A-432337.2 usgsauggucdAadAguccuggauaL96 282 A-461264.1 usdAsucdCadGgacudTudGaccaucasgsa Iv AD-237820.1 TTR 283 A-432339.2 cscsacuacadCcdAucgcagcccuL96 284 A-461265.1 asdGsggdCudGcgaudGgdTguaguggscsg n AD-237821.1 TTR 285 A-432341.2 gsgsgcucacdCadCagaugagaaaL96 286 A-461266.1 usdTsucdTcdAucugdTgdGugagcccsgsu cp AD-237822.1 TTR 287 A-432343.2 ascscaggaudCudTgccaaagcaaL96 288 A-461267.1 usdTsgcdTudTggcadAgdAuccugguscsc t,.) o AD-237823.1 TTR 289 A-432345.2 cscsuggaugdCudGuccgaggcaaL96 290 A-461268.1 usdTsgcdCudCggacdAgdCauccaggsasc o 'a AD-237824.1 TTR 291 A-432347.2 gsgsucaaagdTcdCuggaugcuguL96 292 A-461269.1 asdCsagdCadTccagdGadCuuugaccsasu vi o oe AD-237825.1 TTR 293 A-432349.2 csascgggcudCadCcacagaugaaL96 294 A-461270.1 usdTscadTcdTguggdTgdAgcccgugscsa 1-oe AD-237826.1 TTR 295 A-432351.2 gsgsaucuugdCcdAaagcaguagaL96 296 A-461271.1 usdCsuadCudGcuuudGgdCaagauccsusg AD-237827.1 TTR 297 A-432353.2 gscsucaccadCadGaugagaaguuL96 298 A-461272.1 asdAscudTcdTcaucdTgdTggugagcscsc AD-237828.1 TTR 299 A-432355.2 csuscugaugdGudCaaaguccugaL96 300 A-461273.1 usdCsagdGadCuuugdAcdCaucagagsgsa AD-237829.1 TTR 301 A-432357.2 csusggacacdCadAaucguacugaL96 302 A-461274.1 usdCsagdTadCgauudTgdGuguccagsusu 0 o AD-237830.1 TTR 303 A-432359.2 csgsggcucadCcdAcagaugagaaL96 304 A-461275.1 usdTscudCadTcugudGgdTgagcccgsusg t,.) o AD-237831.1 TTR 305 A-432361.2 usgsgacaccdAadAucguacuggaL96 306 A-461276.1 usdCscadGudAcgaudTudGguguccasgsu 'a o AD-237832.1 TTR 307 A-432363.2 usgsgagagcdTgdCacgggcucaaL96 308 A-461277.1 usdTsgadGcdCcgugdCadGcucuccasgsa o .6.
.6.
AD-237833.1 TTR 309 A-432365.2 gscsccaggadGgdAccaggaucuuL96 310 A-461278.1 asdAsgadTcdCuggudCcdTccugggcsusg AD-237834.1 TTR 311 A-432367.2 gsgsaccaggdAudCuugccaaagaL96 312 A-461279.1 usdCsuudTgdGcaagdAudCcugguccsusc AD-237835.1 TTR 313 A-432369.2 usgscacgggdCudCaccacagauaL96 314 A-461280.1 usdAsucdTgdTggugdAgdCccgugcasgsc AD-237836.1 TTR 315 A-432371.2 gsascaggaudGgdCuucccuucgaL96 316 A-461281.1 usdCsgadAgdGgaagdCcdAuccugucsasg AD-237837.1 TTR 317 A-432373.2 csgsccacuadCadCcaucgcagcaL96 318 A-461282.1 usdGscudGcdGauggdTgdTaguggcgsasu AD-237838.1 TTR 319 A-432375.2 asasguccugdGadTgcuguccgaaL96 320 A-461283.1 usdTscgdGadCagcadTcdCaggacuususg AD-237839.1 TTR 321 A-432377.2 asgsuccuggdAudGcuguccgagaL96 322 A-461284.1 usdCsucdGgdAcagcdAudCcaggacususu p AD-237840.1 TTR 323 A-432379.2 csusgcacggdGcdTcaccacagauL96 324 A-461285.1 asdTscudGudGgugadGcdCcgugcagscsu , , .3 t-) AD-237841.1 TTR 325 A-432381.2 gsasccaggadTcdTugccaaagcaL96 326 A-461286.1 usdGscudTudGgcaadGadTccuggucscsu u, _.]
AD-237842.1 TTR 327 A-432383.2 asascuggacdAcdCaaaucguacuL96 328 A-461287.1 asdGsuadCgdAuuugdGudGuccaguuscsu " r., , ' AD-237843.1 TTR 329 A-432385.2 gsasuggucadAadGuccuggaugaL96 330 A-461288.1 usdCsaudCcdAggacdTudTgaccaucsasg .
..
, AD-237844.1 TTR 331 A-432387.2 asusggucaadAgdTccuggaugcuL96 332 A-461289.1 asdGscadTcdCaggadCudTugaccauscsa AD-237845.1 TTR 333 A-432389.2 gscscacuacdAcdCaucgcagccaL96 334 A-461290.1 usdGsgcdTgdCgaugdGudGuaguggcsgsa AD-237846.1 TTR 335 A-432391.2 usgsacaggadTgdGcuucccuucaL96 336 A-461291.1 usdGsaadGgdGaagcdCadTccugucasgsg AD-237847.1 TTR 337 A-432393.2 asgsagcugcdAcdGggcucaccaaL96 338 A-461292.1 usdTsggdTgdAgcccdGudGcagcucuscsc AD-237848.1 TTR 339 A-432395.2 gsusccuggadTgdCuguccgaggaL96 340 A-461293.1 usdCscudCgdGacagdCadTccaggacsusu AD-237849.1 TTR 341 A-432397.2 asusgcugucdCgdAggcagcccuaL96 342 A-461294.1 usdAsggdGcdTgccudCgdGacagcauscsc Iv AD-237850.1 TTR 343 A-432399.2 gsgsagagcudGcdAcgggcucacaL96 344 A-461295.1 usdGsugdAgdCccgudGcdAgcucuccsasg n AD-237851.1 TTR 345 A-432401.2 csusggaugcdTgdTccgaggcagaL96 346 A-461296.1 usdCsugdCcdTcggadCadGcauccagsgsa cp AD-237852.1 TTR 347 A-432403.2 ascsaccaucdGcdAgcccugcucaL96 348 A-461297.1 usdGsagdCadGggcudGcdGauggugusasg t,.) o AD-237853.1 TTR 349 A-432405.2 cscsaggaggdAcdCaggaucuugaL96 350 A-461298.1 usdCsaadGadTccugdGudCcuccuggsgsc o 'a AD-237854.1 TTR 351 A-432407.2 ascsgggcucdAcdCacagaugagaL96 352 A-461299.1 usdCsucdAudCugugdGudGagcccgusgsc vi o oe AD-237855.1 TTR 353 A-432409.2 gsasucuugcdCadAagcaguagcaL96 354 A-461300.1 usdGscudAcdTgcuudTgdGcaagaucscsu 1-oe AD-237856.1 TTR 355 A-432411.2 uscsuggagadGcdTgcacgggcuaL96 356 A-461301.1 usdAsgcdCcdGugcadGcdTcuccagascsu AD-237857.1 TTR 357 A-432413.2 gscsacgggcdTcdAccacagaugaL96 358 A-461302.1 usdCsaudCudGuggudGadGcccgugcsasg AD-237858.1 TTR 359 A-432415.2 usgsgaugcudGudCcgaggcagcaL96 360 A-461303.1 usdGscudGcdCucggdAcdAgcauccasgsg AD-237859.1 TTR 361 A-432417.2 gsasugcugudCcdGaggcagcccu L96 362 A-461304.1 asdGsggdCudGccucdGgdAcagcaucscsa o AD-237860.1 TTR 363 A-432419.2 gsuscuggagdAgdCugcacgggcuL96 364 A-461305.1 asdGsccdCgdTgcagdCudCuccagacsusc t,.) o AD-237861.1 TTR 365 A-432421.2 csusggagagdCudGcacgggcucaL96 366 A-461306.1 usdGsagdCcdCgugcdAgdCucuccagsasc 'a o AD-237862.1 TTR 367 A-432423.2 gsgscucaccdAcdAgaugagaaguL96 368 A-461307.1 asdCsuudCudCaucudGudGgugagccscsg o .6.
.6.
AD-237863.1 TTR 369 A-432425.2 uscscuggaudGcdTguccgaggcaL96 370 A-461308.1 usdGsccdTcdGgacadGcdAuccaggascsu AD-237864.1 TTR 371 A-432427.2 gsgsaugcugdTcdCgaggcagccaL96 372 A-461309.1 usdGsgcdTgdCcucgdGadCagcauccsasg AD-237865.1 TTR 373 A-432429.2 csasggaggadCcdAggaucuugcaL96 374 A-461310.1 usdGscadAgdAuccudGgdTccuccugsgsg AD-237866.1 TTR 375 A-432431.2 gsasgagcugdCadCgggcucaccaL96 376 A-461311.1 usdGsgudGadGcccgdTgdCagcucucscsa AD-218795.6 TTR 377 A-128292.13 asascagugudTcdTugcucuauaaL96 378 A-432271.4 usdTsaudAgadGcaadGadAcacuguususu AD-238829.1 TTR 379 A-128292.14 asascagugudTcdTugcucuauaaL96 380 A-129907.9 usdTsauagagcaadGadAcacuguususu AD-238830.1 TTR 381 A-128292.15 asascagugudTcdTugcucuauaaL96 382 A-463179.1 usdTsadTagagcaadGadAcacuguususu p AD-238831.1 TTR 383 A-128292.16 asascagugudTcdTugcucuauaaL96 384 A-463180.1 usdTsadTadGagcaadGadAcacuguususu , , .3 t-) AD-238832.1 TTR 385 A-128292.17 asascagugudTcdTugcucuauaaL96 386 A-463181.1 usdTsadTadGadGcaadGadAcacuguususu u, _.]
.6.
AD-238833.1 TTR 387 A-128292.18 asascagugudTcdTugcucuauaaL96 388 A-463182.1 usdTsadTadGadGcdAadGadAcacuguususu " r., , ' AD-238834.1 TTR 389 A-128292.19 asascagugudTcdTugcucuauaaL96 390 A-463183.1 usdTsaudAgdAgdCaadGadAcacuguususu .
..
, AD-238835.1 TTR 391 A-128292.20 asascagugudTcdTugcucuauaaL96 392 A-463184.1 usdTsaudAgagcaadGadAcacuguususu AD-238836.1 TTR 393 A-128292.21 asascagugudTcdTugcucuauaaL96 394 A-463185.1 usdTsauadGagcaadGadAcacuguususu AD-238837.1 TTR 395 A-128292.22 asascagugudTcdTugcucuauaaL96 396 A-463186.1 usdTsauagdAgcaadGadAcacuguususu AD-238838.1 TTR 397 A-128292.23 asascagugudTcdTugcucuauaaL96 398 A-463187.1 usdTsauagadGcaadGadAcacuguususu AD-238839.1 TTR 399 A-128292.24 asascagugudTcdTugcucuauaaL96 400 A-463188.1 usdTsauadGadGcaadGadAcacuguususu AD-238840.1 TTR 401 A-128292.25 asascagugudTcdTugcucuauaaL96 402 A-463189.1 usdTsadTagdAgcaadGadAcacuguususu Iv AD-238841.1 TTR 403 A-128292.26 asascagugudTcdTugcucuauaaL96 404 A-463190.1 usdTsaudAgdAgcaadGadAcacuguususu n AD-238842.1 TTR 405 A-128292.27 asascagugudTcdTugcucuauaaL96 406 A-463191.1 usdTsauagagcaadGadAcdAcuguususu cp AD-238843.1 TTR 407 A-128292.28 asascagugudTcdTugcucuauaaL96 408 A-463192.1 usdTsadTagagcaadGadAcdAcuguususu t,.) o AD-238844.1 TTR 409 A-128292.29 asascagugudTcdTugcucuauaaL96 410 A-463193.1 usdTsadTadGagcaadGadAcdAcuguususu o 'a AD-238845.1 TTR 411 A-128292.30 asascagugudTcdTugcucuauaaL96 412 A-463194.1 usdTsadTadGadGcaadGadAcdAcuguususu vi o oe AD-238846.1 TTR 413 A-128292.31 asascagugudTcdTugcucuauaaL96 414 A-463195.1 usdTsadTadGadGcdAadGadAcdAcuguususu 1-oe AD-238847.1 TTR 415 A-128292.32 asascagugudTcdTugcucuauaaL96 416 A-463196.1 usdTsaudAgdAgdCaadGadAcdAcuguususu AD-238848.1 TTR 417 A-128292.33 asascagugudTcdTugcucuauaaL96 418 A-463197.1 usdTsaudAgagcaadGadAcdAcuguususu AD-238849.1 TTR 419 A-128292.34 asascagugudTcdTugcucuauaaL96 420 A-463198.1 usdTsauadGagcaadGadAcdAcuguususu AD-238850.1 TTR 421 A-128292.35 asascagugudTcdTugcucuauaaL96 422 A-463199.1 usdTsauagdAgcaadGadAcdAcuguususu 0 o AD-238851.1 TTR 423 A-128292.36 asascagugudTcdTugcucuauaaL96 424 A-463200.1 usdTsauagadGcaadGadAcdAcuguususu t,.) o AD-238852.1 TTR 425 A-128292.37 asascagugudTcdTugcucuauaaL96 426 A-463201.1 usdTsauadGadGcaadGadAcdAcuguususu 'a o AD-238853.1 TTR 427 A-128292.38 asascagugudTcdTugcucuauaaL96 428 A-463202.1 usdTsadTagdAgcaadGadAcdAcuguususu .6.
.6.
AD-238854.1 TTR 429 A-128292.39 asascagugudTcdTugcucuauaaL96 430 A-463203.1 usdTsaudAgdAgcaadGadAcdAcuguususu AD-238855.1 TTR 431 A-128292.40 asascagugudTcdTugcucuauaaL96 432 A-463204.1 usdTsdAdTdAdGdAdGcaadGadAcacuguususu AD-238856.1 TTR 433 A-128292.41 asascagugudTcdTugcucuauaaL96 434 A-463205.1 usdTsdAdTdAdGdAdGcaadGadAcdAcuguususu AD-238857.1 TTR 435 A-128292.42 asascagugudTcdTugcucuauaaL96 436 A-463206.1 usdTsdAudAgdAgcaadGadAcacuguususu AD-238858.1 TTR 437 A-128292.43 asascagugudTcdTugcucuauaaL96 438 A-463207.1 usdTsadTdAgdAgcaadGadAcacuguususu AD-238859.1 TTR 439 A-128292.44 asascagugudTcdTugcucuauaaL96 440 A-463208.1 usdTsaudAdGdAgcaadGadAcacuguususu AD-238860.1 TTR 441 A-128292.45 asascagugudTcdTugcucuauaaL96 442 A-463209.1 usdTsaudAgdAdGcaadGadAcacuguususu p AD-238861.1 TTR 443 A-463210.1 asascadGudGudTcdTugcucuauaaL96 444 A-463190.2 usdTsaudAgdAgcaadGadAcacuguususu , , .3 t-) AD-238862.1 TTR 445 A-463211.1 asascagdTdGudTcdTugcucuauaaL96 446 A-463190.3 usdTsaudAgdAgcaadGadAcacuguususu u, _.]
vi AD-238863.1 TTR
447 A-463212.1 (idTs)asascagugudTcdTugcucuauaaL96 448 A-463190.4 usdTsaudAgdAgcaadGadAcacuguususu " r., , ' AD-192134.4 AGT 449 A-250578.65 csascaaugadGadGuaccugugaaL96 450 A-380022.5 usdTscadCadGguacdTcdTcauugugsgsa .
..
, AD-157553.2 AGT 451 A-250578.66 csascaaugadGadGuaccugugaaL96 452 A-250577.10 usdTscacagguacdTcdTcauugugsgsa AD-238872.1 AGT 453 A-250578.67 csascaaugadGadGuaccugugaaL96 454 A-463221.1 usdTscdAcagguacdTcdTcauugugsgsa AD-238873.1 AGT 455 A-250578.68 csascaaugadGadGuaccugugaaL96 456 A-463222.1 usdTscdAcdAgguacdTcdTcauugugsgsa AD-238874.1 AGT 457 A-250578.69 csascaaugadGadGuaccugugaaL96 458 A-463223.1 usdTscdAcdAgdGuacdTcdTcauugugsgsa AD-238875.1 AGT 459 A-250578.70 csascaaugadGadGuaccugugaaL96 460 A-463224.1 usdTscdAcdAgdGudAcdTcdTcauugugsgsa AD-238876.1 AGT 461 A-250578.71 csascaaugadGadGuaccugugaaL96 462 A-463225.1 usdTscadCadGgdTacdTcdTcauugugsgsa Iv AD-192129.4 AGT 463 A-250578.72 csascaaugadGadGuaccugugaaL96 464 A-380017.6 usdTscadCagguacdTcdTcauugugsgsa n AD-238877.1 AGT 465 A-250578.73 csascaaugadGadGuaccugugaaL96 466 A-463226.1 usdTscacdAgguacdTcdTcauugugsgsa cp AD-157552.4 AGT 467 A-250578.74 csascaaugadGadGuaccugugaaL96 468 A-311793.3 usdTscacadGguacdTcdTcauugugsgsa t,.) o AD-238878.1 AGT 469 A-250578.75 csascaaugadGadGuaccugugaaL96 470 A-463227.1 usdTscacagdGuacdTcdTcauugugsgsa o 'a AD-238879.1 AGT 471 A-250578.76 csascaaugadGadGuaccugugaaL96 472 A-463228.1 usdTscacdAgdGuacdTcdTcauugugsgsa vi o oe AD-238880.1 AGT 473 A-250578.77 csascaaugadGadGuaccugugaaL96 474 A-463229.1 usdTscdAcadGguacdTcdTcauugugsgsa 1-oe AD-192135.2 AGT 475 A-250578.78 csascaaugadGadGuaccugugaaL96 476 A-380023.2 usdTscadCagdGuacdTcdTcauugugsgsa AD-238881.1 AGT 477 A-250578.79 csascaaugadGadGuaccugugaaL96 478 A-463230.1 usdTscacagguacdTcdTcdAuugugsgsa AD-238882.1 AGT 479 A-250578.80 csascaaugadGadGuaccugugaaL96 480 A-463231.1 usdTscdAcagguacdTcdTcdAuugugsgsa AD-238883.1 AGT 481 A-250578.81 csascaaugadGadGuaccugugaaL96 482 A-463232.1 usdTscdAcdAgguacdTcdTcdAuugugsgsa 0 o AD-238884.1 AGT 483 A-250578.82 csascaaugadGadGuaccugugaaL96 484 A-463233.1 usdTscdAcdAgdGuacdTcdTcdAuugugsgsa t,.) o AD-238885.1 AGT 485 A-250578.83 csascaaugadGadGuaccugugaaL96 486 A-463234.1 usdTscdAcdAgdGudAcdTcdTcdAuugugsgsa 'a o AD-238886.1 AGT 487 A-250578.84 csascaaugadGadGuaccugugaaL96 488 A-463235.1 usdTscadCadGgdTacdTcdTcdAuugugsgsa .6.
.6.
AD-238887.1 AGT 489 A-250578.85 csascaaugadGadGuaccugugaaL96 490 A-463236.1 usdTscadCagguacdTcdTcdAuugugsgsa AD-238888.1 AGT 491 A-250578.86 csascaaugadGadGuaccugugaaL96 492 A-463237.1 usdTscacdAgguacdTcdTcdAuugugsgsa AD-238889.1 AGT 493 A-250578.87 csascaaugadGadGuaccugugaaL96 494 A-463238.1 usdTscacadGguacdTcdTcdAuugugsgsa AD-238890.1 AGT 495 A-250578.88 csascaaugadGadGuaccugugaaL96 496 A-463239.1 usdTscacagdGuacdTcdTcdAuugugsgsa AD-238891.1 AGT 497 A-250578.89 csascaaugadGadGuaccugugaaL96 498 A-463240.1 usdTscacdAgdGuacdTcdTcdAuugugsgsa AD-238892.1 AGT 499 A-250578.90 csascaaugadGadGuaccugugaaL96 500 A-463241.1 usdTscdAcadGguacdTcdTcdAuugugsgsa AD-238893.1 AGT 501 A-250578.91 csascaaugadGadGuaccugugaaL96 502 A-463242.1 usdTscadCadGguacdTcdTcdAuugugsgsa p AD-238894.1 AGT 503 A-250578.92 csascaaugadGadGuaccugugaaL96 504 A-463243.1 usdTsdCdAdCdAdGdGuacdTcdTcauugugsgsa , , .3 t-) AD-238895.1 AGT 505 A-250578.93 csascaaugadGadGuaccugugaaL96 506 A-463244.1 usdTsdCdAdCdAdGdGuacdTcdTcdAuugugsgsa u, _.]
o AD-238896.1 AGT 507 A-250578.94 csascaaugadGadGuaccugugaaL96 508 A-463245.1 usdTsdCadCadGguacdTcdTcauugugsgsa " r., , ' AD-238897.1 AGT 509 A-250578.95 csascaaugadGadGuaccugugaaL96 510 A-463246.1 usdTscdAdCadGguacdTcdTcauugugsgsa .
..
, AD-238898.1 AGT 511 A-250578.96 csascaaugadGadGuaccugugaaL96 512 A-463247.1 usdTscadCdAdGguacdTcdTcauugugsgsa AD-238899.1 AGT 513 A-250578.97 csascaaugadGadGuaccugugaaL96 514 A-463248.1 usdTscadCadGdGuacdTcdTcauugugsgsa AD-238900.1 AGT .. 515 A-380025.2 csascadAudGadGadGuaccugugaaL96 516 A-380022.6 usdTscadCadGguacdTcdTcauugugsgsa AD-238901.1 AGT 517 A-463249.1 csascaadTdGadGadGuaccugugaaL96 518 A-380022.7 usdTscadCadGguacdTcdTcauugugsgsa AD-238902.1 AGT 519 A-463250.1 (idTs)csascaaugadGadGuaccugugaaL96 520 A-380022.8 usdTscadCadGguacdTcdTcauugugsgsa AD-264561.2 F12 521 A-492568.3 uscsaauaaadGudGcuuugaaaauL96 522 A-511279.2 asdTsuudTcdAaagcdAcdTuuauugasgsu Iv AD-273421.1 F12 523 A-529077.1 uscsdAauaaadGudGcuuugaaaauL96 524 A-511279.3 asdTsuudTcdAaagcdAcdTuuauugasgsu n AD-273422.1 F12 525 A-529078.1 uscsadAuaaadGudGcuuugaaaauL96 526 A-511279.4 asdTsuudTcdAaagcdAcdTuuauugasgsu cp AD-273423.1 F12 527 A-529079.1 uscsaadTaaadGudGcuuugaaaauL96 528 A-511279.5 asdTsuudTcdAaagcdAcdTuuauugasgsu t,.) o AD-273424.1 F12 529 A-529080.1 uscsaaudAaadGudGcuuugaaaauL96 530 A-511279.6 asdTsuudTcdAaagcdAcdTuuauugasgsu o 'a AD-273425.1 F12 531 A-529081.1 uscsaauadAadGudGcuuugaaaauL96 532 A-511279.7 asdTsuudTcdAaagcdAcdTuuauugasgsu vi o oe AD-273426.1 F12 533 A-529082.1 uscsaauaadAdGudGcuuugaaaauL96 534 A-511279.8 asdTsuudTcdAaagcdAcdTuuauugasgsu 1-oe AD-273427.1 F12 535 A-172952.2 uscsaauaaagudGcuuugaaaauL96 536 A-511279.9 asdTsuudTcdAaagcdAcdTuuauugasgsu AD-273428.1 F12 537 A-529083.1 uscsaauaaadGdTdGcuuugaaaauL96 538 A-511279.10 asdTsuudTcdAaagcdAcdTuuauugasgsu AD-273429.1 F12 539 A-529084.1 uscsaauaaadGugcuuugaaaauL96 540 A-511279.11 asdTsuudTcdAaagcdAcdTuuauugasgsu AD-273430.1 F12 541 A-529085.1 uscsaauaaadGudGdCuuugaaaauL96 542 A-511279.12 asdTsuudTcdAaagcdAcdTuuauugasgsu 0 o AD-273431.1 E12 543 A-529086.1 uscsaauaaadGudGcdTuugaaaauL96 544 A-511279.13 asdTsuudTcdAaagcdAcdTuuauugasgsu t,.) o AD-273432.1 E12 545 A-529087.1 uscsaauaaadGudGcudTugaaaauL96 546 A-511279.14 asdTsuudTcdAaagcdAcdTuuauugasgsu 'a o AD-273433.1 E12 547 A-529088.1 uscsaauaaadGudGcuudTgaaaauL96 548 A-511279.15 asdTsuudTcdAaagcdAcdTuuauugasgsu .6.
.6.
AD-273434.1 E12 549 A-529089.1 uscsaauaaadGudGcuuudGaaaauL96 550 A-511279.16 asdTsuudTcdAaagcdAcdTuuauugasgsu AD-273435.1 E12 551 A-529090.1 uscsaauaaadGudGcuuugdAaaauL96 552 A-511279.17 asdTsuudTcdAaagcdAcdTuuauugasgsu AD-273436.1 E12 553 A-529091.1 uscsaauaaadGudGcuuugadAaauL96 554 A-511279.18 asdTsuudTcdAaagcdAcdTuuauugasgsu AD-273437.1 E12 555 A-529092.1 uscsaauaaadGudGcuuugaadAauL96 556 A-511279.19 asdTsuudTcdAaagcdAcdTuuauugasgsu AD-273438.1 E12 557 A-529093.1 uscsaauaaadGudGcuuugaaadAuL96 558 A-511279.20 asdTsuudTcdAaagcdAcdTuuauugasgsu AD-273439.1 E12 559 A-492568.4 uscsaauaaadGudGcuuugaaaauL96 560 A-529094.1 asdTsdTudTcdAaagcdAcdTuuauugasgsu AD-273440.1 E12 561 A-492568.5 uscsaauaaadGudGcuuugaaaauL96 562 A-529095.1 asdTsudTdTcdAaagcdAcdTuuauugasgsu p AD-273441.1 E12 563 A-492568.6 uscsaauaaadGudGcuuugaaaauL96 564 A-529096.1 asdTsuuucdAaagcdAcdTuuauugasgsu , , .3 t-) AD-273442.1 F12 565 A-492568.7 uscsaauaaadGudGcuuugaaaauL96 566 A-529097.1 asdTsuudTdCdAaagcdAcdTuuauugasgsu u, _.]

AD-273443.1 E12 567 A-492568.8 uscsaauaaadGudGcuuugaaaauL96 568 A-529098.1 asdTsuudTcaaagcdAcdTuuauugasgsu " r., , ' AD-273444.1 E12 569 A-492568.9 uscsaauaaadGudGcuuugaaaauL96 570 A-529099.1 asdTsuudTcdAdAagcdAcdTuuauugasgsu .
..
, AD-273445.1 E12 571 A-492568.10 uscsaauaaadGudGcuuugaaaauL96 572 A-529100.1 asdTsuudTcdAadAgcdAcdTuuauugasgsu AD-273446.1 E12 573 A-492568.11 uscsaauaaadGudGcuuugaaaauL96 574 A-529101.1 asdTsuudTcdAaadGcdAcdTuuauugasgsu AD-273447.1 E12 575 A-492568.12 uscsaauaaadGudGcuuugaaaauL96 576 A-529102.1 asdTsuudTcdAaagdCdAcdTuuauugasgsu AD-273448.1 E12 577 A-492568.13 uscsaauaaadGudGcuuugaaaauL96 578 A-529103.1 asdTsuudTcdAaagcacdTuuauugasgsu AD-273449.1 E12 579 A-492568.14 uscsaauaaadGudGcuuugaaaauL96 580 A-529104.1 asdTsuudTcdAaagcdAdCdTuuauugasgsu AD-273450.1 E12 581 A-492568.15 uscsaauaaadGudGcuuugaaaauL96 582 A-529105.1 asdTsuudTcdAaagcdAcuuuauugasgsu Iv AD-273451.1 E12 583 A-492568.16 uscsaauaaadGudGcuuugaaaauL96 584 A-529106.1 asdTsuudTcdAaagcdAcdTdTuauugasgsu n AD-273452.1 E12 585 A-492568.17 uscsaauaaadGudGcuuugaaaauL96 586 A-529107.1 asdTsuudTcdAaagcdAcdTudTauugasgsu cp AD-273453.1 E12 587 A-492568.18 uscsaauaaadGudGcuuugaaaauL96 588 A-529108.1 asdTsuudTcdAaagcdAcdTuudAuugasgsu t,.) o AD-273454.1 E12 589 A-492568.19 uscsaauaaadGudGcuuugaaaauL96 590 A-529109.1 asdTsuudTcdAaagcdAcdTuuadTugasgsu o 'a AD-273455.1 E12 591 A-492568.20 uscsaauaaadGudGcuuugaaaauL96 592 A-529110.1 asdTsuudTcdAaagcdAcdTuuaudTgasgsu vi o oe AD-273456.1 E12 593 A-492568.21 uscsaauaaadGudGcuuugaaaauL96 594 A-529111.1 asdTsuudTcdAaagcdAcdTuuauudGasgsu 1-oe AD-264567.2 E12 595 A-492580.3 csuscaauaadAgdTgcuuugaaaaL96 596 A-511285.2 usdTsuudCadAagcadCudTuauugagsusu AD-273457.1 F12 597 A-529112.1 csusdCaauaadAgdTgcuuugaaaaL96 598 A-511285.3 usdTsuudCadAagcadCudTuauugagsusu AD-273458.1 F12 599 A-529113.1 csuscdAauaadAgdTgcuuugaaaaL96 600 A-511285.4 usdTsuudCadAagcadCudTuauugagsusu AD-273459.1 F12 601 A-529114.1 csuscadAuaadAgdTgcuuugaaaaL96 602 A-511285.5 usdTsuudCadAagcadCudTuauugagsusu 0 o AD-273460.1 E12 603 A-529115.1 csuscaadTaadAgdTgcuuugaaaaL96 604 A-511285.6 usdTsuudCadAagcadCudTuauugagsusu t,.) o AD-273461.1 E12 605 A-529116.1 csuscaaudAadAgdTgcuuugaaaaL96 606 A-511285.7 usdTsuudCadAagcadCudTuauugagsusu 'a o AD-273462.1 E12 607 A-529117.1 csuscaauadAdAgdTgcuuugaaaaL96 608 A-511285.8 usdTsuudCadAagcadCudTuauugagsusu .6.
.6.
AD-273463.1 E12 609 A-172964.2 csuscaauaaagdTgcuuugaaaaL96 610 A-511285.9 usdTsuudCadAagcadCudTuauugagsusu AD-273464.1 E12 611 A-529118.1 csuscaauaadAdGdTgcuuugaaaaL96 612 A-511285.10 usdTsuudCadAagcadCudTuauugagsusu AD-273465.1 E12 613 A-529119.1 csuscaauaadAgugcuuugaaaaL96 614 A-511285.11 usdTsuudCadAagcadCudTuauugagsusu AD-273466.1 E12 615 A-529120.1 csuscaauaadAgdTdGcuuugaaaaL96 616 A-511285.12 usdTsuudCadAagcadCudTuauugagsusu AD-273467.1 E12 617 A-529121.1 csuscaauaadAgdTgdCuuugaaaaL96 618 A-511285.13 usdTsuudCadAagcadCudTuauugagsusu AD-273468.1 E12 619 A-529122.1 csuscaauaadAgdTgcdTuugaaaaL96 620 A-511285.14 usdTsuudCadAagcadCudTuauugagsusu AD-273469.1 E12 621 A-529123.1 csuscaauaadAgdTgcudTugaaaaL96 622 A-511285.15 usdTsuudCadAagcadCudTuauugagsusu p AD-273470.1 E12 623 A-529124.1 csuscaauaadAgdTgcuudTgaaaaL96 624 A-511285.16 usdTsuudCadAagcadCudTuauugagsusu , , .3 t-) AD-273471.1 F12 625 A-529125.1 csuscaauaadAgdTgcuuudGaaaaL96 626 A-511285.17 usdTsuudCadAagcadCudTuauugagsusu u, _.]
oe AD-273472.1 E12 627 A-529126.1 csuscaauaadAgdTgcuuugdAaaaL96 628 A-511285.18 usdTsuudCadAagcadCudTuauugagsusu " r., , ' AD-273473.1 E12 629 A-529127.1 csuscaauaadAgdTgcuuugadAaaL96 630 A-511285.19 usdTsuudCadAagcadCudTuauugagsusu .
..
, AD-273474.1 E12 631 A-529128.1 csuscaauaadAgdTgcuuugaadAaL96 632 A-511285.20 usdTsuudCadAagcadCudTuauugagsusu AD-273475.1 E12 633 A-492580.4 csuscaauaadAgdTgcuuugaaaaL96 634 A-529129.1 usdTsdTudCadAagcadCudTuauugagsusu AD-273476.1 E12 635 A-492580.5 csuscaauaadAgdTgcuuugaaaaL96 636 A-529130.1 usdTsudTdCadAagcadCudTuauugagsusu AD-273477.1 E12 637 A-492580.6 csuscaauaadAgdTgcuuugaaaaL96 638 A-529131.1 usdTsuucadAagcadCudTuauugagsusu AD-273478.1 E12 639 A-492580.7 csuscaauaadAgdTgcuuugaaaaL96 640 A-529132.1 usdTsuudCdAdAagcadCudTuauugagsusu AD-273479.1 E12 641 A-492580.8 csuscaauaadAgdTgcuuugaaaaL96 642 A-529133.1 usdTsuudCaaagcadCudTuauugagsusu Iv AD-273480.1 E12 643 A-492580.9 csuscaauaadAgdTgcuuugaaaaL96 644 A-529134.1 usdTsuudCadAdAgcadCudTuauugagsusu n AD-273481.1 E12 645 A-492580.10 csuscaauaadAgdTgcuuugaaaaL96 646 A-529135.1 usdTsuudCadAadGcadCudTuauugagsusu cp AD-273482.1 E12 647 A-492580.11 csuscaauaadAgdTgcuuugaaaaL96 648 A-529136.1 usdTsuudCadAagdCadCudTuauugagsusu t,.) o AD-273483.1 E12 649 A-492580.12 csuscaauaadAgdTgcuuugaaaaL96 650 A-529137.1 usdTsuudCadAagcdAdCudTuauugagsusu o 'a AD-273484.1 E12 651 A-492580.13 csuscaauaadAgdTgcuuugaaaaL96 652 A-529138.1 usdTsuudCadAagcacudTuauugagsusu vi o oe AD-273485.1 E12 653 A-492580.14 csuscaauaadAgdTgcuuugaaaaL96 654 A-529139.1 usdTsuudCadAagcadCdTdTuauugagsusu 1-oe AD-273486.1 E12 655 A-492580.15 csuscaauaadAgdTgcuuugaaaaL96 656 A-529140.1 usdTsuudCadAagcadCuuuauugagsusu AD-273487.1 F12 657 A-492580.16 csuscaauaadAgdTgcuuugaaaaL96 658 A-529141.1 usdTsuudCadAagcadCudTdTauugagsusu AD-273488.1 F12 659 A-492580.17 csuscaauaadAgdTgcuuugaaaaL96 660 A-529142.1 usdTsuudCadAagcadCudTudAuugagsusu AD-273489.1 F12 661 A-492580.18 csuscaauaadAgdTgcuuugaaaaL96 662 A-529143.1 usdTsuudCadAagcadCudTuadTugagsusu 0 o AD-273490.1 E12 663 A-492580.19 csuscaauaadAgdTgcuuugaaaaL96 664 A-529144.1 usdTsuudCadAagcadCudTuaudTgagsusu t,.) o AD-273491.1 E12 665 A-492580.20 csuscaauaadAgdTgcuuugaaaaL96 666 A-529145.1 usdTsuudCadAagcadCudTuauudGagsusu 'a o AD-273492.1 E12 667 A-492580.21 csuscaauaadAgdTgcuuugaaaaL96 668 A-529146.1 usdTsuudCadAagcadCudTuauugdAgsusu .6.
.6.
AD-238841.2 TTR 669 A-128292.48 asascagugudTcdTugcucuauaaL96 670 A-463190.5 usdTsaudAgdAgcaadGadAcacuguususu AD-273493.1 TTR 671 A-529147.1 asasdCagugudTcdTugcucuauaaL96 672 A-463190.6 usdTsaudAgdAgcaadGadAcacuguususu AD-273494.1 TTR 673 A-529148.1 asascdAgugudTcdTugcucuauaaL96 674 A-463190.7 usdTsaudAgdAgcaadGadAcacuguususu AD-273495.1 TTR 675 A-529149.1 asascadGugudTcdTugcucuauaaL96 676 A-463190.8 usdTsaudAgdAgcaadGadAcacuguususu AD-273496.1 TTR 677 A-529150.1 asascagdTgudTcdTugcucuauaaL96 678 A-463190.9 usdTsaudAgdAgcaadGadAcacuguususu AD-273497.1 TTR 679 A-529151.1 asascagudGudTcdTugcucuauaaL96 680 A-463190.10 usdTsaudAgdAgcaadGadAcacuguususu AD-273498.1 TTR 681 A-529152.1 asascagugdTdTcdTugcucuauaaL96 682 A-463190.11 usdTsaudAgdAgcaadGadAcacuguususu p AD-273499.1 TTR 683 A-123259.13 asascaguguucdTugcucuauaaL96 684 A-463190.12 usdTsaudAgdAgcaadGadAcacuguususu , , .3 t-) AD-273500.1 TTR 685 A-529153.1 asascagugudTdCdTugcucuauaaL96 686 A-463190.13 usdTsaudAgdAgcaadGadAcacuguususu u, _.]
o AD-273501.1 TTR 687 A-529154.1 asascagugudTcuugcucuauaaL96 688 A-463190.14 usdTsaudAgdAgcaadGadAcacuguususu " r., , ' AD-273502.1 TTR 689 A-529155.1 asascagugudTcdTdTgcucuauaaL96 690 A-463190.15 usdTsaudAgdAgcaadGadAcacuguususu .
..
, AD-273503.1 TTR 691 A-529156.1 asascagugudTcdTudGcucuauaaL96 692 A-463190.16 usdTsaudAgdAgcaadGadAcacuguususu AD-273504.1 TTR 693 A-529157.1 asascagugudTcdTugdCucuauaaL96 694 A-463190.17 usdTsaudAgdAgcaadGadAcacuguususu AD-273505.1 TTR 695 A-529158.1 asascagugudTcdTugcdTcuauaaL96 696 A-463190.18 usdTsaudAgdAgcaadGadAcacuguususu AD-273506.1 TTR 697 A-529159.1 asascagugudTcdTugcudCuauaaL96 698 A-463190.19 usdTsaudAgdAgcaadGadAcacuguususu AD-273507.1 TTR 699 A-529160.1 asascagugudTcdTugcucdTauaaL96 700 A-463190.20 usdTsaudAgdAgcaadGadAcacuguususu AD-273508.1 TTR 701 A-529161.1 asascagugudTcdTugcucudAuaaL96 702 A-463190.21 usdTsaudAgdAgcaadGadAcacuguususu Iv AD-273509.1 TTR 703 A-529162.1 asascagugudTcdTugcucuadTaaL96 704 A-463190.22 usdTsaudAgdAgcaadGadAcacuguususu n AD-273510.1 TTR 705 A-529163.1 asascagugudTcdTugcucuaudAaL96 706 A-463190.23 usdTsaudAgdAgcaadGadAcacuguususu cp AD-238857.2 TTR 707 A-128292.49 asascagugudTcdTugcucuauaaL96 708 A-463206.2 usdTsdAudAgdAgcaadGadAcacuguususu t,.) o AD-238858.2 TTR 709 A-128292.50 asascagugudTcdTugcucuauaaL96 710 A-463207.2 usdTsadTdAgdAgcaadGadAcacuguususu o 'a AD-238837.2 TTR 711 A-128292.51 asascagugudTcdTugcucuauaaL96 712 A-463186.2 usdTsauagdAgcaadGadAcacuguususu vi o oe AD-238859.2 TTR 713 A-128292.52 asascagugudTcdTugcucuauaaL96 714 A-463208.2 usdTsaudAdGdAgcaadGadAcacuguususu 1-oe AD-238835.2 TTR 715 A-128292.53 asascagugudTcdTugcucuauaaL96 716 A-463184.2 usdTsaudAgagcaadGadAcacuguususu AD-238860.2 TTR 717 A-128292.54 asascagugudTcdTugcucuauaaL96 718 A-463209.2 usdTsaudAgdAdGcaadGadAcacuguususu AD-238834.2 TTR 719 A-128292.55 asascagugudTcdTugcucuauaaL96 720 A-463183.2 usdTsaudAgdAgdCaadGadAcacuguususu AD-273511.1 TTR 721 A-128292.56 asascagugudTcdTugcucuauaaL96 722 A-529164.1 usdTsaudAgdAgcdAadGadAcacuguususu 0 o AD-273512.1 TTR 723 A-128292.57 asascagugudTcdTugcucuauaaL96 724 A-529165.1 usdTsaudAgdAgcadAdGadAcacuguususu t,.) o AD-273513.1 TTR 725 A-128292.58 asascagugudTcdTugcucuauaaL96 726 A-529166.1 usdTsaudAgdAgcaagadAcacuguususu 'a o AD-273514.1 TTR 727 A-128292.59 asascagugudTcdTugcucuauaaL96 728 A-529167.1 usdTsaudAgdAgcaadGdAdAcacuguususu .6.
.6.
AD-273515.1 TTR 729 A-128292.60 asascagugudTcdTugcucuauaaL96 730 A-529168.1 usdTsaudAgdAgcaadGaacacuguususu AD-273516.1 TTR 731 A-128292.61 asascagugudTcdTugcucuauaaL96 732 A-529169.1 usdTsaudAgdAgcaadGadAdCacuguususu AD-238854.2 TTR 733 A-128292.62 asascagugudTcdTugcucuauaaL96 734 A-463203.2 usdTsaudAgdAgcaadGadAcdAcuguususu AD-273517.1 TTR 735 A-128292.63 asascagugudTcdTugcucuauaaL96 736 A-529170.1 usdTsaudAgdAgcaadGadAcadCuguususu AD-273518.1 TTR 737 A-128292.64 asascagugudTcdTugcucuauaaL96 738 A-529171.1 usdTsaudAgdAgcaadGadAcacdTguususu AD-273519.1 TTR 739 A-128292.65 asascagugudTcdTugcucuauaaL96 740 A-529172.1 usdTsaudAgdAgcaadGadAcacudGuususu AD-273520.1 TTR 741 A-128292.66 asascagugudTcdTugcucuauaaL96 742 A-529173.1 usdTsaudAgdAgcaadGadAcacugdTususu p AD-237793.2 TTR 743 A-432285.3 asgsuguucudTgdCucuauaaacaL96 744 A-461238.2 usdGsuudTadTagagdCadAgaacacusgsu , , .3 t-) AD-273521.1 TTR 745 A-529174.1 asgsdTguucudTgdCucuauaaacaL96 746 A-461238.3 usdGsuudTadTagagdCadAgaacacusgsu u, _.]
o AD-273522.1 TTR 747 A-529175.1 asgsudGuucudTgdCucuauaaacaL96 748 A-461238.4 usdGsuudTadTagagdCadAgaacacusgsu " r., , ' AD-273523.1 TTR 749 A-529176.1 asgsugdTucudTgdCucuauaaacaL96 750 A-461238.5 usdGsuudTadTagagdCadAgaacacusgsu .
..
, AD-273524.1 TTR 751 A-529177.1 asgsugudTcudTgdCucuauaaacaL96 752 A-461238.6 usdGsuudTadTagagdCadAgaacacusgsu AD-273525.1 TTR 753 A-529178.1 asgsuguudCudTgdCucuauaaacaL96 754 A-461238.7 usdGsuudTadTagagdCadAgaacacusgsu AD-273526.1 TTR 755 A-529179.1 asgsuguucdTdTgdCucuauaaacaL96 756 A-461238.8 usdGsuudTadTagagdCadAgaacacusgsu AD-273527.1 TTR 757 A-529180.1 asgsuguucuugdCucuauaaacaL96 758 A-461238.9 usdGsuudTadTagagdCadAgaacacusgsu AD-273528.1 TTR 759 A-529181.1 asgsuguucudTdGdCucuauaaacaL96 760 A-461238.10 usdGsuudTadTagagdCadAgaacacusgsu AD-273529.1 TTR 761 A-529182.1 asgsuguucudTgcucuauaaacaL96 762 A-461238.11 usdGsuudTadTagagdCadAgaacacusgsu Iv AD-273530.1 TTR 763 A-529183.1 asgsuguucudTgdCdTcuauaaacaL96 764 A-461238.12 usdGsuudTadTagagdCadAgaacacusgsu n AD-273531.1 TTR 765 A-529184.1 asgsuguucudTgdCudCuauaaacaL96 766 A-461238.13 usdGsuudTadTagagdCadAgaacacusgsu cp AD-273532.1 TTR 767 A-529185.1 asgsuguucudTgdCucdTauaaacaL96 768 A-461238.14 usdGsuudTadTagagdCadAgaacacusgsu t,.) o AD-273533.1 TTR 769 A-529186.1 asgsuguucudTgdCucudAuaaacaL96 770 A-461238.15 usdGsuudTadTagagdCadAgaacacusgsu o 'a AD-273534.1 TTR 771 A-529187.1 asgsuguucudTgdCucuadTaaacaL96 772 A-461238.16 usdGsuudTadTagagdCadAgaacacusgsu vi o oe AD-273535.1 TTR 773 A-529188.1 asgsuguucudTgdCucuaudAaacaL96 774 A-461238.17 usdGsuudTadTagagdCadAgaacacusgsu 1-oe AD-273536.1 TTR 775 A-529189.1 asgsuguucudTgdCucuauadAacaL96 776 A-461238.18 usdGsuudTadTagagdCadAgaacacusgsu AD-273537.1 TTR 777 A-529190.1 asgsuguucudTgdCucuauaadAcaL96 778 A-461238.19 usdGsuudTadTagagdCadAgaacacusgsu AD-273538.1 TTR 779 A-529191.1 asgsuguucudTgdCucuauaaadCaL96 780 A-461238.20 usdGsuudTadTagagdCadAgaacacusgsu AD-273539.1 TTR 781 A-432285.4 asgsuguucudTgdCucuauaaacaL96 782 A-529192.1 usdGsdTudTadTagagdCadAgaacacusgsu 0 o AD-273540.1 TTR 783 A-432285.5 asgsuguucudTgdCucuauaaacaL96 784 A-529193.1 usdGsudTdTadTagagdCadAgaacacusgsu t,.) o AD-273541.1 TTR 785 A-432285.6 asgsuguucudTgdCucuauaaacaL96 786 A-529194.1 usdGsuuuadTagagdCadAgaacacusgsu 'a o AD-273542.1 TTR 787 A-432285.7 asgsuguucudTgdCucuauaaacaL96 788 A-529195.1 usdGsuudTdAdTagagdCadAgaacacusgsu .6.
.6.
AD-273543.1 TTR 789 A-432285.8 asgsuguucudTgdCucuauaaacaL96 790 A-529196.1 usdGsuudTauagagdCadAgaacacusgsu AD-273544.1 TTR 791 A-432285.9 asgsuguucudTgdCucuauaaacaL96 792 A-529197.1 usdGsuudTadTdAgagdCadAgaacacusgsu AD-273545.1 TTR 793 A-432285.10 asgsuguucudTgdCucuauaaacaL96 794 A-529198.1 usdGsuudTadTadGagdCadAgaacacusgsu AD-273546.1 TTR 795 A-432285.11 asgsuguucudTgdCucuauaaacaL96 796 A-529199.1 usdGsuudTadTagdAgdCadAgaacacusgsu AD-273547.1 TTR 797 A-432285.12 asgsuguucudTgdCucuauaaacaL96 798 A-529200.1 usdGsuudTadTagadGdCadAgaacacusgsu AD-273548.1 TTR 799 A-432285.13 asgsuguucudTgdCucuauaaacaL96 800 A-529201.1 usdGsuudTadTagagcadAgaacacusgsu AD-273549.1 TTR 801 A-432285.14 asgsuguucudTgdCucuauaaacaL96 802 A-529202.1 usdGsuudTadTagagdCdAdAgaacacusgsu p AD-273550.1 TTR 803 A-432285.15 asgsuguucudTgdCucuauaaacaL96 804 A-529203.1 usdGsuudTadTagagdCaagaacacusgsu , , .3 t-) AD-273551.1 TTR 805 A-432285.16 asgsuguucudTgdCucuauaaacaL96 806 A-529204.1 usdGsuudTadTagagdCadAdGaacacusgsu u, _.]

AD-273552.1 TTR 807 A-432285.17 asgsuguucudTgdCucuauaaacaL96 808 A-529205.1 usdGsuudTadTagagdCadAgdAacacusgsu " r., , ' AD-273553.1 TTR 809 A-432285.18 asgsuguucudTgdCucuauaaacaL96 810 A-529206.1 usdGsuudTadTagagdCadAgadAcacusgsu .
..
, AD-273554.1 TTR 811 A-432285.19 asgsuguucudTgdCucuauaaacaL96 812 A-529207.1 usdGsuudTadTagagdCadAgaadCacusgsu AD-273555.1 TTR 813 A-432285.20 asgsuguucudTgdCucuauaaacaL96 814 A-529208.1 usdGsuudTadTagagdCadAgaacdAcusgsu AD-273556.1 TTR 815 A-432285.21 asgsuguucudTgdCucuauaaacaL96 816 A-529209.1 usdGsuudTadTagagdCadAgaacadCusgsu AD-273557.1 C5 817 A-529210.1 usgsacaaaadTadAcucacuauaaL96 818 A-529211.1 usdTsaudAgdTgagudTadTuuugucasasu AD-273558.1 C5 819 A-529212.1 usgsdAcaaaadTadAcucacuauaaL96 820 A-529211.2 usdTsaudAgdTgagudTadTuuugucasasu AD-273559.1 C5 821 A-529213.1 usgsadCaaaadTadAcucacuauaaL96 822 A-529211.3 usdTsaudAgdTgagudTadTuuugucasasu Iv AD-273560.1 C5 823 A-529214.1 usgsacdAaaadTadAcucacuauaaL96 824 A-529211.4 usdTsaudAgdTgagudTadTuuugucasasu n AD-273561.1 C5 825 A-529215.1 usgsacadAaadTadAcucacuauaaL96 826 A-529211.5 usdTsaudAgdTgagudTadTuuugucasasu cp AD-273562.1 C5 827 A-529216.1 usgsacaadAadTadAcucacuauaaL96 828 A-529211.6 usdTsaudAgdTgagudTadTuuugucasasu t,.) o AD-273563.1 C5 829 A-529217.1 usgsacaaadAdTadAcucacuauaaL96 830 A-529211.7 usdTsaudAgdTgagudTadTuuugucasasu o 'a AD-273564.1 C5 831 A-529218.1 usgsacaaaauadAcucacuauaaL96 832 A-529211.8 usdTsaudAgdTgagudTadTuuugucasasu vi o oe AD-273565.1 C5 833 A-529219.1 usgsacaaaadTdAdAcucacuauaaL96 834 A-529211.9 usdTsaudAgdTgagudTadTuuugucasasu 1-oe AD-273566.1 C5 835 A-529220.1 usgsacaaaadTaacucacuauaaL96 836 A-529211.10 usdTsaudAgdTgagudTadTuuugucasasu AD-273567.1 C5 837 A-529221.1 usgsacaaaadTadAdCucacuauaaL96 838 A-529211.11 usdTsaudAgdTgagudTadTuuugucasasu AD-273568.1 C5 839 A-529222.1 usgsacaaaadTadAcdTcacuauaaL96 840 A-529211.12 usdTsaudAgdTgagudTadTuuugucasasu AD-273569.1 C5 841 A-529223.1 usgsacaaaadTadAcudCacuauaaL96 842 A-529211.13 usdTsaudAgdTgagudTadTuuugucasasu 0 o AD-273570.1 C5 843 A-529224.1 usgsacaaaadTadAcucdAcuauaaL96 844 A-529211.14 usdTsaudAgdTgagudTadTuuugucasasu t,.) o AD-273571.1 C5 845 A-529225.1 usgsacaaaadTadAcucadCuauaaL96 846 A-529211.15 usdTsaudAgdTgagudTadTuuugucasasu 'a o AD-273572.1 C5 847 A-529226.1 usgsacaaaadTadAcucacdTauaaL96 848 A-529211.16 usdTsaudAgdTgagudTadTuuugucasasu .6.
.6.
AD-273573.1 C5 849 A-529227.1 usgsacaaaadTadAcucacudAuaaL96 850 A-529211.17 usdTsaudAgdTgagudTadTuuugucasasu AD-273574.1 C5 851 A-529228.1 usgsacaaaadTadAcucacuadTaaL96 852 A-529211.18 usdTsaudAgdTgagudTadTuuugucasasu AD-273575.1 C5 853 A-529229.1 usgsacaaaadTadAcucacuaudAaL96 854 A-529211.19 usdTsaudAgdTgagudTadTuuugucasasu AD-273576.1 C5 855 A-529210.2 usgsacaaaadTadAcucacuauaaL96 856 A-529230.1 usdTsdAudAgdTgagudTadTuuugucasasu AD-273577.1 C5 857 A-529210.3 usgsacaaaadTadAcucacuauaaL96 858 A-529231.1 usdTsadTdAgdTgagudTadTuuugucasasu AD-273578.1 C5 859 A-529210.4 usgsacaaaadTadAcucacuauaaL96 860 A-529232.1 usdTsauagdTgagudTadTuuugucasasu AD-273579.1 C5 861 A-529210.5 usgsacaaaadTadAcucacuauaaL96 862 A-529233.1 usdTsaudAdGdTgagudTadTuuugucasasu p AD-273580.1 C5 863 A-529210.6 usgsacaaaadTadAcucacuauaaL96 864 A-529234.1 usdTsaudAgugagudTadTuuugucasasu , , .3 t-) AD-273581.1 C5 865 A-529210.7 usgsacaaaadTadAcucacuauaaL96 866 A-529235.1 usdTsaudAgdTdGagudTadTuuugucasasu u, _.]
AD-273582.1 C5 867 A-529210.8 usgsacaaaadTadAcucacuauaaL96 868 A-529236.1 usdTsaudAgdTgdAgudTadTuuugucasasu " r., , ' AD-273583.1 C5 869 A-529210.9 usgsacaaaadTadAcucacuauaaL96 870 A-529237.1 usdTsaudAgdTgadGudTadTuuugucasasu .
..
, AD-273584.1 C5 871 A-529210.10 usgsacaaaadTadAcucacuauaaL96 872 A-529238.1 usdTsaudAgdTgagdTdTadTuuugucasasu AD-273585.1 C5 873 A-529210.11 usgsacaaaadTadAcucacuauaaL96 874 A-529239.1 usdTsaudAgdTgaguuadTuuugucasasu AD-273586.1 C5 875 A-529210.12 usgsacaaaadTadAcucacuauaaL96 876 A-529240.1 usdTsaudAgdTgagudTdAdTuuugucasasu AD-273587.1 C5 877 A-529210.13 usgsacaaaadTadAcucacuauaaL96 878 A-529241.1 usdTsaudAgdTgagudTauuuugucasasu AD-273588.1 C5 879 A-529210.14 usgsacaaaadTadAcucacuauaaL96 880 A-529242.1 usdTsaudAgdTgagudTadTdTuugucasasu AD-273589.1 C5 881 A-529210.15 usgsacaaaadTadAcucacuauaaL96 882 A-529243.1 usdTsaudAgdTgagudTadTudTugucasasu AD-273590.1 C5 883 A-529210.16 usgsacaaaadTadAcucacuauaaL96 884 A-529244.1 usdTsaudAgdTgagudTadTuudTgucasasu Iv n AD-273591.1 C5 885 A-529210.17 usgsacaaaadTadAcucacuauaaL96 886 A-529245.1 usdTsaudAgdTgagudTadTuuudGucasasu cp AD-273592.1 C5 887 A-529210.18 usgsacaaaadTadAcucacuauaaL96 888 A-529246.1 usdTsaudAgdTgagudTadTuuugdTcasasu t,.) o AD-273593.1 C5 889 A-529210.19 usgsacaaaadTadAcucacuauaaL96 890 A-529247.1 usdTsaudAgdTgagudTadTuuugudCasasu o 'a AD-273594.1 C5 891 A-529248.1 asasgcaagadTadTuuuuauaauaL96 892 A-529249.1 usdAsuudAudAaaaadTadTcuugcuususu vi o oe AD-273595.1 C5 893 A-529250.1 asasdGcaagadTadTuuuuauaauaL96 894 A-529249.2 usdAsuudAudAaaaadTadTcuugcuususu 1-oe AD-273596.1 C5 895 A-529251.1 asasgdCaagadTadTuuuuauaauaL96 896 A-529249.3 usdAsuudAudAaaaadTadTcuugcuususu AD-273597.1 C5 897 A-529252.1 asasgcdAagadTadTuuuuauaauaL96 898 A-529249.4 usdAsuudAudAaaaadTadTcuugcuususu AD-273598.1 C5 899 A-529253.1 asasgcadAgadTadTuuuuauaauaL96 900 A-529249.5 usdAsuudAudAaaaadTadTcuugcuususu AD-273599.1 C5 901 A-529254.1 asasgcaadGadTadTuuuuauaauaL96 902 A-529249.6 usdAsuudAudAaaaadTadTcuugcuususu 0 o AD-273600.1 C5 903 A-529255.1 asasgcaagdAdTadTuuuuauaauaL96 904 A-529249.7 usdAsuudAudAaaaadTadTcuugcuususu t,.) o AD-273601.1 C5 905 A-125131.2 asasgcaagauadTuuuuauaauaL96 906 A-529249.8 usdAsuudAudAaaaadTadTcuugcuususu 'a o AD-273602.1 C5 907 A-529256.1 asasgcaagadTdAdTuuuuauaauaL96 908 A-529249.9 usdAsuudAudAaaaadTadTcuugcuususu .6.
.6.
AD-273603.1 C5 909 A-529257.1 asasgcaagadTauuuuuauaauaL96 910 A-529249.10 usdAsuudAudAaaaadTadTcuugcuususu AD-273604.1 C5 911 A-529258.1 asasgcaagadTadTdTuuuauaauaL96 912 A-529249.11 usdAsuudAudAaaaadTadTcuugcuususu AD-273605.1 C5 913 A-529259.1 asasgcaagadTadTudTuuauaauaL96 914 A-529249.12 usdAsuudAudAaaaadTadTcuugcuususu AD-273606.1 C5 915 A-529260.1 asasgcaagadTadTuudTuauaauaL96 916 A-529249.13 usdAsuudAudAaaaadTadTcuugcuususu AD-273607.1 C5 917 A-529261.1 asasgcaagadTadTuuudTauaauaL96 918 A-529249.14 usdAsuudAudAaaaadTadTcuugcuususu AD-273608.1 C5 919 A-529262.1 asasgcaagadTadTuuuudAuaauaL96 920 A-529249.15 usdAsuudAudAaaaadTadTcuugcuususu AD-273609.1 C5 921 A-529263.1 asasgcaagadTadTuuuuadTaauaL96 922 A-529249.16 usdAsuudAudAaaaadTadTcuugcuususu p AD-273610.1 C5 923 A-529264.1 asasgcaagadTadTuuuuaudAauaL96 924 A-529249.17 usdAsuudAudAaaaadTadTcuugcuususu , , .3 t-) AD-273611.1 C5 925 A-529265.1 asasgcaagadTadTuuuuauadAuaL96 926 A-529249.18 usdAsuudAudAaaaadTadTcuugcuususu u, _.]
AD-273612.1 C5 927 A-529266.1 asasgcaagadTadTuuuuauaadTaL96 928 A-529249.19 usdAsuudAudAaaaadTadTcuugcuususu " r., , ' AD-273613.1 C5 929 A-529248.2 asasgcaagadTadTuuuuauaauaL96 930 A-529267.1 usdAsdTudAudAaaaadTadTcuugcuususu .
..
, AD-273614.1 C5 931 A-529248.3 asasgcaagadTadTuuuuauaauaL96 932 A-529268.1 usdAsudTdAudAaaaadTadTcuugcuususu AD-273615.1 C5 933 A-529248.4 asasgcaagadTadTuuuuauaauaL96 934 A-529269.1 usdAsuuaudAaaaadTadTcuugcuususu AD-273616.1 C5 935 A-529248.5 asasgcaagadTadTuuuuauaauaL96 936 A-529270.1 usdAsuudAdTdAaaaadTadTcuugcuususu AD-273617.1 C5 937 A-529248.6 asasgcaagadTadTuuuuauaauaL96 938 A-529271.1 usdAsuudAuaaaaadTadTcuugcuususu AD-273618.1 C5 939 A-529248.7 asasgcaagadTadTuuuuauaauaL96 940 A-529272.1 usdAsuudAudAdAaaadTadTcuugcuususu AD-273619.1 C5 941 A-529248.8 asasgcaagadTadTuuuuauaauaL96 942 A-529273.1 usdAsuudAudAadAaadTadTcuugcuususu AD-273620.1 C5 943 A-529248.9 asasgcaagadTadTuuuuauaauaL96 944 A-529274.1 usdAsuudAudAaadAadTadTcuugcuususu Iv n AD-273621.1 C5 945 A-529248.10 asasgcaagadTadTuuuuauaauaL96 946 A-529275.1 usdAsuudAudAaaadAdTadTcuugcuususu cp AD-273622.1 C5 947 A-529248.11 asasgcaagadTadTuuuuauaauaL96 948 A-529276.1 usdAsuudAudAaaaauadTcuugcuususu t,.) o AD-273623.1 C5 949 A-529248.12 asasgcaagadTadTuuuuauaauaL96 950 A-529277.1 usdAsuudAudAaaaadTdAdTcuugcuususu o 'a AD-273624.1 C5 951 A-529248.13 asasgcaagadTadTuuuuauaauaL96 952 A-529278.1 usdAsuudAudAaaaadTaucuugcuususu vi o oe AD-273625.1 C5 953 A-529248.14 asasgcaagadTadTuuuuauaauaL96 954 A-529279.1 usdAsuudAudAaaaadTadTdCuugcuususu 1-oe AD-273626.1 C5 955 A-529248.15 asasgcaagadTadTuuuuauaauaL96 956 A-529280.1 usdAsuudAudAaaaadTadTcdTugcuususu AD-273627.1 C5 957 A-529248.16 asasgcaagadTadTuuuuauaauaL96 958 A-529281.1 usdAsuudAudAaaaadTadTcudTgcuususu AD-273628.1 C5 959 A-529248.17 asasgcaagadTadTuuuuauaauaL96 960 A-529282.1 usdAsuudAudAaaaadTadTcuudGcuususu AD-273629.1 C5 961 A-529248.18 asasgcaagadTadTuuuuauaauaL96 962 A-529283.1 usdAsuudAudAaaaadTadTcuugdCuususu 0 o AD-273630.1 C5 963 A-529248.19 asasgcaagadTadTuuuuauaauaL96 964 A-529284.1 usdAsuudAudAaaaadTadTcuugcdTususu t,.) o 'a o o .6.
Table 2:
.6.
% of Control 50 nM 50 nM 10 nM 10 nM 1 nM 1 nM 0.1nM 0.1 nM
Duplex Number Restrictions Cell Type Method (Avg) (SD) (Avg) (SD) (Avg) (SD) (Avg) (SD) AD-157529.3 AGT01-related Cyno hepatocyte Transfection 8.2 1.5 78.0 7.9 AD-191860.3 AGT01-related Cyno hepatocyte Transfection 7.3 2.3 68.1 8.9 AD-192113.1 AGT01-related Cyno hepatocyte Transfection 3.8 0.4 59.9 9.6 P
AD-192114.1 AGT01-related Cyno hepatocyte Transfection 4.1 0.4 58.4 9.6 , , .3 t-) AD-192115.1 AGT01-related Cyno hepatocyte Transfection 3.9 1.1 69.6 5.6 _.]
.6.
r., AD-192116.1 AGT01-related Cyno hepatocyte Transfection 4.8 0.6 62.4 5.1 .
r., , , AD-192117.1 AGT01-related Cyno hepatocyte Transfection 4.4 0.6 61.8 7.6 .
..
, AD-192118.1 AGT01-related Cyno hepatocyte Transfection 5.4 0.3 63.7 9.0 .
AD-192119.1 AGT01-related Cyno hepatocyte Transfection 4.3 0.4 61.8 6.0 AD-192120.1 AGT01-related Cyno hepatocyte Transfection 4.2 0.8 61.1 9.3 Not AGT01-AD-157541.2 related Cyno hepatocyte Transfection 15.9 1.7 85.1 3.3 Not AGT01-AD-192121.1 related Cyno hepatocyte Transfection 7.7 1.3 72.2 6.5 1-d n Not AGT01-AD-192122.1 related Cyno hepatocyte Transfection 19.7 2.8 86.9 4.3 cp Not AGT01-o o AD-192123.1 related Cyno hepatocyte Transfection 12.6 3.0 76.3 4.6 'a vi Not AGT01-o oe AD-192124.1 related Cyno hepatocyte Transfection 15.0 3.7 81.4 10.1 oe Not AGT01-AD-192125.1 related Cyno hepatocyte Transfection 8.5 0.6 76.8 6.1 Not AGT01-AD-192126.1 related Cyno hepatocyte Transfection 15.1 0.9 92.8 6.8 t,.) o Not AGT01-t,.) =
AD-192127.1 related Cyno hepatocyte Transfection 11.9 2.5 94.6 8.1 'a o Not AGT01-o .6.
.6.
AD-192128.1 related Cyno hepatocyte Transfection 9.9 2.1 70.3 5.8 Not AGT01-AD-157552.3 related Cyno hepatocyte Transfection 25.7 1.7 91.8 1.1 Not AGT01-AD-192129.1 related Cyno hepatocyte Transfection 18.1 2.4 98.0 5.3 Not AGT01-AD-192130.1 related Cyno hepatocyte Transfection 10.6 1.8 92.0 9.7 Not AGT01-P
AD-192131.1 related Cyno hepatocyte Transfection 26.7 3.2 107.2 9.6 .
, , Not AGT01-.3 u, vi AD-192132.1 related Cyno hepatocyte Transfection 17.3 3.7 85.8 5.5 Not AGT01-, , .
AD-192133.1 related Cyno hepatocyte Transfection 10.9 1.4 80.3 6.8 ..
, Not AGT01-.
AD-192134.1 related Cyno hepatocyte Transfection 7.2 1.3 70.4 6.2 Not AGT01-AD-192135.1 related Cyno hepatocyte Transfection 13.8 1.6 81.6 5.8 Not AGT01-AD-192136.1 related Cyno hepatocyte Transfection 8.1 1.5 79.4 6.9 Not AGT01-1-d n AD-192137.1 related Cyno hepatocyte Transfection 8.4 2.0 78.9 7.3 1-3 Not AGT01-cp AD-157563.2 related Cyno hepatocyte Transfection 37.4 2.8 95.9 2.9 t,.) Not AGT01-o 'a AD-192138.1 related Cyno hepatocyte Transfection 20.4 2.4 91.2 3.1 vi o oe Not AGT01-oe AD-192139.1 related Cyno hepatocyte Transfection 14.3 1.2 94.5 3.1 Not AGT01-AD-192140.1 related Cyno hepatocyte Transfection 15.4 1.0 87.3 3.1 Not AGT01-AD-192141.1 related Cyno hepatocyte Transfection 8.8 1.6 77.3 4.8 t,.) o Not AGT01-t,.) =
AD-192142.1 related Cyno hepatocyte Transfection 28.4 1.5 103.1 4.3 'a o Not AGT01-o .6.
.6.
AD-192143.1 related Cyno hepatocyte Transfection 13.8 1.6 86.0 2.8 Not AGT01-AD-192144.1 related Cyno hepatocyte Transfection 22.4 2.1 92.5 4.4 Not AGT01-AD-192145.1 related Cyno hepatocyte Transfection 13.5 4.2 87.3 5.5 Not AGT01-AD-192146.1 related Cyno hepatocyte Transfection 8.6 1.1 85.5 5.9 Not AGT01-P
AD-157574.2 related Cyno hepatocyte Transfection 35.5 8.5 112.2 8.3 .
, , Not AGT01-.3 u, o _.]
AD-192147.1 related Cyno hepatocyte Transfection 17.0 3.4 90.6 5.3 Not AGT01-, , AD-192148.1 related Cyno hepatocyte Transfection 12.4 1.6 82.5 7.1 ..
, Not AGT01-.
AD-192149.1 related Cyno hepatocyte Transfection 17.9 1.0 87.8 3.5 Not AGT01-AD-192150.1 related Cyno hepatocyte Transfection 9.7 2.6 78.3 6.3 Not AGT01-AD-192151.1 related Cyno hepatocyte Transfection 20.1 0.9 89.0 3.7 Not AGT01-1-d n AD-192152.1 related Cyno hepatocyte Transfection 7.5 1.3 80.6 4.6 1-3 Not AGT01-cp AD-192153.1 related Cyno hepatocyte Transfection 13.1 1.2 86.9 4.3 t,.) Not AGT01-o 'a AD-192154.1 related Cyno hepatocyte Transfection 15.4 3.9 94.9 11.0 vi o oe Not AGT01-oe AD-192155.1 related Cyno hepatocyte Transfection 10.2 2.8 85.2 3.2 Not AGT01-AD-157584.2 related Cyno hepatocyte Transfection 91.7 1.6 99.3 3.4 Not AGT01-AD-192156.1 related Cyno hepatocyte Transfection 61.9 3.3 96.8 4.5 t,.) o Not AGT01-=
'a AD-192157.1 related Cyno hepatocyte Transfection 36.8 2.0 102.6 2.1 o Not AGT01-o AD-192158.1 related Cyno hepatocyte Transfection 96.3 16.3 118.3 17.2 Not AGT01-AD-192159.1 related Cyno hepatocyte Transfection 79.3 17.3 105.2 8.9 Not AGT01-AD-192160.1 related Cyno hepatocyte Transfection 65.5 3.7 97.0 6.1 Not AGT01-AD-192161.1 related Cyno hepatocyte Transfection 47.4 4.6 99.6 4.3 Not AGT01-P
AD-192162.1 related Cyno hepatocyte Transfection 62.1 4.7 95.4 2.8 , , .3 Not AGT01-u, --4 AD-192163.1 related Cyno hepatocyte Transfection 51.8 1.8 97.9 3.1 r., r., Not AGT01-, , .
AD-192164.1 related Cyno hepatocyte Transfection 31.6 2.8 97.4 7.6 ..
, Primary Mouse AD-264555.1 Unknown Hepatocytes Transfection 20.2 0.7 74.4 4.9 Primary Mouse AD-264556.1 Unknown Hepatocytes Transfection 21.6 3.4 70.0 7.7 Primary Mouse AD-264557.1 Unknown Hepatocytes Transfection 62.6 4.7 91.3 10.8 Primary Mouse 1-d n AD-264558.1 Unknown Hepatocytes Transfection 22.8 2.3 52.9 4.7 1-3 Primary Mouse cp AD-264559.1 Unknown Hepatocytes Transfection 77.4 5.4 105.0 5.8 o Primary Mouse 'a vi AD-264560.1 Unknown Hepatocytes Transfection 51.4 5.6 106.6 5.5 o oe Primary Mouse Mouse oe AD-264561.1 Unknown Hepatocytes Transfection 19.0 3.4 69.2 3.5 Primary Mouse AD-264562.1 Unknown Hepatocytes Transfection 57.9 8.0 91.1 14.2 Primary Mouse AD-264563.1 Unknown Hepatocytes Transfection 88.3 5.6 106.6 4.9 t,.) o = Primary Mouse 'a AD-264564.1 Unknown Hepatocytes Transfection 23.5 2.2 81.6 2.8 o o Primary Mouse AD-264565.1 Unknown Hepatocytes Transfection 63.5 6.2 106.3 1.1 Primary Mouse AD-264566.1 Unknown Hepatocytes Transfection 91.8 6.5 98.5 9.4 Primary Mouse AD-264567.1 Unknown Hepatocytes Transfection 18.5 1.6 71.2 3.8 Primary Mouse AD-264568.1 Unknown Hepatocytes Transfection 53.7 4.4 98.4 16.1 P
Primary Mouse .
AD-264569.1 Unknown Hepatocytes Transfection 56.4 4.4 93.5 13.0 , , .3 u, Primary Mouse _.]
oe AD-264570.1 Unknown Hepatocytes Transfection 52.9 6.0 91.0 26.7 r., , , Primary Mouse .
..
, AD-264571.1 Unknown Hepatocytes Transfection 20.6 2.1 72.0 1.8 Primary Mouse AD-264572.1 Unknown Hepatocytes Transfection 99.5 19.3 78.0 18.8 Primary Mouse AD-264573.1 Unknown Hepatocytes Transfection 73.2 4.4 96.8 17.1 Primary Mouse AD-264574.1 Unknown Hepatocytes Transfection 74.3 10.5 104.4 5.3 1-d Primary Mouse n AD-264575.1 Unknown Hepatocytes Transfection 39.6 2.2 75.9 26.0 1-3 Primary Mouse cp AD-264576.1 Unknown Hepatocytes Transfection 25.0 2.1 80.7 7.1 o Primary Mouse 'a vi AD-264577.1 Unknown Hepatocytes Transfection 55.3 3.7 89.7 10.3 o oe Primary Mouse Mouse oe AD-264578.1 Unknown Hepatocytes Transfection 22.6 1.7 86.6 14.2 Primary Mouse AD-264579.1 Unknown Hepatocytes Transfection 30.6 2.0 85.6 4.4 Primary Mouse AD-264580.1 Unknown Hepatocytes Transfection 11.2 2.2 36.8 6.4 t,.) o = Primary Mouse 'a AD-264581.1 Unknown Hepatocytes Transfection 22.7 1.4 78.6 8.7 o o Primary Mouse AD-264582.1 Unknown Hepatocytes Transfection 26.3 6.2 77.2 8.5 Primary Mouse AD-264583.1 Unknown Hepatocytes Transfection 24.4 2.3 60.5 8.1 Primary Mouse AD-264584.1 Unknown Hepatocytes Transfection 46.2 4.4 94.4 7.1 Primary Mouse AD-264585.1 Unknown Hepatocytes Transfection 20.0 1.9 85.5 5.9 P
Primary Mouse .
AD-264586.1 Unknown Hepatocytes Transfection 32.4 7.5 88.8 29.5 , , .3 u, Primary Mouse _.]
o AD-264587.1 Unknown Hepatocytes Transfection 21.8 1.4 81.5 8.8 r., , , Primary Mouse .
..
, AD-264588.1 Unknown Hepatocytes Transfection 13.0 1.0 68.2 3.3 Primary Mouse AD-264589.1 Unknown Hepatocytes Transfection 14.9 0.7 75.1 8.0 Primary Mouse AD-264590.1 Unknown Hepatocytes Transfection 31.7 7.8 96.3 10.1 Primary Mouse AD-264591.1 Unknown Hepatocytes Transfection 77.8 1.7 99.0 1.4 1-d Primary Mouse n AD-264592.1 Unknown Hepatocytes Transfection 23.3 2.9 71.0 6.5 1-3 Primary Mouse cp AD-264593.1 Unknown Hepatocytes Transfection 49.1 7.4 92.8 6.4 o Primary Mouse 'a vi AD-264594.1 Unknown Hepatocytes Transfection 40.2 3.7 101.0 9.9 o oe Primary Mouse Mouse oe AD-264595.1 Unknown Hepatocytes Transfection 31.8 2.8 84.4 6.5 Primary Mouse AD-264596.1 Unknown Hepatocytes Transfection 17.8 0.7 98.7 50.8 Primary Mouse AD-264597.1 Unknown Hepatocytes Transfection 18.2 3.1 84.4 6.9 t,.) o Primary Mouse =
'a AD-264598.1 Unknown Hepatocytes Transfection 35.3 3.1 90.8 7.9 o o Primary Mouse AD-264599.1 Unknown Hepatocytes Transfection 40.7 3.4 95.3 3.8 Primary Mouse AD-264600.1 Unknown Hepatocytes Transfection 15.7 0.4 67.2 5.4 Primary Mouse AD-264601.1 Unknown Hepatocytes Transfection 22.6 1.4 73.0 5.3 AD-237788.1 Unknown Unknown Transfection 28.1 4.6 66.3 18.2 AD-237789.1 Unknown Unknown Transfection 17.3 4.7 51.4 13.7 P
AD-237790.1 Unknown Unknown Transfection 18.0 1.7 44.1 22.0 .
, AD-237791.1 Unknown Unknown Transfection 21.2 11.5 47.9 19.5 , .3 u, o AD-237792.1 Unknown Unknown Transfection 23.4 2.4 70.7 16.6 r., AD-237793.1 Unknown Unknown Transfection 14.6 2.8 47.3 1.1 , , AD-237794.1 Unknown Unknown Transfection 50.2 8.4 96.6 16.1 t AD-237795.1 Unknown Unknown Transfection 52.0 26.8 82.7 13.0 AD-237796.1 Unknown Unknown Transfection 25.3 3.3 65.3 18.8 AD-237797.1 Unknown Unknown Transfection 39.4 16.7 89.1 8.2 AD-237798.1 Unknown Unknown Transfection 51.0 1.7 81.6 19.7 AD-237799.1 Unknown Unknown Transfection 78.9 33.6 81.1 22.9 AD-237800.1 Unknown Unknown Transfection 41.0 16.2 102.1 16.3 1-d n AD-237801.1 Unknown Unknown Transfection 79.4 12.9 108.9 8.2 1-3 AD-237802.1 Unknown Unknown Transfection 56.2 4.5 91.5 14.4 cp AD-237803.1 Unknown Unknown Transfection 48.4 7.3 61.9 25.2 o o AD-237804.1 Unknown Unknown Transfection 19.8 7.3 70.3 7.9 'a vi o AD-237805.1 Unknown Unknown Transfection 83.1 8.9 106.0 13.8 oe oe AD-237806.1 Unknown Unknown Transfection 42.1 17.0 99.1 9.4 AD-237807.1 Unknown Unknown Transfection 74.6 24.0 75.6 18.7 AD-237808.1 Unknown Unknown Transfection 33.4 4.6 99.3 20.1 AD-237809.1 Unknown Unknown Transfection 60.1 13.3 99.7 11.2 0 o AD-237810.1 Unknown Unknown Transfection 61.2 6.9 91.7 14.1 t,.) o AD-237811.1 Unknown Unknown Transfection 49.1 6.9 96.2 0.6 'a o AD-237812.1 Unknown Unknown Transfection 64.6 5.3 82.0 0.5 .6.
.6.
AD-237813.1 Unknown Unknown Transfection 24.0 5.7 122.3 32.4 AD-237814.1 Unknown Unknown Transfection 52.0 7.9 122.6 37.0 AD-237815.1 Unknown Unknown Transfection 45.6 6.4 112.5 39.3 AD-237816.1 Unknown Unknown Transfection 56.1 7.2 96.0 10.2 AD-237817.1 Unknown Unknown Transfection 74.0 10.0 94.4 18.4 AD-237818.1 Unknown Unknown Transfection 35.3 9.9 95.8 9.9 AD-237819.1 Unknown Unknown Transfection 45.1 8.8 113.1 27.2 p AD-237820.1 Unknown Unknown Transfection 76.9 17.6 97.6 15.0 , , .3 t-) AD-237821.1 Unknown Unknown Transfection 78.4 15.3 88.2 11.1 u, _.]

AD-237822.1 Unknown Unknown Transfection 66.9 13.2 112.1 14.5 " r., , AD-237823.1 Unknown Unknown Transfection 67.1 10.0 117.0 16.5 ..
, AD-237824.1 Unknown Unknown Transfection 64.8 10.8 106.0 23.5 AD-237825.1 Unknown Unknown Transfection 79.7 11.6 84.3 4.1 AD-237826.1 Unknown Unknown Transfection 42.7 8.3 101.6 13.9 AD-237827.1 Unknown Unknown Transfection 39.3 11.3 109.6 14.9 AD-237828.1 Unknown Unknown Transfection 92.3 8.0 97.8 13.7 AD-237829.1 Unknown Unknown Transfection 68.4 11.9 95.9 15.5 AD-237830.1 Unknown Unknown Transfection 82.9 5.9 68.1 33.3 1-d n 1-i AD-237831.1 Unknown Unknown Transfection 33.6 21.1 101.6 15.0 cp AD-237832.1 Unknown Unknown Transfection 107.6 19.5 104.8 18.4 t,.) o AD-237833.1 Unknown Unknown Transfection 46.8 14.4 83.9 12.9 o 'a AD-237834.1 Unknown Unknown Transfection 79.5 21.3 110.0 22.4 vi o oe AD-237835.1 Unknown Unknown Transfection 57.9 17.2 101.2 11.1 1-oe AD-237836.1 Unknown Unknown Transfection 14.6 4.7 75.6 17.7 AD-237837.1 Unknown Unknown Transfection 63.6 14.2 81.0 6.2 AD-237838.1 Unknown Unknown Transfection 64.1 10.4 65.2 6.3 AD-237839.1 Unknown Unknown Transfection 67.8 7.7 88.6 24.4 0 o AD-237840.1 Unknown Unknown Transfection 78.4 8.1 92.8 16.2 t,.) o AD-237841.1 Unknown Unknown Transfection 56.8 25.9 87.6 9.1 'a o AD-237842.1 Unknown Unknown Transfection 27.7 4.7 67.9 13.0 .6.
.6.
AD-237843.1 Unknown Unknown Transfection 47.9 13.1 119.3 12.3 AD-237844.1 Unknown Unknown Transfection 73.2 12.8 101.2 11.5 AD-237845.1 Unknown Unknown Transfection 81.8 8.7 99.3 5.3 AD-237846.1 Unknown Unknown Transfection 27.7 3.1 62.0 20.8 AD-237847.1 Unknown Unknown Transfection 84.6 12.9 120.3 16.3 AD-237848.1 Unknown Unknown Transfection 60.6 14.9 106.2 16.6 AD-237849.1 Unknown Unknown Transfection 76.1 4.3 94.3 5.6 p AD-237850.1 Unknown Unknown Transfection 75.4 21.5 83.3 38.0 , , .3 t-) AD-237851.1 Unknown Unknown Transfection 63.0 22.6 108.0 24.4 u, _.]
AD-237852.1 Unknown Unknown Transfection 88.9 14.3 111.4 7.1 " r., , AD-237853.1 Unknown Unknown Transfection 49.5 7.1 97.7 12.4 ..
, AD-237854.1 Unknown Unknown Transfection 64.7 24.0 65.8 27.2 AD-237855.1 Unknown Unknown Transfection 71.6 14.6 121.0 6.4 AD-237856.1 Unknown Unknown Transfection 93.1 12.6 112.3 18.9 AD-237857.1 Unknown Unknown Transfection 95.8 22.7 106.9 17.1 AD-237858.1 Unknown Unknown Transfection 83.0 16.7 93.3 23.7 AD-237859.1 Unknown Unknown Transfection 111.8 19.6 129.9 34.3 AD-237860.1 Unknown Unknown Transfection 94.0 28.8 112.1 14.3 1-d n 1-i AD-237861.1 Unknown Unknown Transfection 82.0 7.9 94.7 30.5 cp AD-237862.1 Unknown Unknown Transfection 102.1 27.9 104.1 30.0 t,.) o AD-237863.1 Unknown Unknown Transfection 103.5 28.9 120.3 12.5 o 'a AD-237864.1 Unknown Unknown Transfection 99.3 15.4 105.9 9.4 vi o oe AD-237865.1 Unknown Unknown Transfection 72.8 12.7 115.3 22.1 1-oe AD-237866.1 Unknown Unknown Transfection 94.9 19.5 73.4 12.9 AD-218795.6 Unknown Unknown Transfection 17.0 3.4 15.3 3.5 21.6 4.7 AD-238829.1 Unknown Unknown Transfection 15.2 5.7 18.8 4.7 18.5 5.4 AD-238830.1 Unknown Unknown Transfection 18.1 2.5 19.7 2.0 23.3 4.5 0 o AD-238831.1 Unknown Unknown Transfection 12.9 2.5 19.1 5.5 16.4 1.4 t,.) o AD-238832.1 Unknown Unknown Transfection 19.5 2.6 18.0 4.0 21.4 0.7 'a o AD-238833.1 Unknown Unknown Transfection 13.3 2.5 15.1 3.8 26.2 2.6 .6.
.6.
AD-238834.1 Unknown Unknown Transfection 12.1 3.0 8.2 2.3 15.9 1.4 AD-238835.1 Unknown Unknown Transfection 13.5 3.1 13.5 1.5 20.1 2.4 AD-238836.1 Unknown Unknown Transfection 13.7 3.1 12.2 1.8 25.1 3.3 AD-238837.1 Unknown Unknown Transfection 10.0 2.2 10.4 3.2 15.3 0.9 AD-238838.1 Unknown Unknown Transfection 26.7 3.4 22.6 1.8 30.0 4.8 AD-238839.1 Unknown Unknown Transfection 18.8 4.5 15.5 4.0 27.1 3.5 AD-238840.1 Unknown Unknown Transfection 11.3 1.8 13.0 2.2 14.9 2.1 p AD-238841.1 Unknown Unknown Transfection 10.5 4.7 8.3 2.9 14.8 1.1 , , .3 t-) AD-238842.1 Unknown Unknown Transfection 15.0 2.1 17.6 3.1 24.8 5.5 u, _.]
AD-238843.1 Unknown Unknown Transfection 12.6 3.1 12.0 1.0 17.5 4.1 " r., , AD-238844.1 Unknown Unknown Transfection 8.6 4.3 11.8 1.3 11.6 1.6 ..
, AD-238845.1 Unknown Unknown Transfection 10.4 2.1 9.2 0.8 11.9 3.1 AD-238846.1 Unknown Unknown Transfection 9.0 3.0 10.8 0.1 11.9 2.8 AD-238847.1 Unknown Unknown Transfection 10.2 2.2 11.5 2.9 13.1 2.3 AD-238848.1 Unknown Unknown Transfection 12.0 1.2 12.0 1.2 14.8 2.6 AD-238849.1 Unknown Unknown Transfection 9.0 1.9 12.3 2.3 20.2 3.3 AD-238850.1 Unknown Unknown Transfection 10.7 1.4 10.8 4.2 16.9 4.4 AD-238851.1 Unknown Unknown Transfection 16.1 2.7 19.4 2.3 23.3 3.0 1-d n 1-i AD-238852.1 Unknown Unknown Transfection 13.8 3.5 13.6 0.5 20.2 4.4 cp AD-238853.1 Unknown Unknown Transfection 9.9 3.4 10.0 0.4 13.1 2.3 t,.) o AD-238854.1 Unknown Unknown Transfection 6.7 2.0 10.1 1.9 13.5 0.9 o 'a AD-238855.1 Unknown Unknown Transfection 14.8 1.6 14.2 2.5 23.6 2.6 vi o oe AD-238856.1 Unknown Unknown Transfection 11.9 1.7 12.5 5.0 13.4 2.3 1-oe AD-238857.1 Unknown Unknown Transfection 12.2 1.8 12.3 2.5 16.0 4.5 AD-238858.1 Unknown Unknown Transfection 15.0 3.7 17.0 5.3 18.0 4.2 AD-238859.1 Unknown Unknown Transfection 11.2 1.8 9.9 0.9 17.2 2.3 AD-238860.1 Unknown Unknown Transfection 16.1 2.7 12.9 1.8 15.3 4.4 0 o AD-238861.1 Unknown Unknown Transfection 6.3 2.6 7.9 1.8 10.3 1.4 t,.) o AD-238862.1 Unknown Unknown Transfection 10.3 5.2 8.5 2.0 9.7 3.7 'a o AD-238863.1 Unknown Unknown Transfection 10.4 2.9 13.4 3.2 17.8 4.5 .6.
.6.
Not AGT01-AD-192134.4 related Unknown Transfection 43.0 17.5 44.1 10.6 68.0 15.6 Not AGT01-AD-157553.2 related Unknown Transfection 118.9 46.7 87.1 19.3 99.0 14.4 Not AGT01-AD-238872.1 related Unknown Transfection 91.9 42.5 90.0 28.9 90.8 19.0 Not AGT01-AD-238873.1 related Unknown Transfection 57.6 22.2 64.5 10.0 83.0 16.0 Q
Not AGT01-, , AD-238874.1 related Unknown Transfection 39.9 16.4 61.8 9.8 67.9 13.6 .3 _., .6. Not AGT01-c, AD-238875.1 related Unknown Transfection 26.5 9.3 49.0 4.9 75.6 10.9 , , c, Not AGT01-..
, AD-238876.1 related Unknown Transfection 17.0 3.4 38.4 6.9 67.0 13.0 c, Not AGT01-AD-192129.4 related Unknown Transfection 57.1 17.5 61.6 11.4 90.7 0.9 Not AGT01-AD-238877.1 related Unknown Transfection 52.3 20.5 71.1 18.7 82.0 7.8 Not AGT01-AD-157552.4 related Unknown Transfection 54.4 4.7 95.9 13.6 91.3 4.1 1-d n Not AGT01-AD-238878.1 related Unknown Transfection 91.3 20.5 100.3 19.4 92.5 17.9 cp Not AGT01-o 1-, AD-238879.1 related Unknown Transfection 36.4 12.1 70.8 16.8 93.8 8.9 o 'a Not AGT01-vi o oe AD-238880.1 related Unknown Transfection 58.0 20.3 68.5 12.0 77.6 9.8 oe Not AGT01-AD-192135.2 related Unknown Transfection 50.3 14.9 60.1 23.2 93.9 20.5 Not AGT01-AD-238881.1 related Unknown Transfection 74.0 2.7 84.4 7.1 101.7 13.9 t,.) o Not AGT01-=
'a AD-238882.1 related Unknown Transfection 51.2 15.6 73.6 15.0 102.5 19.2 o o Not AGT01-.6.
.6.
AD-238883.1 related Unknown Transfection 48.9 18.6 61.9 20.8 94.6 14.5 Not AGT01-AD-238884.1 related Unknown Transfection 30.2 10.6 52.0 13.7 83.7 10.9 Not AGT01-AD-238885.1 related Unknown Transfection 32.2 17.4 37.5 4.8 77.7 11.9 Not AGT01-AD-238886.1 related Unknown Transfection 25.0 6.7 39.2 9.7 74.2 12.6 Not AGT01-P
AD-238887.1 related Unknown Transfection 40.8 9.8 65.4 11.8 105.2 25.1 , , .3 Not AGT01-u, _.]
vi AD-238888.1 related Unknown Transfection 40.8 15.7 71.0 20.9 89.9 5.1 r., Not AGT01-, , ..
, AD-238889.1 related Unknown Transfection 39.5 21.1 76.5 24.9 78.9 10.1 Not AGT01-AD-238890.1 related Unknown Transfection 49.9 8.5 73.1 5.6 102.4 16.9 Not AGT01-AD-238891.1 related Unknown Transfection 45.9 27.7 54.1 25.3 80.0 8.1 Not AGT01-AD-238892.1 related Unknown Transfection 38.7 11.9 65.6 9.1 80.4 9.8 Not AGT01-1-d n AD-238893.1 related Unknown Transfection 27.6 10.1 46.8 7.0 79.8 8.0 1-3 Not AGT01-cp AD-238894.1 related Unknown Transfection 36.6 10.6 44.0 14.6 90.5 5.7 o Not AGT01-'a vi AD-238895.1 related Unknown Transfection 38.6 22.6 39.0 7.0 70.8 9.9 o oe Not AGT01-oe AD-238896.1 related Unknown Transfection 27.5 12.5 49.1 5.1 71.6 11.4 Not AGT01-AD-238897.1 related Unknown Transfection 26.0 8.4 48.3 8.6 63.1 16.4 Not AGT01-AD-238898.1 related Unknown Transfection 40.8 17.1 53.3 10.3 84.5 21.6 t,.) o Not AGT01-=
'a AD-238899.1 related Unknown Transfection 14.5 5.6 48.6 13.3 65.8 4.2 o o Not AGT01-.6.
.6.
AD-238900.1 related Unknown Transfection 28.0 7.4 38.0 10.0 77.8 17.4 Not AGT01-AD-238901.1 related Unknown Transfection 42.9 11.9 57.6 22.4 77.0 27.2 Not AGT01-AD-238902.1 related Unknown Transfection 31.7 6.0 43.9 11.1 96.3 22.3 AD-264561.2 Unknown Unknown Transfection 17.6 4.5 66.6 22.3 AD-273421.1 Unknown Unknown Transfection 16.8 7.3 79.3 26.5 P
AD-273422.1 Unknown Unknown Transfection 18.0 3.9 54.8 25.8 .
, AD-273423.1 Unknown Unknown Transfection 15.3 6.9 72.7 24.8 , .3 u, c: AD-273424.1 Unknown Unknown Transfection 12.9 4.9 68.3 22.5 r., AD-273425.1 Unknown Unknown Transfection 11.7 1.4 69.1 23.9 , , AD-273426.1 Unknown Unknown Transfection 14.4 6.4 59.4 10.8 ..
, AD-273427.1 Unknown Unknown Transfection 16.1 6.5 45.7 4.0 AD-273428.1 Unknown Unknown Transfection 13.8 5.1 69.6 26.0 AD-273429.1 Unknown Unknown Transfection 17.2 2.9 73.1 26.9 AD-273430.1 Unknown Unknown Transfection 14.0 2.9 75.8 14.7 AD-273431.1 Unknown Unknown Transfection 16.3 7.5 67.7 19.8 AD-273432.1 Unknown Unknown Transfection 16.9 6.3 71.8 19.5 1-d n AD-273433.1 Unknown Unknown Transfection 16.4 5.5 64.4 20.0 1-3 AD-273434.1 Unknown Unknown Transfection 13.5 6.7 59.0 15.8 cp AD-273435.1 Unknown Unknown Transfection 11.1 3.3 75.7 18.3 o o AD-273436.1 Unknown Unknown Transfection 11.8 3.8 63.5 17.9 'a vi o AD-273437.1 Unknown Unknown Transfection 17.2 7.3 46.0 7.2 oe oe AD-273438.1 Unknown Unknown Transfection 12.7 5.7 47.0 12.1 AD-273439.1 Unknown Unknown Transfection 14.9 6.0 53.6 6.0 AD-273440.1 Unknown Unknown Transfection 22.5 6.5 65.8 5.8 AD-273441.1 Unknown Unknown Transfection 22.0 12.6 69.1 9.7 0 o AD-273442.1 Unknown Unknown Transfection 13.0 4.4 67.7 18.9 t,.) o AD-273443.1 Unknown Unknown Transfection 16.4 11.8 55.6 9.3 'a o AD-273444.1 Unknown Unknown Transfection 16.4 5.4 74.0 11.7 .6.
.6.
AD-273445.1 Unknown Unknown Transfection 20.6 4.1 56.1 12.1 AD-273446.1 Unknown Unknown Transfection 13.8 3.5 66.8 24.8 AD-273447.1 Unknown Unknown Transfection 16.5 4.8 63.4 22.8 AD-273448.1 Unknown Unknown Transfection 14.9 9.1 67.4 13.9 AD-273449.1 Unknown Unknown Transfection 17.8 7.6 60.0 25.3 AD-273450.1 Unknown Unknown Transfection 13.4 3.5 58.8 22.0 AD-273451.1 Unknown Unknown Transfection 17.4 9.7 65.4 9.0 p AD-273452.1 Unknown Unknown Transfection 14.3 1.4 73.6 9.7 , , .3 t-) AD-273453.1 Unknown Unknown Transfection 16.6 4.8 51.1 12.5 u, _.]

AD-273454.1 Unknown Unknown Transfection 16.1 4.2 58.4 8.1 " r., , AD-273455.1 Unknown Unknown Transfection 20.2 6.7 63.9 19.0 ..
, AD-273456.1 Unknown Unknown Transfection 12.9 3.7 71.0 16.3 AD-264567.2 Unknown Unknown Transfection 12.2 5.2 51.5 18.2 AD-273457.1 Unknown Unknown Transfection 9.6 3.6 48.8 15.4 AD-273458.1 Unknown Unknown Transfection 14.1 3.5 55.2 17.3 AD-273459.1 Unknown Unknown Transfection 12.0 4.1 58.5 15.0 AD-273460.1 Unknown Unknown Transfection 13.1 5.3 64.2 12.3 AD-273461.1 Unknown Unknown Transfection 12.0 3.0 52.5 19.2 1-d n 1-i AD-273462.1 Unknown Unknown Transfection 13.5 2.5 51.3 25.3 cp AD-273463.1 Unknown Unknown Transfection 17.7 6.3 57.7 18.0 t,.) o AD-273464.1 Unknown Unknown Transfection 11.7 4.1 52.7 23.6 o 'a AD-273465.1 Unknown Unknown Transfection 15.0 6.9 67.6 19.2 vi o oe AD-273466.1 Unknown Unknown Transfection 12.5 5.9 55.8 7.5 1-oe AD-273467.1 Unknown Unknown Transfection 13.8 2.9 62.0 25.5 AD-273468.1 Unknown Unknown Transfection 10.2 4.2 65.5 16.8 AD-273469.1 Unknown Unknown Transfection 11.4 1.2 44.8 12.5 AD-273470.1 Unknown Unknown Transfection 14.8 7.2 51.3 11.2 0 o AD-273471.1 Unknown Unknown Transfection 9.3 2.5 43.7 14.0 t,.) o AD-273472.1 Unknown Unknown Transfection 11.7 6.1 54.0 7.3 'a o AD-273473.1 Unknown Unknown Transfection 11.0 3.3 48.4 10.7 .6.
.6.
AD-273474.1 Unknown Unknown Transfection 14.6 4.5 59.4 8.3 AD-273475.1 Unknown Unknown Transfection 10.5 4.2 47.5 13.9 AD-273476.1 Unknown Unknown Transfection 10.0 4.1 50.8 5.2 AD-273477.1 Unknown Unknown Transfection 11.9 1.8 74.1 24.2 AD-273478.1 Unknown Unknown Transfection 9.3 2.9 46.2 12.9 AD-273479.1 Unknown Unknown Transfection 11.1 3.3 52.8 9.7 AD-273480.1 Unknown Unknown Transfection 12.5 5.4 38.6 8.3 p AD-273481.1 Unknown Unknown Transfection 14.6 3.3 56.3 6.2 , , .3 t-) AD-273482.1 Unknown Unknown Transfection 11.8 4.6 52.1 8.3 u, _.]
oe AD-273483.1 Unknown Unknown Transfection 9.6 3.9 51.3 14.7 " r., , AD-273484.1 Unknown Unknown Transfection 12.2 3.1 59.4 27.2 ..
, AD-273485.1 Unknown Unknown Transfection 12.9 6.4 45.9 6.3 AD-273486.1 Unknown Unknown Transfection 14.6 5.9 63.0 16.0 AD-273487.1 Unknown Unknown Transfection 7.8 2.0 52.4 9.2 AD-273488.1 Unknown Unknown Transfection 12.3 2.1 46.6 17.6 AD-273489.1 Unknown Unknown Transfection 11.3 2.1 49.2 11.9 AD-273490.1 Unknown Unknown Transfection 10.6 3.9 63.4 16.9 AD-273491.1 Unknown Unknown Transfection 9.8 3.1 45.1 10.1 1-d n 1-i AD-273492.1 Unknown Unknown Transfection 12.4 6.4 63.9 6.8 cp AD-238841.2 Unknown Unknown Transfection 10.1 2.2 52.2 23.3 t,.) o AD-273493.1 Unknown Unknown Transfection 3.1 2.2 25.6 17.0 o 'a AD-273494.1 Unknown Unknown Transfection 5.1 1.5 30.2 9.7 vi o oe AD-273495.1 Unknown Unknown Transfection 7.0 1.5 44.2 11.5 1-oe AD-273496.1 Unknown Unknown Transfection 6.7 1.4 46.3 20.0 AD-273497.1 Unknown Unknown Transfection 5.7 1.8 39.7 29.4 AD-273498.1 Unknown Unknown Transfection 8.4 0.2 58.3 10.2 AD-273499.1 Unknown Unknown Transfection 9.7 1.4 53.6 30.3 0 o AD-273500.1 Unknown Unknown Transfection 5.0 0.8 35.8 17.5 t,.) o AD-273501.1 Unknown Unknown Transfection 7.0 1.8 31.1 17.4 'a o AD-273502.1 Unknown Unknown Transfection 6.4 0.9 41.4 31.4 .6.
.6.
AD-273503.1 Unknown Unknown Transfection 8.8 2.1 33.2 18.4 AD-273504.1 Unknown Unknown Transfection 7.5 1.5 50.1 18.5 AD-273505.1 Unknown Unknown Transfection 7.2 1.2 82.4 26.7 AD-273506.1 Unknown Unknown Transfection 7.3 0.9 44.8 25.5 AD-273507.1 Unknown Unknown Transfection 3.5 1.2 44.4 24.6 AD-273508.1 Unknown Unknown Transfection 5.1 1.8 50.8 26.4 AD-273509.1 Unknown Unknown Transfection 3.6 2.2 28.5 11.9 p AD-273510.1 Unknown Unknown Transfection 7.3 1.7 57.0 13.3 , , .3 t-) AD-238857.2 Unknown Unknown Transfection 10.9 1.3 54.7 17.6 u, _.]
o AD-238858.2 Unknown Unknown Transfection 5.8 0.4 49.4 16.5 " r., , AD-238837.2 Unknown Unknown Transfection 10.8 1.2 51.7 31.2 ..
, AD-238859.2 Unknown Unknown Transfection 6.4 2.0 61.5 9.2 AD-238835.2 Unknown Unknown Transfection 10.7 1.5 46.0 9.0 AD-238860.2 Unknown Unknown Transfection 8.7 3.7 21.4 2.1 AD-238834.2 Unknown Unknown Transfection 5.5 1.7 57.6 28.3 AD-273511.1 Unknown Unknown Transfection 8.6 1.1 67.9 24.2 AD-273512.1 Unknown Unknown Transfection 7.7 2.3 75.6 6.7 AD-273513.1 Unknown Unknown Transfection 10.6 3.4 94.2 7.5 1-d n 1-i AD-273514.1 Unknown Unknown Transfection 8.9 1.8 77.5 6.9 cp AD-273515.1 Unknown Unknown Transfection 16.8 0.9 90.2 24.3 t,.) o AD-273516.1 Unknown Unknown Transfection 6.2 2.6 37.6 14.4 o 'a AD-238854.2 Unknown Unknown Transfection 6.0 2.7 30.5 6.6 vi o oe AD-273517.1 Unknown Unknown Transfection 8.7 3.0 26.7 10.2 1-oe AD-273518.1 Unknown Unknown Transfection 6.9 0.4 55.6 13.3 AD-273519.1 Unknown Unknown Transfection 14.0 2.3 59.5 23.4 AD-273520.1 Unknown Unknown Transfection 8.3 1.9 77.2 20.0 AD-237793.2 Unknown Unknown Transfection 10.5 4.5 76.2 12.4 0 o AD-273521.1 Unknown Unknown Transfection 8.3 2.9 54.1 15.5 t,.) o AD-273522.1 Unknown Unknown Transfection 5.6 1.9 45.1 24.2 'a o AD-273523.1 Unknown Unknown Transfection 5.3 3.1 38.1 14.2 .6.
.6.
AD-273524.1 Unknown Unknown Transfection 9.4 0.9 82.2 9.4 AD-273525.1 Unknown Unknown Transfection 10.0 1.0 51.8 25.7 AD-273526.1 Unknown Unknown Transfection 8.9 1.3 44.3 27.9 AD-273527.1 Unknown Unknown Transfection 12.1 7.0 91.5 11.8 AD-273528.1 Unknown Unknown Transfection 9.8 1.4 56.5 37.4 AD-273529.1 Unknown Unknown Transfection 11.7 2.3 49.0 27.4 AD-273530.1 Unknown Unknown Transfection 9.5 3.1 27.8 8.2 p AD-273531.1 Unknown Unknown Transfection 8.0 6.2 40.9 29.7 , , .3 t-) AD-273532.1 Unknown Unknown Transfection 7.7 4.2 42.3 27.7 u, .6.
_.]
o AD-273533.1 Unknown Unknown Transfection 9.3 2.4 45.0 26.6 " r., , AD-273534.1 Unknown Unknown Transfection 8.0 1.3 59.1 40.0 ..
, AD-273535.1 Unknown Unknown Transfection 7.3 2.3 59.2 26.3 AD-273536.1 Unknown Unknown Transfection 7.9 2.7 37.0 17.9 AD-273537.1 Unknown Unknown Transfection 9.5 0.5 56.4 13.6 AD-273538.1 Unknown Unknown Transfection 5.8 1.9 46.1 38.1 AD-273539.1 Unknown Unknown Transfection 6.4 4.5 42.6 27.9 AD-273540.1 Unknown Unknown Transfection 6.7 1.3 36.6 23.1 AD-273541.1 Unknown Unknown Transfection 14.4 3.0 65.9 27.3 1-d n 1-i AD-273542.1 Unknown Unknown Transfection 17.1 3.1 79.4 57.3 cp AD-273543.1 Unknown Unknown Transfection 15.0 2.6 57.4 31.4 t,.) o AD-273544.1 Unknown Unknown Transfection 10.2 2.8 45.0 29.1 o 'a AD-273545.1 Unknown Unknown Transfection 10.5 1.6 56.8 18.6 vi o oe AD-273546.1 Unknown Unknown Transfection 6.6 2.7 33.6 19.7 1-oe AD-273547.1 Unknown Unknown Transfection 8.7 1.1 40.6 13.6 AD-273548.1 Unknown Unknown Transfection 13.2 3.4 50.0 27.7 AD-273549.1 Unknown Unknown Transfection 8.5 2.3 45.5 28.1 AD-273550.1 Unknown Unknown Transfection 18.7 2.2 40.5 6.5 0 o AD-273551.1 Unknown Unknown Transfection 11.0 3.1 59.4 22.8 t,.) o AD-273552.1 Unknown Unknown Transfection 10.6 2.5 47.0 14.2 'a o AD-273553.1 Unknown Unknown Transfection 11.2 8.4 46.4 19.3 .6.
.6.
AD-273554.1 Unknown Unknown Transfection 4.8 0.8 26.2 12.6 AD-273555.1 Unknown Unknown Transfection 3.6 0.9 29.3 13.2 AD-273556.1 Unknown Unknown Transfection 5.5 2.5 22.1 6.9 AD-273557.1 Unknown Unknown Transfection 12.9 5.4 53.6 15.0 AD-273558.1 Unknown Unknown Transfection 13.0 3.1 76.1 18.9 AD-273559.1 Unknown Unknown Transfection 8.7 2.6 45.3 17.1 AD-273560.1 Unknown Unknown Transfection 8.3 3.9 35.8 12.1 p AD-273561.1 Unknown Unknown Transfection 8.1 0.8 40.1 13.9 , , .3 t-) AD-273562.1 Unknown Unknown Transfection 8.3 0.6 65.9 16.8 u, .6.
_.]

AD-273563.1 Unknown Unknown Transfection 16.7 7.3 70.0 13.5 " r., , AD-273564.1 Unknown Unknown Transfection 11.2 3.7 61.5 17.1 ..
, AD-273565.1 Unknown Unknown Transfection 12.8 2.8 64.5 26.1 AD-273566.1 Unknown Unknown Transfection 9.9 4.1 49.4 14.3 AD-273567.1 Unknown Unknown Transfection 10.1 4.0 76.8 31.7 AD-273568.1 Unknown Unknown Transfection 13.0 7.7 43.0 8.7 AD-273569.1 Unknown Unknown Transfection 6.1 2.9 40.6 19.3 AD-273570.1 Unknown Unknown Transfection 12.5 4.9 62.4 9.8 AD-273571.1 Unknown Unknown Transfection 15.5 1.3 64.0 19.4 1-d n 1-i AD-273572.1 Unknown Unknown Transfection 10.1 3.0 54.0 16.2 cp AD-273573.1 Unknown Unknown Transfection 11.7 6.7 43.4 15.5 t,.) o AD-273574.1 Unknown Unknown Transfection 7.7 0.7 51.4 9.4 o 'a AD-273575.1 Unknown Unknown Transfection 14.0 4.8 46.0 9.8 vi o oe AD-273576.1 Unknown Unknown Transfection 10.9 7.6 39.4 9.3 1-oe AD-273577.1 Unknown Unknown Transfection 5.8 3.7 30.7 7.7 AD-273578.1 Unknown Unknown Transfection 12.9 8.8 83.1 3.4 AD-273579.1 Unknown Unknown Transfection 14.4 5.7 65.6 18.9 AD-273580.1 Unknown Unknown Transfection 14.2 5.9 81.2 18.1 0 o AD-273581.1 Unknown Unknown Transfection 14.1 5.9 80.5 23.6 t,.) o AD-273582.1 Unknown Unknown Transfection 17.3 6.9 54.7 11.4 'a o AD-273583.1 Unknown Unknown Transfection 15.7 6.6 57.4 24.4 .6.
.6.
AD-273584.1 Unknown Unknown Transfection 14.5 8.8 59.6 11.2 AD-273585.1 Unknown Unknown Transfection 7.5 2.1 26.3 8.5 AD-273586.1 Unknown Unknown Transfection 10.6 5.8 52.7 17.0 AD-273587.1 Unknown Unknown Transfection 27.2 8.8 89.1 34.9 AD-273588.1 Unknown Unknown Transfection 11.1 5.0 61.4 18.2 AD-273589.1 Unknown Unknown Transfection 8.9 3.9 65.4 15.5 AD-273590.1 Unknown Unknown Transfection 17.5 4.5 68.9 30.5 p AD-273591.1 Unknown Unknown Transfection 8.8 2.7 57.3 19.1 , , .3 t-) AD-273592.1 Unknown Unknown Transfection 5.6 2.2 19.6 5.9 u, .6.
_.]
AD-273593.1 Unknown Unknown Transfection 8.4 3.4 45.2 13.3 " r., , AD-273594.1 Unknown Unknown Transfection 9.3 4.1 49.1 16.1 ..
, AD-273595.1 Unknown Unknown Transfection 5.3 2.8 44.1 16.2 AD-273596.1 Unknown Unknown Transfection 4.7 2.8 47.8 11.5 AD-273597.1 Unknown Unknown Transfection 8.2 5.2 43.9 11.8 AD-273598.1 Unknown Unknown Transfection 7.8 4.9 45.5 16.6 AD-273599.1 Unknown Unknown Transfection 3.5 0.6 22.6 7.3 AD-273600.1 Unknown Unknown Transfection 4.0 0.9 38.3 14.3 AD-273601.1 Unknown Unknown Transfection 4.8 1.0 33.7 10.9 1-d n 1-i AD-273602.1 Unknown Unknown Transfection 8.2 3.5 46.1 24.4 cp AD-273603.1 Unknown Unknown Transfection 6.7 1.5 33.3 10.8 t,.) o AD-273604.1 Unknown Unknown Transfection 5.9 0.6 52.9 13.8 o 'a AD-273605.1 Unknown Unknown Transfection 8.3 3.4 43.3 16.0 vi o oe AD-273606.1 Unknown Unknown Transfection 5.5 2.1 38.4 4.4 1-oe AD-273607.1 Unknown Unknown Transfection 4.3 0.3 22.1 5.9 AD-273608.1 Unknown Unknown Transfection 4.8 2.1 37.2 15.4 AD-273609.1 Unknown Unknown Transfection 4.9 3.3 39.4 15.6 AD-273610.1 Unknown Unknown Transfection 5.1 1.7 36.3 17.4 0 o AD-273611.1 Unknown Unknown Transfection 5.7 1.8 41.1 12.0 t,.) o AD-273612.1 Unknown Unknown Transfection 6.2 1.6 26.2 13.1 'a o AD-273613.1 Unknown Unknown Transfection 5.5 2.5 43.7 11.8 .6.
.6.
AD-273614.1 Unknown Unknown Transfection 8.3 4.0 60.1 9.0 AD-273615.1 Unknown Unknown Transfection 6.6 4.5 28.1 4.3 AD-273616.1 Unknown Unknown Transfection 15.2 8.0 54.1 23.2 AD-273617.1 Unknown Unknown Transfection 8.0 2.9 36.4 11.4 AD-273618.1 Unknown Unknown Transfection 7.1 3.4 29.5 5.5 AD-273619.1 Unknown Unknown Transfection 5.5 4.6 34.2 8.3 AD-273620.1 Unknown Unknown Transfection 6.6 2.8 56.1 16.6 p AD-273621.1 Unknown Unknown Transfection 8.6 4.7 43.6 20.7 , , .3 t-) AD-273622.1 Unknown Unknown Transfection 8.4 4.2 38.0 7.5 u, .6.
_.]
AD-273623.1 Unknown Unknown Transfection 7.1 5.1 27.2 3.8 " r., , AD-273624.1 Unknown Unknown Transfection 12.0 6.8 52.6 7.1 ..
, AD-273625.1 Unknown Unknown Transfection 5.3 3.1 40.4 10.0 AD-273626.1 Unknown Unknown Transfection 3.4 1.5 41.4 17.3 AD-273627.1 Unknown Unknown Transfection 12.6 4.6 28.9 4.0 AD-273628.1 Unknown Unknown Transfection 15.0 10.4 46.8 12.2 AD-273629.1 Unknown Unknown Transfection 8.4 2.8 26.2 12.3 AD-273630.1 Unknown Unknown Transfection 6.5 4.7 36.0 3.0 1-d n 1-i cp t..) o ,-, yD
O-u, yD
oe ,-, oe DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:

Claims

WO 2020/097044 PCT/US2019/059818We claim:

1. A dsRNA agent comprising a sense strand and antisense strand having a length of 15-35 nucleotides; at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5' end of the antisense strand; at least three, four, five or six 2'-deoxy on the sense and/or antisense strands; wherein the duplex region is between 19 to 25 base pairs; wherein the dsRNA agent comprises a ligand, and wherein the sense strand does not comprise a glycol nucleic acid (GNA).

2. The dsRNA agent of claim 1, wherein the dsRNA agents have all natural nucleotides, or less than 20%, less than 15%, and less than 10% non-natural nucleotides.

3. The dsRNA agent of claim 1, wherein the dsRNA comprises a sense strand having a length of 18-30 nucleotides, and at least two 2'-deoxy modifications in a central region of the sense strand.

4. The dsRNA agent of claim 3, wherein the central region is within positions 7 to 13 counting from the 5'-end of the sense strand.

5. The dsRNA agent of claim 1, wherein the dsRNA comprises an antisense strand having a length of 18-30 nucleotides, and at least two 2'-deoxy modifications in a central region of the antisense strand.

6. The dsRNA agent of claim 5, wherein the central region is within positions 10 to 16 counting from the 5'-end of the antisense strand.

7. The dsRNA agent of claim 1, wherein the dsRNA comprises an antisense strand having a length of 18-23 nucleotides, and at least five 2'-deoxy modifications in the antisense strand at positions 2, 5, 7, 12 and 14 counting from the 5'-end of the antisense strands.

8. The dsRNA agent of claim 1, wherein at least two of the 2'-deoxy modifications are in the antisense strand at positions 2 and 14, counting from the 5'-end of the antisense strand, and at least one of the 2'-deoxy modification is in the sense strand at position 11, counting from the 5'-end of the sense strand.

9. The dsRNA agent of claim 1, wherein at least three of the 2'-deoxy modifications are in the antisense strand at positions 2, 12 and 14, counting from the 5'-end of the antisense strand, and at least two of the 2'-deoxy modifications are in the sense strand at positions 9 and 11 counting from the 5'-end of the sense strand.

10. The dsRNA agent of claim 1, wherein at least five of the 2'-deoxy modifications are in the antisense strand at positions 2, 5, 7, 12 and 14 counting from the 5'-end of the antisense strand, and at least two of the 2'-deoxy modifications are in the sense strand at positions 9 and 11 counting from the 5'-end of the sense strand.

11. The dsRNA agent of claim 1, wherein the non-natural nucleotide is selected from the group consisting of acyclic nucleotides, locked nucleic acid (LNA) nucleotides, hexitol nucleic acid (HNA) nucleotides, cyclohexenyl nucleioc acid (CeNA) nucleotides, 2'-methoxyethyl nucleotides, 2'-0-ally1 nucleotides, 2'-C-ally1 nucleotides, 2'-fluoro nucleotides, 2'-0-N-methylacetamido (2'-0-NMA) nucleotides, 2'-0-dimethylaminoethoxyethyl (2'-0-DMAEOE) nucleotides, 2'-0-aminopropyl (2'-0-AP) nucleotides, and 2'-ara-F nucleotides.

12. The dsRNA agent of claim 1, wherein the natural nucleotide is a 2'-OH, 2'-0Me, and 2'-deoxy.

13. The dsRNA agent of claim 1, wherein the ligand is an ASGPR ligand.

14. A dsRNA agent comprising a sense strand having a length of 17-30 nucleotides with at least one 2'-deoxy modifications in the central region of the sense strand; an antisense strand haying a length of 17-30 nucleotides with at least two 2'-deoxy modifications in the central region of the antisense strand.

15. A dsRNA agent comprising a sense strand haying a length of 17-30 nucleotides with at least two 2'-deoxy modifications in the central region of the sense strand; an antisense strand haying a length of 17-30 nucleotides with at least one 2'-deoxy modifications in the central region of the antisense strand.